cabergoline has been researched along with ergoline in 969 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (1.55) | 18.7374 |
| 1990's | 138 (14.24) | 18.2507 |
| 2000's | 406 (41.90) | 29.6817 |
| 2010's | 387 (39.94) | 24.3611 |
| 2020's | 23 (2.37) | 2.80 |
| Authors | Studies |
|---|---|
| Ciccarelli, E; D'Alberton, A; Falsetti, L; Ferrari, C; Fioretti, P; Giordano, G; L'Hermite, M; Piscitelli, G; Polli, A; Webster, J | 2 |
| Demedts, M; Dom, R; Frans, E | 1 |
| Bellotti, V; La Croix, R; Pianezzola, E; Strolin Benedetti, M | 1 |
| Broutin, F; Fonte, G; Persiani, S; Pianezzola, E; Strolin Benedetti, M | 1 |
| Benedetti, MS; Cocchiara, G | 1 |
| Crosignani, P; D'Alberton, A; de Vincentiis, S; Ferrari, C; Mattei, AM; Paracchi, A | 1 |
| Blandini, F; Cavallini, A; Fariello, R; Martignoni, E; Micieli, G; Nappi, G | 1 |
| Caballero, JL; Caballero-Gordo, A; Calderay, M; Lopez-Nazareno, N; Mancheño, E; Sghedoni, D | 1 |
| Bhatt, MH; Calne, DB; Fleetham, JA; Keenan, SP | 1 |
| Ambrosi, B; Conti, A; Faglia, G; Morabito, F; Muratori, M; Sartorio, A | 1 |
| Barone, D; Benedetti, MS; Dostert, P; Efthymiopoulos, C; Peretti, G; Roncucci, R | 1 |
| Casazza, S; D'Alberton, A; de Vincentiis, S; Fadin, M; Giorda, G; Motta, T | 1 |
| Bassi, S; Calloni, E; Camerlingo, M; Canal, N; Franceschi, M; Frattola, L; Giusti, MC; Jori, MC; Mamoli, A; Piolti, R | 1 |
| Lera, G; Muruzabal, J; Obeso, JA; Vaamonde, J | 1 |
| Dominoni, P; Ferrari, L; Gianola, D; Gualteroni, L; Montini, M; Pagani, G; Pagani, MD; Sileo, F; Stroppa, S; Tengattini, F | 1 |
| Fioretti, P; Gambacciani, M; Mais, V; Melis, GB; Paoletti, AM; Sghedoni, D | 1 |
| Camanni, F; Ciccarelli, E; Giordano, G; Giusti, M; Miola, C; Potenzoni, F; Sghedoni, D | 1 |
| Durante, R; Giordano, G; Giusti, M; Lomeo, A; Mazzocchi, G; Sghedoni, D; Torre, R | 1 |
| Arbeiter, K; Ballabio, R; D'Ver, AS; Jöchle, W; Post, K | 1 |
| Crosignani, PG; Faglia, G; Ferrari, C; Mattei, A; Melis, GB; Muratori, M; Paracchi, A; Sghedoni, D | 1 |
| Barreca, A; Boghen, M; Dubini, A; Ferrari, C; Fortini, P; Gerevini, G; Paracchi, A; Romano, C | 1 |
| Arbeiter, K; Barsch, E | 1 |
| Baroldi, P; Cavioni, V; Crosignani, PG; Ferrari, C; Galparoli, C; Gerevini, G; Mattei, AM; Paracchi, A; Romano, C; Spellecchia, D | 1 |
| Beneventi, F; Fioretti, P; Gambacciani, M; Mais, V; Melis, GB; Paoletti, AM | 1 |
| Cancio, E; Cocchi, D; Dall'Ara, A; Devesa, J; Di Salle, E; Lima, L; Müller, EE | 1 |
| Cammelli, L; Dubini, A; Mangili, R; Pontiroli, AE; Viberti, GC | 1 |
| Baroldi, P; Beneventi, F; Fioretti, P; Gambacciani, M; Mais, V; Melis, GB; Paoletti, AM | 1 |
| Baroldi, P; Cammelli, L; Pontiroli, AE; Pozza, G | 1 |
| Barbieri, C; Boghen, M; Caldara, R; Codecasa, F; Dubini, A; Ferrari, C; Mucci, M; Paracchi, A; Romano, C | 1 |
| Zaccheo, T | 1 |
| Arvigo, M; Barreca, A; Cariola, G; Foppiani, L; Giordano, G; Minuto, F; Ponzani, P | 1 |
| Arita, K; Eguchi, K; Ito, A; Kawamoto, K; Kurisu, K; Uozumi, T | 2 |
| Berger, HJ; Horstink, MW; van de Vlasakker, CJ | 1 |
| Bryson, HM; Fitton, A; Rains, CP | 1 |
| Riva di Sanseverino, L; Sabatino, P; Tonani, R | 1 |
| Bosc, M; Leclere, J; Pascal-Vigneron, V; Weryha, G | 1 |
| Mark, MH; Sage, JI | 1 |
| Andreotti, AC; Pacciarini, MA; Persiani, S; Pianezzola, E; Pontiroli, AE; Strolin Benedetti, M | 1 |
| Bizollon, CA; Edwards, DM; Persiani, S; Pianezzola, E; Piscitelli, G; Poggesi, I; Sassolas, G; Strolin Benedetti, M | 1 |
| Bevan, JS; Davis, JR | 1 |
| Donnay, I; Onclin, K; Silva, LD; Verstegen, JP | 2 |
| Lera, G; Obeso, JA; Rodriguez, M; Vaamonde, J | 1 |
| Battaglia, R; Castelli, MG; Cocchiara, G; Dostert, P; Mantegani, S; Strolin Benedetti, M | 1 |
| Fraser, RB; Jones, TH | 1 |
| Carraro, A; Cuttica, M; Giordano, G; Giusti, M; Porcella, E; Valenti, S | 1 |
| Ferrari, CI; Ismail, I; Piscitelli, G; Polli, A; Scanlon, MF; Webster, J | 1 |
| Serri, O | 1 |
| Ajossa, S; Depau, GF; Guerriero, S; Mais, V; Melis, GB; Paoletti, AM | 1 |
| Ahlskog, JE; Lieberman, A; Maraganore, DM; Matsumoto, JY; Muenter, MD; Wheeler, K; Wright, KF | 1 |
| Ahlskog, JE; Imke, S; Lieberman, A; Maraganore, DM; Matsumoto, JY; Muenter, M; Schoenfelder, J; Wheeler, K; Wright, KF | 1 |
| Delahaut, P; Ectors, F; Onclin, K; Silva, LD; Verstegen, JP; Wouters-Ballman, P | 1 |
| Jöchle, M; Jöchle, W | 1 |
| Brewer, MA; Hutton, JT; Morris, JL | 1 |
| Ahlskog, JE; Kokmen, E; Low, PA; Nickander, KK; Petersen, RC; Tyce, GM; Uitti, RJ | 1 |
| Inzelberg, R; Korczyn, AD; Nisipeanu, P; Rabey, MJ | 1 |
| Colombo, N; D'Alberton, A; de Vincentiis, S; Marchini, M; Motta, T | 1 |
| Crosignani, PG; Ferrari, C; Piscitelli, G | 1 |
| Arai, N; Fukuyama, J; Isaji, M; Kuno, S; Miyata, H; Mizuta, E | 1 |
| Delgrange, E; Donckier, J; Maiter, D | 1 |
| Webster, J | 4 |
| Bedard, PJ; Blanchet, P; Chen, JS; Doucet, JP; Grondin, R; Hope, BT; Iadarola, MJ; Jasmin, BJ; Nakabeppu, Y; Nestler, EJ; Robertson, GS; St-Jean, M; Wigle, N | 1 |
| Adler, CH; Ahlskog, JE; Muenter, MD; Wright, KF | 1 |
| Onclin, K; Verstegen, JP | 2 |
| Rabey, JM | 1 |
| Bosc, M; Deffond, D; Dordain, G; Dostert, P; Fiorentini, F; La Croix, R; Persiani, S; Strolin Benedetti, M; Vernay, D | 1 |
| Bonuccelli, U; Colzi, A; Del Dotto, P; Dubini, A; Grimaldi, R; Lucetti, C; Pardini, C | 1 |
| Adler, CH; Ahlskog, JE; Hiner, BC; Hurtig, HI; Hutton, JT; Koller, WC; Lieberman, A; Morris, JL; Muenter, MD; Pahwa, R; Pfeiffer, RF; Rodnitzky, RL; Stern, MB; Waters, CH | 1 |
| Catz, T; Inzelberg, R; Kippervasser, S; Korczyn, AD; Nisipeanu, P; Orlov, E; Rabey, JM; Schechtman, E | 1 |
| Ajossa, S; Cagnacci, A; Depau, GF; Melis, GB; Orrù, M; Paoletti, AM | 1 |
| Holt, B; Pacciarini, MA; Persiani, S; Rocchetti, M; Strolin-Benedetti, M; Toon, S | 1 |
| Caraceni, T; Fetoni, V; Geminiani, G; Genitrini, S; Giovannini, P; Tamma, F | 1 |
| Simons, JA | 1 |
| Anderson, T; El-Debas, T; Findley, LJ; Marsden, CD; Steiger, MJ | 1 |
| Arai, N; Isaji, M; Itoh, F; Kojima, M; Miyagi, M; Taya, F; Ujiie, A | 1 |
| Bédard, PJ; Di Paolo, T; Goulet, M; Grondin, R | 1 |
| Arai, N; Isaji, M; Itoh, F; Kojima, M; Komatsu, Y; Miyagi, M; Taya, F | 1 |
| Biller, BM; Cannistraro, KB; Davis, KR; Klibanski, A; Molitch, ME; Schoenfelder, JR; Simons, JA; Vance, ML | 1 |
| Arai, N; Isaji, M; Kojima, M; Kuno, S; Mizuta, E | 1 |
| Cerbone, G; Cirillo, S; Colao, A; Di Sarno, A; Ferone, D; Lombardi, G; Marzullo, P; Merola, B; Sarnacchiaro, F | 1 |
| Bracco, F; Chouza, C; Dubini, A; Dupont, E; Gershanik, O; Grimaldi, R; Marsden, CD; Marti Masso, JF; Montastruc, JL; Orlando, N; Rinne, UK | 1 |
| Annunziato, L; Colao, A; Di Renzo, G; Di Sarno, A; Ferone, D; Lombardi, G; Merola, B; Sarnacchiaro, F | 1 |
| Koide, SS; Negishi, H | 1 |
| Korczyn, AD; Nisipeanu, P | 1 |
| Abs, R; Bevan, JS; Brabant, G; Ciccarelli, E; Ferrari, CI; Motta, T; Mucci, M; Muratori, M; Musatti, L; Scanlon, MF; Verbessem, G | 1 |
| Delgrange, E; Donckier, J | 1 |
| Colao, A; Lombardi, G | 2 |
| Fowler, J; Howlett, TA; Jackson, SN | 1 |
| Ballabio, R; Cauvin, A; Dale, M; Harvey, MJ; Lindley, S | 1 |
| Baylis, PH; Foster, S; Harris, PE; Hurel, SJ; Kelly, WF; McNicol, AM | 1 |
| Jeffreys, R; Leese, G; Vora, J | 1 |
| Inzelberg, R; Korczyn, AD; Nissipeanu, P; Rabey, JM | 1 |
| Bonuccelli, U; Colzi, A; Del Dotto, P; Fariello, R; Musatti, E; Persiani, S; Strolin Benedetti, M | 1 |
| Alldredge, BK; Aminoff, MJ; Bainbridge, JL; Dowling, GA; Gottwald, MD | 1 |
| Annunziato, L; Cataldi, M; Cirillo, S; Colao, A; Di Sarno, A; Facciolli, G; Landi, ML; Lombardi, G; Merola, B; Pivonello, R; Sarnacchiaro, F | 1 |
| Jeukenne, P; Verstegen, J | 1 |
| Onclin, K; Verstegen, J | 1 |
| Arosio, M; Biella, O; Faglia, G; Gambino, G; Muratori, M; Romano, C | 1 |
| Bertagna, A; Camanni, F; Camanni, M; Cammarota, T; Ciccarelli, E; Cirillo, S; Gaia, D; Grottoli, S; Razzore, P | 1 |
| LeWitt, PA | 2 |
| Allievi, C; Dostert, P | 1 |
| Armentano, G; Bracco, PL; Pellegrini, A; Sugliano, GC; Tornatore, GP | 1 |
| Abs, R; Beckers, A; Coolens, JL; Mahler, C; Maiter, D; Nobels, F; Van Acker, K; Verhelst, J | 1 |
| Fariello, RG | 1 |
| Marsden, CD | 1 |
| Bracco, F; Chouza, C; Dupont, E; Gershanik, O; Marsden, CD; Marti Masso, JF; Montastruc, JL; Rinne, UK | 1 |
| Colao, A; Di Sarno, A; Di Somma, C; Facciolli, G; Klain, M; Landi, ML; Lombardi, G; Panza, N; Pivonello, R; Salvatore, M | 1 |
| Fukuda, T; Iwata, SI; Kaseda, S; Kita, S; Nomoto, M | 1 |
| Baldelli, R; Bultrini, A; Caracciolo, B; Ferretti, E; Gulino, A; Jaffrain-Rea, ML; Minniti, G; Tamburrano, G | 1 |
| Hettling, P | 1 |
| Conner, P; Fried, G | 1 |
| Colao, A; De Rosa, M; Di Sarno, A; Ferone, D; Landi, ML; Lombardi, G; Merola, B; Paesano, L; Zarrilli, S | 1 |
| Crabbé, J; Delgrange, E; Donckier, J | 1 |
| Chervin, A; Fideleff, HL; Gurucharri, C; Holland, ME; Sinai, I | 1 |
| De Rensis, F; Foxcroft, GR; Quintavalla, F | 1 |
| Coppola, A; Cuomo, MA | 1 |
| Hearn, CM; Renfree, MB; Shaw, G; Short, RV | 1 |
| Fujimoto, S; Furuta, I; Koide, SS; Negishi, H; Ushigoe, K | 1 |
| Lange, KW | 1 |
| Krack, P; Mönig, H | 1 |
| Attanasio, R; Barausse, M; Branca, V; Cozzi, R; Da Re, N; Dallabonzana, D; Gelli, D; Oppizzi, G; Orlandi, P | 1 |
| Bédard, PJ; Di Paolo, T; Goulet, M; Grondin, R; Morissette, M | 1 |
| Ajossa, S; Floris, S; Guerriero, S; Mannias, M; Melis, GB; Paoletti, AM | 1 |
| Inada, Y; Kojima, M; Komatsu, H; Miyata, H; Moro, M; Torii, R | 1 |
| Ahlskog, JE; Limper, AH; Ling, LH; Munger, TM; Oh, JK | 1 |
| Bartolone, L; Blandino, A; Cannavò, S; Galatioto, S; Spinella, S; Trimarchi, F | 1 |
| Dale, MJ; Harvey, MJ; Lindley, S; Waterston, MM | 1 |
| Almoto, B; Cannavò, S; Curtò, L; Squadrito, S; Trimarchi, F; Vieni, A | 1 |
| Bédard, PJ; Blanchet, PJ; Calon, F; Di Paolo, T; Goulet, M; Grondin, R; Morissette, M | 2 |
| Abs, R; Beckers, A; Coremans, P; Lamberigts, G; Mahler, C; Maiter, D; Mockel, J; Petrossians, P; Raftopoulos, C; Stevenaert, A; van den Bruel, A; Vandeweghe, M; Velkeniers, B; Verhelst, J; Verlooy, J | 1 |
| Brambilla, E; Mantegani, S; Varasi, M | 1 |
| Abs, R; Berwaerts, J; Mahler, C; Verhelst, J | 1 |
| Montastruc, JL; Rascol, O; Senard, JM | 1 |
| Becke, B; Frank, W; Moritz, R; Pauli, R | 1 |
| Delgrange, E; Donckier, JE | 1 |
| Verhelst, JA | 1 |
| Caminiti, M; Camisasca, R; Cucchi, E; Pacchioni, M; Pontiroli, AE | 1 |
| Kaltsas, T; Krassas, GE; Pontikides, N | 1 |
| Lam, YW | 1 |
| Atkin, SL; Foy, PM; Hadden, DR; Leong, KS; MacFarlane, IA; Swift, AC | 1 |
| Colao, A; Di Salle, F; Faggiano, A; Filippella, M; Lombardi, G; Pivonello, R | 1 |
| Colao, A; Di Sarno, A; Di Somma, C; Klain, M; Loche, S; Lombardi, G; Pietrosante, M; Pivonello, R; Salvatore, M | 1 |
| Concannon, PW; Onclin, K; Silva, LD; Verstegen, JP | 1 |
| Ballaux, D; De Deyn, PP; Mahler, C; Pickut, B; Verhelst, J | 1 |
| Cerbone, G; Colao, A; Di Sarno, A; Di Somma, C; Ferone, D; Lastoria, S; Lombardi, G; Lucci, R | 1 |
| Dimitriadis, A; Galli-Tsinopoulou, A; Karamouzis, M; Mitsiakos, G; Nousia-Arvanitakis, S | 1 |
| Andreotti, AC; Caminiti, M; Camisasca, R; Pacchioni, M; Pontiroli, AE | 1 |
| Oertel, WH; Röbbecke, J; Schüler, P; Stiasny, K | 1 |
| Annunziato, L; Cappabianca, P; Cirillo, S; Colao, A; Di Salle, F; Di Sarno, A; Landi, ML; Lombardi, G; Pivonello, R; Scavuzzo, F; Volpe, R | 1 |
| Abs, R; Appel, B; Berwaerts, J; Mahler, C; Verhelst, J | 1 |
| Cerbone, G; Colao, A; Di Sarno, A; Di Somma, C; Landi, ML; Lombardi, G; Marzullo, P; Pivonello, R | 1 |
| Bédard, PJ; Di Paolo, T; Falardeau, P; Goulet, M; Grondin, R; Maltais, S; Morissette, M | 1 |
| Castagna, L; Finotti, N; Marzatico, F; Moretti, A | 1 |
| Herman-Bonert, V; Kovacs, K; Maheshwari, HG; Melmed, S; Prezant, TR; Shahinian, H | 1 |
| Krassas, GE; Pontikides, N | 1 |
| Kaltsas, T; Krassas, GE; Nikopoulou, E; Pontikides, N | 1 |
| Colao, A; Di Somma, C; Ferone, D; Filippella, M; Lombardi, G; Marzullo, P; Pivonello, R | 1 |
| Davies, JS; George, LD; Nicolau, N; Scanlon, MF | 1 |
| Brannan, T; Prikhojan, A; Yahr, MD | 1 |
| Andersen, M; Bjerre, P; Edal, A; Hagen, C; Høilund-Carlsen, PF; Pedersen, PH; Schrøder, HD | 1 |
| Botella, I; De Luis, DA; Hurtado, A; Marcos, L | 1 |
| Beckers, A; Bloch, B; Kalife, A; Petrossians, P; Ronci, N; Stevenaert, A; Tabarin, A; Valdés Socin, H | 1 |
| Maschek, W; Pichler, R | 1 |
| Tomov, I | 1 |
| Tollin, SR | 1 |
| De Santis, L; Doldi, N; Ferrari, A; Papaleo, E | 1 |
| Annunziato, L; Colao, A; Lombardi, G | 1 |
| Delamere, JP; Erb, N; Kitas, GD; Pace, AV | 1 |
| Agapito, C; Bhattacharya, KF; Chaudhuri, KR; Pal, S | 1 |
| Agostini, S; Billeci, D; Conte, N; De Menis, E; Marton, E; Tramontin, P; Visentin, A | 1 |
| Clarke, CE; Deane, KH | 1 |
| Clarke, CE; Deane, KD | 1 |
| Cappabianca, P; Cavallo, LM; Colao, A; Cozzi, R; Di Sarno, A; Felisati, G; Giombini, S; Lodrini, S; Peca, C | 1 |
| Cappabianca, P; Colao, A; Del Basso de Caro, ML; Faggiano, A; Ferone, D; Lastoria, S; Lombardi, G; Pivonello, R | 1 |
| de la Sota, RL; Gobello, C; Goya, RG | 1 |
| Atkinson, AB; Bell, PM; Courtney, CH; Ellis, PK; Hadden, DR; Leslie, H; McCance, DR; Sheridan, B | 1 |
| Jalkanen, L; Marks, CA; Savolainen, R; Short, RV | 1 |
| Ichikawa, K; Kojima, M | 1 |
| Bédard, PJ; Blanchet, PJ; Calon, F; Di Paolo, T; Goulet, M; Grondin, R; Lévesque, D; Morissette, M | 1 |
| Miki, N | 1 |
| Arikan, E; Hatemi, H; Sabuncu, T; Tasan, E | 1 |
| De Santis, L; Doldi, N; Ferrari, A; Marelli, G; Marsiglio, E; Papaleo, E; Rofena, S | 1 |
| DeLiberto, TJ; Johnston, JJ; Kimball, BA | 1 |
| Cappabianca, P; Colao, A; Di Salle, F; Di Sarno, A; Di Somma, C; Faggiano, A; Landi, ML; Lombardi, G; Pivonello, R; Rossi, FW | 1 |
| Katayama, S | 1 |
| Baas, HK; Schueler, P | 1 |
| Stiasny, K | 1 |
| Nippoldt, TB; Sheehan, MT | 1 |
| Bozhinova, S; Penkov, V; Porozhanova, V | 1 |
| Baeza Pertegaz, I; Goikolea Alberdi, JM; Parellada Rodón, E | 1 |
| Biederman, J; Cohen, LG | 1 |
| Abe, K; Kashihara, K; Manabe, Y; Murakami, T | 1 |
| Jöchle, W; Lengwinat, T; Meyer, HH | 1 |
| Benecke, R; Dressler, D; Wittstock, M | 1 |
| Cantore, G; Delfini, R; Esposito, V; Ferrante, L; Jaffrain-Rea, ML; Minniti, G; Santoro, A | 1 |
| Defeyter, I; Rubens, R; T'Sjoen, G; Van De Saffele, J; Vandeweghe, M | 1 |
| Marks, CA | 1 |
| Colao, A; di Sarno, A; di Somma, C; Lombardi, G; Pivonello, R | 1 |
| Castex, G; Corrada, Y; Gobello, C | 1 |
| Brzozowski, M; Clark, M; Marks, CA; Zurek, H | 1 |
| Góth, M; Hubina, E; Kovács, L; Szabolcs, I | 1 |
| Asanuma, M; Fujita, N; Higashi, Y; Miyazaki, I; Ogawa, N; Tanaka, Ki; Yoshioka, M | 1 |
| Biesold, M; Guenzel, S; Lohmann, T; Paschke, R; Prothmann, S; Schober, R; Trantakis, C | 1 |
| Liu, C; Tyrrell, JB | 1 |
| Okamoto, K; Sohmiya, M; Suzuki, Y; Tanaka, M; Yoshida, T | 1 |
| DeLiberto, TJ; Jöchle, W; Kimball, B; Seglund, A | 1 |
| Anderson, AM; Ashford, SW; Henegar, KE; Wuts, PG | 1 |
| Brunner, H; Friess, E; Hogl, B; Trenkwalder, C; Wetter, TC; Yassouridis, A | 1 |
| Freed, DJ; Gillam, MP; Middler, S; Molitch, ME | 1 |
| Gekht, AB | 1 |
| Appiah-Kubi, LS; Chaudhuri, KR; Marco, AD | 1 |
| Keogh, MA; Wittert, GA | 1 |
| Bain, PG; Navan, P | 1 |
| Bretz, F; Hothorn, LA | 1 |
| Akintoye, SO; Bianco, P; Booher, S; Chebli, C; Cherman, N; Collins, MT; Feuillan, P; Kushner, H; Leroith, D; Robey, PG; Wientroub, S | 1 |
| Battaglia, A; Canonico, PL; Lombardi, G; Miglio, G; Papini, MG; Varsaldi, F | 1 |
| Christensen, J; Dupont, E; ØStergaard, K | 1 |
| Clarke, CE; Guttman, M | 1 |
| Grauer, MT; Sieb, JP | 1 |
| Archbald, LF; Hernandez, J; Larsen, RE; Phillips, TC; Samuelson, D; Shille, VM; Strachan, L | 1 |
| Mah, PM; Webster, J | 1 |
| Berardelli, A; De Pandis, MF; Modugno, N; Ruggieri, S; Stocchi, F; Thomas, A; Vacca, L; Valente, M | 1 |
| Carlson, AA; McNeilly, AS; Nicol, L; Parlow, AF; Young, AJ | 1 |
| Freda, PU; Korner, J; Lo, J; Wardlaw, SL | 1 |
| Cavallero, D; Fazzuoli, L; Giusti, M; Valenti, S | 1 |
| Goadsby, PJ; Levy, MJ; Matharu, MS | 1 |
| Biondi, B; Briganti, F; Cappabianca, P; Colao, A; Faggiano, A; Lombardi, G; Pivonello, R; Sarno, AD; Somma, CD | 1 |
| Amoroso, S; Annunziato, L; Castaldo, P; D'Alessio, A; Di Renzo, G; Formisano, L; Ingleton, P; Secondo, A; Sirabella, R | 1 |
| Heller, R; Hughes, N; Paul, G; Schoen, A; Schweingruber, H; Winnik, W | 1 |
| Bauduceau, B; Bordier, L; Dupuy, O; Le Marec, E; Mayaudon, H; Rilminger, H | 1 |
| Buchfelder, M; Harms, E; Hüfner, M; Saeger, W; Siggelkow, H | 1 |
| Altomare, M; Colosimo, C; Corsello, SM; Lovicu, RM; Migneco, MG; Rota, CA; Ubertini, G | 1 |
| Calda, P; Pavlista, D; Zivný, J | 1 |
| Pastor, P; Tolosa, E | 1 |
| Fujinami, A; Kuno, S; Matsui, H; Mizuta, I; Ohta, K; Ohta, M | 1 |
| Bankowski, BJ; Zacur, HA | 1 |
| Abe, K; Hotta, K; Igarashi, K; Kasuya, F; Sakoda, S | 1 |
| Kodama, R; Kondo, T; Miwa, H; Morita, S | 1 |
| Bonuccelli, U; Del Dotto, P | 1 |
| Högl, B; Rothdach, A; Trenkwalder, C; Wetter, TC | 1 |
| Matsubara, K; Ohtaki, K; Shimizu, K; Shiono, H | 1 |
| Berger, KB; Dodel, RC; DuChane, J; Köhne-Volland, R; Machat, O; Meyer, D; Oertel, WH; Reuther, M; Siebert, U; Smala, AM; Spottke, EA | 1 |
| Amad, M; Dunyach, JJ; Hughes, N; Paul, G; Splendore, M; Winnik, W | 1 |
| Chaudhuri, KR | 1 |
| Broglia, G; Castex, G; Corrada, Y; Gobello, C | 1 |
| Inzelberg, R; Nisipeanu, P; Schechtman, E | 1 |
| Kondo, T; Miwa, H | 1 |
| Ball, SG; Hall, K; James, RA; Kendall-Taylor, P; Pearce, SH; Quinton, R; Sibal, L; Ugwu, P | 1 |
| Brabant, G; Bremer, M; Cuarezma, JS; Karstens, JH; Lenarz, T; Samii, M; Schöfl, C; Schöfl-Siegert, B; von zur Mühlen, A | 1 |
| Bernardini, S; Berti, C; Bonuccelli, U; Caneparo, D; Del Dotto, P; Gambaccini, G | 1 |
| Cappabianca, P; Colao, A; Di Sarno, A; Di Somma, C; Lombardi, G; Pivonello, R | 1 |
| Gabai, G; Marinelli, L; Mollo, A; Rota, A; Vincenti, L | 1 |
| Castronovo, C; Ferini-Strambi, L; Oldani, A; Zucconi, M | 1 |
| Exton, MS; Haake, P; Hartmann, U; Haverkamp, J; Krämer, M; Krüger, TH; Leygraf, N; Saller, B; Schedlowski, M | 1 |
| Bédard, PJ; Bélanger, N; Grégoire, L; Hadj Tahar, A | 1 |
| Molitch, ME | 7 |
| Harada, H; Hashimoto, H; Kono, I; Nakagawa, M; Yoshida, T; Yoshikawa, K | 1 |
| Arai, T; Fujiwara, H; Sekizawa, K; Toshima, S; Yoshimi, N | 1 |
| Braucks, GR; Gadelha, MR; Naliato, EC; Tabet, AL; Violante, AH | 1 |
| Colao, A; De Rosa, M; Di Somma, C; Lombardi, G; Orio, F; Tauchmanova', L; Vitale, G; Zarrilli, S | 1 |
| Bolko, P; Jaskuła, M; Sowiński, J; Waśko, R; Wołuń, M | 1 |
| Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM | 1 |
| Friedman, TC | 1 |
| Couldwell, WT; Laws, ER; Weiss, MH | 1 |
| Ayala, AR; Hurtado Amador, R | 1 |
| Angelone, SM; Cavallaro, R; Cocchi, F; Lattuada, E; Smeraldi, E | 1 |
| Falaschi, P; Martocchia, A; Missale, C; Sigala, S; Spano, P | 1 |
| Arbeiter, K; Aslan, S; Erünal-Maral, N; Findik, M; Handler, J; Yüksel, N | 1 |
| Annunziato, L; Cappabianca, P; Cavallo, LM; Colao, A; Di Somma, C; Filippella, M; Lombardi, G; Matrone, C; Pivonello, R | 1 |
| Briganti, F; Cappabianca, P; Ciccarelli, A; Colao, A; De Rosa, M; Lombardi, G; Vitale, G; Zarrilli, S | 1 |
| Battaglia, A; Canonico, PL; Francioli, E; Lombardi, G; Miglio, G; Varsaldi, F | 1 |
| Chang, JY; Kattah, JC; Orth, EH; Talkad, AV; Xu, MY | 1 |
| Annunziato, L; Arvigo, M; Colao, A; De Caro, ML; de Herder, WW; Ferone, D; Hofland, LJ; Kros, JM; Lamberts, SW; Lombardi, G; Pivonello, R | 1 |
| Díez, JJ; Iglesias, P; Macho, LP | 1 |
| Fujinami, A; Kawahara, Y; Kuno, S; Matsui, H; Ohta, K; Ohta, M; Sakakimoto, A | 1 |
| Hotta, M; Kamo, T; Kawakami, M; Nemoto, S; Oshima, J; Shimojo, S; Shiraishi, M; Sugihara, H; Takahashi, Y; Yasaki, S | 1 |
| Ciccarelli, A; Colao, A; Di Sarno, A; Guerra, E; Lombardi, G; Spiezia, S; Vitale, G | 1 |
| Couldwell, WT; Liu, JK | 1 |
| Ezzat, S | 1 |
| Burkhard, PR; Flachsbart, KD; Fross, RD; Horvath, J; Kleiner-Fisman, G; Lang, AE; Lerch, R; Liaudat, S; Pache, JC; Rakowski, H; Raskoff, WJ; Stalder, H | 1 |
| Clarke, CE; Gray, R; Ives, N; Wheatley, K | 1 |
| Marras, C | 1 |
| Fujisawa, A; Okamoto, K; Sohmiya, M; Tanaka, M; Yamamoto, Y | 1 |
| MacIver, DH; Townsend, M | 1 |
| Attanasio, R; Cozzi, R; Lasio, G; Lodrini, S | 1 |
| Benes, H; Heinrich, CR; Kohnen, R; Ueberall, MA | 1 |
| Battaglia, A; Bracco, F; Chouza, C; Dupont, E; Gershanik, O; Marti Masso, JF; Montastruc, JL | 1 |
| Curran, MP; Perry, CM | 1 |
| Hermus, AR; Nooijen, P; Pieters, GF; van Alfen, N; van Lindert, E; van Uum, SH; Wesseling, P | 1 |
| Grosset, D; Grosset, K; Macphee, G; Needleman, F | 1 |
| Saito, N; Shimizu, M; Shimizu, S; Sugiura, Y; Yamamoto, T | 1 |
| Johansen, SS; Karkov, J | 1 |
| Baran, AS; Rack, MJ; Richert, AC; Roffwarg, HP | 1 |
| Basu, S; Chaudhuri, KR; Dhawan, V; Jackson, G; Odin, P | 1 |
| Werner, S | 1 |
| Trifonov, I | 1 |
| Casulari, LA; Mello, PA; Naves, LA; Papadia, C; Pereira Neto, A | 1 |
| Ogawa, N; Tanaka, K | 1 |
| Cuevas, R; Hutchison, K; Jankowiak, J | 1 |
| Rye, DB | 1 |
| Benes, H; Emser, W; Holinka, B; Hornyak, M; Kohnen, R; Leroux, M; Oertel, WH; Peglau, I; Stiasny-Kolster, K; Wessel, K | 1 |
| Freda, PU; Khandji, AG; Nuruzzaman, AT; Post, KD; Reyes, CM; Sundeen, RE | 1 |
| Brooks, PL; Vella, ET; Wynne-Edwards, KE | 1 |
| Ling, W; Majewska, MD; Montgomery, MA; Rawson, RA; Reiber, C; Shoptaw, S; Watson, DW | 1 |
| Date, I; Hashimoto, K; Inagaki, K; Makino, H; Miyoshi, T; Ogura, T; Otsuka, F; Suzuki, J; Takeda, M | 1 |
| Gomes, MC; Knoepfelmacher, M; Melo, ME; Mendonca, BB | 1 |
| Rickels, MR; Snyder, PJ | 1 |
| Bloch, DA; Elkashef, A; Leiderman, DB; LoCastro, J; Montgomery, A; Shoptaw, S; Vocci, F | 1 |
| Basu, S; Chaudhuri, KR; Dhawan, V; Jackson, G; Luce, P; Medcalf, P; Odin, P; Stegie, F | 1 |
| Newell-Price, J; Ross, R; Selvarajah, D; Webster, J | 1 |
| Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
| Comella, C; Widnell, KL | 1 |
| Abs, R; Verhelst, J | 1 |
| Goadsby, PJ; Levy, MJ; Matharu, MS; Meeran, K; Powell, M | 1 |
| Crawford, JL; Demmer, J; Eckery, DC; Lun, S | 1 |
| Colao, A; Ferone, D; Lamberts, SW; Pivonello, R | 1 |
| Kawai, M; Misumi, S; Morimatsu, M; Negoro, K; Ogasawara, J; Tada, Y | 1 |
| Howell, DL; Hudgins, RJ; Mazewski, CM; Meacham, LR; Wasilewski, K | 1 |
| Biswas, M; Davies, JS; Evans, LM; Jadon, D; McEwan, P; Rees, DA; Scanlon, MF; Smith, J | 1 |
| Ball, SG; Connolly, V; James, RA; Kane, P; Kelly, WF; Kendall-Taylor, P; Mathias, D; Perros, P; Quinton, R; Sibal, L; Vaidya, B | 1 |
| Albertelli, M; Arvigo, M; Barreca, A; Culler, MD; Ferone, D; Jaquet, P; Minuto, F; Moreau, JP; Saveanu, A; Semino, C; Taylor, JE | 1 |
| Afandi, B; Al-Zubaidi, AS | 1 |
| Arthur, K; Foley, SR; Kelly, BD | 1 |
| Adamo, V; Manno, M; Marchesan, E; Tomei, F | 2 |
| Catargi, B; Gatta, B; Hau, DH; Roger, P; Tabarin, A | 1 |
| Giovanelli, M; Losa, M; Mortini, P; Scarone, P | 1 |
| Delgrange, E; Gustin, T | 1 |
| Fortes, J; Marcos-Alberca, P; Pinero, A | 1 |
| Crosignani, PG | 1 |
| Dieleman, SJ; Günzel-Apel, AR; Hoppen, HO; Koch, A; Kooistra, HS | 1 |
| Góth, MI; Iván, G; Nagy, GM; Oláh, M; Szigeti-Csúcs, N | 1 |
| Boianov, M; Khristov, V; Vezenkova, L | 1 |
| Ludolph, A; Odin, P; Oehlwein, C; Polzer, U; Renner, R; Schüler, P; Shing, M; Storch, A; Werner, G | 1 |
| Moritoyo, H; Moritoyo, T; Nagai, M; Nakatsuka, A; Nishikawa, N; Nomoto, M; Nomura, T; Yabe, H | 1 |
| Bronstein, MD | 2 |
| Ciccarelli, A; Colao, A; De Rosa, M; Guerra, E; Lombardi, G; Milone, F; Zarrilli, S | 1 |
| Boulos, PT; Hamilton, DK; Laws, ER; Vance, ML | 1 |
| Elder, DA; Eyal, O; Naffaa, LN | 1 |
| Delgrange, E | 1 |
| Barlier, A; Jaquet, P | 1 |
| Arias, D; Corrada, Y; Gobello, C; Rodríguez, R; Tortora, M | 1 |
| Almond, RE; Brown, GR; Keverne, EB | 1 |
| Günzel-Apel, AR; Hoeftmann, T; Meyer-Lindenberg, A; Politt, E; Schoon, HA; Steiger, K | 1 |
| Ciccarelli, A; Colao, A; De Rosa, M; Di Sarno, A; Gaccione, M; Guerra, E; Lombardi, G; Zarrilli, S | 1 |
| Larner, AJ | 1 |
| Akkus, DE; Diramali, AB | 1 |
| Ballabio, R; De Rensis, F; Scaramuzzi, RJ; Spattini, G | 1 |
| Beauchamp, MC; Li, L; Maingrette, F; Mamputu, JC; Renier, G; Serri, O | 1 |
| Delgrange, E; Duprez, T; Maiter, D | 1 |
| Fleseriu, M; Hamrahian, AH; Lee, M; Pineyro, MM; Reddy, SK; Siraj, ES; Skugor, M | 1 |
| Bonelli, RM; Kapfhammer, HP; Magnet, MK | 1 |
| Csoka, AB; Shipko, S | 1 |
| Abe, T; Isobe, C; Kikuchi, T; Murata, T; Sato, C; Terayama, Y | 1 |
| Aburakawa, Y; Aizawa, H; Enomoto, H; Kikuchi, K; Kimura, T; Makita, Y; Suzuki, Y; Yahara, O | 1 |
| Ducros, A; Jublanc, C; Sarov, M; Valade, D | 1 |
| Higuchi, H; Sugawara, Y; Yoshida, K | 1 |
| Brusa, L; Cervellino, A; Giacomini, P; Grossi, K; Izzi, F; Marciani, MG; Pierantozzi, M; Placidi, F; Romigi, A; Stanzione, P | 1 |
| Frank, MJ; O'Reilly, RC | 1 |
| Andreasen, JJ; Hjortshøj, SP; Poulsen, SH | 1 |
| Shimon, I; Shraga-Slutzky, I; Weinshtein, R | 1 |
| Ilić, TV; Korchounov, A; Ziemann, U | 1 |
| Alonso-Muriel, I; Gomez, R; Gonzalez-Izquierdo, M; Novella-Maestre, E; Pellicer, A; Remohi, J; Sanchez-Criado, J; Simon, C; Zimmermann, RC | 1 |
| Benes, H; Bodenschatz, R; Cassel, W; Geisler, P; Happe, S; Kohnen, R; Leroux, M; Oertel, WH; Peglau, I; Stiasny-Kolster, K; Warmuth, R | 1 |
| Colao, A; De Leo, M; Di Sarno, A; Guerra, E; Lombardi, G; Mentone, A | 1 |
| Ausserer, H; Bratti, A; Covi, M; Lochner, P; Marth, R; Nardone, R; Tezzon, F | 1 |
| Danilovic, DL; Knoepfelmacher, M; Mendonça, BB; Rosa Nasser, RH | 1 |
| Linazasoro, G; van Blercom, N | 1 |
| Burger, E; Härtter, S; Kvernmo, T | 1 |
| Kanzato, N; Murao, H; Nishihira, T; Takara, H | 1 |
| Ak, K; Bacinoglu, S; Cangul, IT; Cirit, U; Kaya, HH; Taş, M | 1 |
| Bodei, L; Colao, A; de Herder, WW; de Krijger, RR; Faggiano, A; Ferone, D; Hofland, LJ; Lamberts, SW; Lombardi, G; Pivonello, R | 1 |
| Culler, MD; Dufour, H; Guillen, S; Gunz, G; Jaquet, P; Saveanu, A | 1 |
| Diaz Molina, B; Iglesias-Cubero, G; Martin, M; Moris De la Tassa, C | 1 |
| de Herder, WW; Feelders, RA; Krenning, EP; Kwekkeboom, DJ; Reijs, AE; Tanghe, HL; van Aken, MO; van der Lely, AJ | 1 |
| Dubois-Ginouves, S; Illouz, F; Laboureau, S; Rodien, P; Rohmer, V | 1 |
| Fuhrmann, JT; Junghanns, S; Koch, R; Oelwein, C; Reichmann, H; Simonis, G; Storch, A; Strasser, RH | 1 |
| Brändle, M; Schmid, C | 1 |
| Grotas, AB; Nagler, HM | 1 |
| Khandwala, HM | 1 |
| Atkinson, AB; Cooke, RS; Herron, B; Hunter, SJ; McCall, D; Sheridan, B | 1 |
| Roth, BL | 1 |
| Andersohn, F; Garbe, E; Haverkamp, W; Schade, R; Suissa, S | 1 |
| Antonini, A; Gatto, G; Gentile, R; Pezzoli, G; Tesei, S; Zanettini, R | 2 |
| Georgieva, J; Nussbaum, G; Rochlitz, H; Steinhoff, M; Zouboulis, CC | 1 |
| Christ, ER; Jenni, S; Seiler, R; Stettler, C | 1 |
| Jiménez Caballero, PE | 1 |
| Enseñat, J; Mesa, J; Obiols, G; Ortega, A; Sahuquillo, J; Topcewski, T; Vilalta, J | 1 |
| Grotenhuis, JA; Hermus, AR; Netea-Maier, RT; Schakenraad, EL; Timmers, H; van Lindert, EJ | 1 |
| Cappabianca, P; Colao, A; Cozzi, R; Ghigo, E; Martino, E; Scanarini, M | 1 |
| Benes, H; Grote, L; Happe, S; Högl, B; Kohnen, R; Mathis, J; Saletu-Zyhlarz, GM; Trenkwalder, C | 1 |
| Benbassat, C; Hadani, M; Shimon, I | 1 |
| Erginöz, E; Kenangil, G; Koldas, L; Ozekmekçi, S; Sahin, T | 1 |
| Mascarell, S; Sarne, DH | 1 |
| Bianchi, F; Culler, MD; Dadati, P; Ferone, D; Jaquet, P; Minuto, F; Ravetti, JL; Rebora, A; Resmini, E; Saveanu, A; Spaziante, R; Zona, G | 1 |
| Bowsher, T; Chatfield, J; Loskutoff, N; O'Neill, K; Ramey, J; Zhang, L | 1 |
| Tokhunts, KA | 1 |
| Farzadi, L; Madarek, EO; Melli, MS | 1 |
| England, GC; Freeman, SL; Russo, M | 2 |
| Colao, A; Di Somma, C; Lombardi, G; Pivonello, R; Savastano, S; Tauchmanovà, L | 1 |
| Cağlar, S; Onal, A | 1 |
| Freeman, B; Gorman, JM; Levy, W | 1 |
| Ionescu, A; Price, DE; Stephens, JW | 1 |
| Altschuler, EL; Kast, RE | 1 |
| Alvarez, C; Fernández-Sánchez, M; Gómez, R; Martí-Bonmatí, L; Novella-Maestre, E; Pellicer, A; Sanz, R; Simón, C | 1 |
| Chuang, E; Molitch, ME | 1 |
| Deuschl, G; Fox, GC; Gordin, A; Roscher, T; Schremmer, D; Vaitkus, A | 1 |
| Abrams, PJ; Abs, R; Verhelst, JA | 1 |
| Atkin, SL; Lowry, M; Manuchehri, AM; Rowland-Hill, C; Sathyapalan, T; Turnbull, LW | 1 |
| Balarini Lima, GA; Dos Santos Silva, CM; Filho, PN; Gadelha, MR; Machado, Ede O | 1 |
| Briganti, F; Cappabianca, P; Caranci, F; Cavallo, LM; Cirillo, S; Colao, A; Di Sarno, A; Elefante, A; Guerra, E; Lombardi, G; Pivonello, R | 1 |
| Greenman, Y | 1 |
| Ciraru-Vigneron, N; Laloi-Michelin, M; Meas, T | 1 |
| Senol, MG; Togrol, RE | 1 |
| Ali, O; Banerjee, S; Kelly, DF; Lee, PD | 1 |
| Besouw, MT; Levtchenko, EN; Noordam, K; Willemsen, MA | 1 |
| Fuhrmann, JT; Simonis, G; Strasser, RH | 1 |
| Aboulghar, MA | 1 |
| Balogh, L; Borghi, V; De Rensis, F; Scaramuzzi, RJ; Spattini, G; Thuróczy, J | 1 |
| Antonini, A; Poewe, W | 1 |
| Aksoy, OA; Aslan, S; Beceriklisoy, HB; Einspanier, A; Hoppen, HO; Schäfer-Somi, S | 1 |
| Abs, R; Bárcena, DG; Chanson, P; Colao, A; Kleinberg, DL; Paulus, W | 1 |
| Allen, K; Byrne, JV; Cudlip, S; De Silva, SR; Soni, A; Wass, JA | 1 |
| Belleville, I; Boujon, B; Chague, F; Petit, JM | 2 |
| Cabrera Blatter, MF; Castillo, VA; García, JD; Gómez, NV; Lalia, JC | 1 |
| De Tommasi, A; De Tommasi, C; Guastamacchia, E; Losa, M; Luzzi, S; Resta, F; Sabbà, C; Tafaro, E; Terreni, MR; Triggiani, V | 1 |
| Gayete, A; Grau, S; Orozco-Levi, M; Ramírez-Sarmiento, A; Villavicencio, C | 1 |
| Benes, H; Högl, B; Kohnen, R; Trenkwalder, C | 1 |
| Alonso-Muriel, I; Alvarez, C; Bellver, J; Crespo, J; García, G; Pellicer, A; Simón, C | 1 |
| Hanada, T; Higaki, Y; Hiroe, K; Inoue, S; Murakami, R; Oda, T; Okada, S; Ota, T; Shimizu, K | 1 |
| Adeva-Bartolomé, T; Alonso-Navarro, H; Jiménez-Jiménez, FJ; Ruiz-Ezquerro, JJ | 1 |
| Horikawa, F; Kawabata, Y; Miki, N; Miyake, H; Ono, M; Ueno, Y | 1 |
| Ansorge, O; Fazal-Sanderson, V; Fernandez, A; Karavitaki, N; Wass, JA | 1 |
| Bédard, PJ; Bélanger, N; Calon, F; Di Paolo, T; Dridi, M; Grégoire, L; Hadj Tahar, A; Morissette, M; Samadi, P | 1 |
| Hornyak, M; Spiegelhalder, K | 1 |
| Dupont, E; Egeblad, H; Poulsen, SH; Rasmussen, VG; Safikhany, G; Østergaard, K | 1 |
| Davie, M | 1 |
| Cohen, MX; Elger, CE; Krohn-Grimberghe, A; Weber, B | 1 |
| Gorsler, A; Liepert, J | 1 |
| Miles, AN; Schug, S; Wang, LP | 1 |
| Ahmed, B; Ellison, WA; Kaushik, P; Kaushik, R; Soule, MR | 1 |
| Marinov, B; Milanova, K | 1 |
| El Solh, AA; Saliba, R | 1 |
| Frey, N; Helmke, B; Katus, HA; Luedde, M | 1 |
| Bellastella, A; Bellastella, G; Bizzarro, A; Colao, A; Conte, M; Coronella, C; De Bellis, A; Lombardi, G; Pasquali, D; Pivonello, R; Savoia, A; Sinisi, AA | 1 |
| Barlier, A; Brue, T; Jaquet, P; Saveanu, A | 1 |
| Arcoraci, V; Morgante, L; Savica, R; Tari, M; Trifirò, G | 1 |
| Caldas, D; Cesar de Oliveira Naliato, E; Colao, A; Dutra Violante, AH; Fontes, R; Gomes de Souza, R; Guerra, E; Lamounier Filho, A; Rezende Loureiro, C; Schrank, Y; Sebastian, A; Vaisman, M | 1 |
| Flannery, D; Lyons, K | 1 |
| Buhendwa, L; Firmenich, P; Harries, AD; Kazima, J; Massaquoi, M; Teck, R; Zachariah, R | 1 |
| Dengler, R; Joppich, G; Möbes, J; Schröder, C; Stiebritz, F | 1 |
| Ambrosi, B; Angioni, AR; Baglioni, S; Barbieri, AM; Beck-Peccoz, P; Borretta, G; Brogioni, S; Cannavò, S; Colao, A; Filopanti, M; Fustini, MF; Gasco, V; Gasperi, M; Grottoli, S; Jaffrain-Rea, ML; Lania, A; Mantovani, G; Monte, PD; Peri, A; Pigliaru, F; Spada, A | 1 |
| Inoue, T; Izumi, T; Kitaichi, Y; Koyama, T; Masui, T; Nakagawa, S; Tanaka, T | 1 |
| Katzman, P; Lindgren, H; Löndahl, M; Nilsson, A | 1 |
| Daida, H; Hatano, T; Hattori, N; Iwama, Y; Komine-Kobayashi, M; Mizuno, Y; Mochizuki, H; Nakayama, T; Sakai, M; Urabe, T; Yamashiro, K | 1 |
| Barlier, A; Culler, MD; Dufour, H; Fusco, A; Germanetti, AL; Gunz, G; Jaquet, P; Saveanu, A | 1 |
| Fujieda, K; Ishi, N; Ishizu, K; Jo, W; Tajima, T; Tsubaki, J | 1 |
| Alexandraki, KI; Grossman, AB | 1 |
| Duarte, J; Fernández-Reyes, MJ; Heras, M; Iglesias, P; Jiménez, MJ; Muñoz, H; Sánchez, R; Tajada, P | 1 |
| Beckers, A; Betea, D; Burlacu, MC; Daly, AF; Lancellotti, P; Livadariu, E; Markov, M; Pierard, L | 1 |
| Basu, A; Brabant, G; Gnanalingham, KK | 1 |
| Bogazzi, F; Boresi, F; Buralli, S; Cigni, T; Lombardi, M; Manetti, L; Martino, E; Raffaelli, V; Salvetti, A; Taddei, S | 1 |
| Assaker, R; Blond, S; Cortet-Rudelli, C; Defoort-Dhellemmes, S; Faivre-Defrance, F; Mouton, F; Soto-Ares, G; Vantyghem, MC; Wemeau, JL | 1 |
| Brusa, L; Galati, S; Izzi, F; Marciani, MG; Pasqualetti, P; Pierantozzi, M; Placidi, F; Romigi, A; Sperli, F; Stanzione, P | 1 |
| Barbieri, F; Culler, MD; Dong, J; Dufour, H; Feelders, RA; Florio, T; Gunz, G; Hofland, LJ; Jaquet, P; Moreau, JP; Saveanu, A; Spaziante, R; Stalla, GK; Taylor, JE; Theodoropoulou, M; van Koetsveld, PM; Zona, G | 1 |
| Bax, JJ; Delgado, V; Feelders, RA; Holman, ER; Kars, M; Pereira, AM; Romijn, JA; Smit, JW | 1 |
| Aris-Jilwan, N; Beauregard, H; Delorme, S; Garfield, N; Houde, G; Kahtani, N; Rivera, J; Santagata, P; Serri, K; Serri, O; Vallette, S | 1 |
| Atkin, SL; Clark, AL; Kallvikbacka-Bennett, A; Rigby, AS; Wakil, A | 1 |
| Ferrario, JE; Gershanik, OS; Larramendy, C; Murer, MG; Saborido, MD; Taravini, IR | 1 |
| Bolu, E; Kebapcilar, L; Kutlu, M; Sahin, M; Taslipinar, A; Uckaya, G | 1 |
| Borson-Chazot, F; Delemer, B; Jacob, M; Jouanneau, E; Pugeat, M; Raverot, G; Vighetto, A | 1 |
| Colao, A; D'Andrea, M; Di Sarno, A; Gaccione, M; Galderisi, M; Guerra, E; Lerro, G; Lombardi, G; Pardo, M; Pivonello, R | 1 |
| Arda, N; Comlekci, A; Men, S; Yener, S; Yesil, S | 1 |
| Bax, JJ; Kars, M; Pereira, AM; Romijn, JA | 1 |
| Belkhir, S; Di Paolo, T; Dridi, M; Grégoire, L; Meltzer, LT; Morissette, M; Ouattara, B; Samadi, P | 1 |
| Drake, WM; Metcalfe, KA; Moyes, VJ | 1 |
| Hiramoto, T; Kikuchi, A; Onodera, J; Onoue, N; Oumi, M; Sato, T | 1 |
| Pobereskin, L; Vaidya, B; Watt, A | 1 |
| Banerjee, A; Hatfield, EC; Martin, NM; Meeran, K; Tan, T; Williamson, C; Wynne, K | 1 |
| Amano, K; Hori, T; Kawamata, T; Kubo, O; Makino, R; Miki, N; Ono, M; Seki, T; Takano, K | 1 |
| Jin, ZM | 1 |
| Acharya, SV; Bandgar, TR; Gopal, RA; Joshi, SR; Menon, PS; Shah, NS | 1 |
| Cappabianca, P; Colao, A; De Leo, M; De Martino, MC; Faggiano, A; Hofland, LJ; Lamberts, SW; Lombardi, G; Pivonello, R | 1 |
| Camras, C; Crosson, C; Drace, C; Husain, S; Katoli, P; Kelly, CR; McLaughlin, MA; Sharif, NA; Toris, C; Zhan, GL | 1 |
| Beyerbach, M; Dieleman, SJ; Eschricht, FM; Günzel-Apel, AR; Hoppen, HO; Koivisto, M; Kramer, S; Mischke, R; Seefeldt, A; Urhausen, C | 1 |
| Blevins, LS; Byrd, BF; Devin, JK; Lakhani, VT | 1 |
| Buchfelder, M | 1 |
| Chung, TT; Drake, WM; Higham, CE; Lawrance, J; Trainer, PJ | 1 |
| Burri, E; Nüesch, R; Zulewski, H | 1 |
| Endo, T; Kawamura, S; Maruta, M; Sakai, A | 1 |
| Abdelmassih, R; Abdelmassih, S; Abdelmassih, V; Carizza, C; Jine, LT; Nagy, P; Ravizzini, P; Salgueiro, L; Salgueiro, PT | 1 |
| Doi, K; Isono, T; Kawamura, T; Kitagawa, N; Kuno, S; Masaki, M; Mizuta, E; Oeda, T; Sawada, H; Taniguchi, S; Yaku, H; Yamamoto, K; Yutani, C | 1 |
| Binder, S; Deuschl, G; Volkmann, J | 1 |
| Chau, KY; Cooper, JM; Korlipara, LV; Schapira, AH | 1 |
| Becher, H; Herring, N; Karavitaki, N; Szmigielski, C; Wass, JA | 1 |
| Korchounov, AM | 1 |
| Arai, H; Hatta, K; Hattori, N; Ishikawa, K; Kamigaichi, R; Kubo, S; Mochizuki, H; Ogaki, K; Usui, C; Yokoyama, K | 1 |
| Angelini, F; Barini, A; Bianchi, A; de Marinis, L; Fusco, A; Lauriola, L; Lugli, F; Maira, G; Pontecorvi, A; Sacco, E; Tilaro, L; Tofani, A | 1 |
| Bouma, BJ; de Jong, JS; Rietveld, K; van Lochem, LT | 1 |
| Caldas, D; Colao, A; Costa, FS; Fontes, R; Gaccione, M; Lamounier Filho, A; Loureiro, CR; Naliato, EC; Schrank, Y; Violante, AH | 1 |
| Andersohn, F; Garbe, E | 1 |
| Ballarino, C; Becu-Villalobos, D; Cristina, C; Mallea-Gil, MS; Perez-Millan, MI; Stalldecker, G; Villafañe, AM | 1 |
| Sherlock, M; Steeds, R; Toogood, AA | 1 |
| Carda, C; García-Velasco, JA; Noguera, I; Novella-Maestre, E; Pellicer, A; Ruiz-Saurí, A; Simón, C | 1 |
| Agha, A; Behan, LA; Crowley, RK; Draman, MS; King, T; Moran, C; O'Sullivan, EP; Smith, D; Thompson, CJ | 1 |
| Conaglen, HM; Conaglen, JV | 1 |
| Abs, R; Daems, T; Delgrange, E; Maiter, D; Verhelst, J | 1 |
| Genís-Batlle, D; Haro-Estarriol, M; Obrador-Lagares, A; Rodríguez-Jerez, F; Sabater-Talaverano, G; Sendra-Salillas, S | 1 |
| Ahmadiantehrani, S; Bartlett, SE; Carnicella, S; He, DY; Janak, PH; Nielsen, CK; Ron, D | 1 |
| Falhammar, H; Yarker, JY | 1 |
| Kulisevsky, J; Martinez-Corral, M; Pagonabarraga, J | 1 |
| Bogazzi, F; Lombardi, M; Manetti, L; Martino, E; Raffaelli, V; Rossi, G | 1 |
| Martin, NM; Meeran, K; Tan, T | 1 |
| Fujioka, S; Iwamoto, K; Kawamura, M; Nakajima, M; Ohno, H | 1 |
| Courtney, HC; Hunter, SJ; Johnston, PC; Mc Cance, DR | 1 |
| Kulstad, R; Kuo, JS; Shenker, Y | 1 |
| Kharlip, J; Salvatori, R; Wand, GS; Yenokyan, G | 1 |
| Albuquerque, LA; Almeida, JP; Ferraz, CL; Ferraz, TM; Gondim, J; Mota, I | 1 |
| Dhanwal, DK; Sharma, AK | 1 |
| Pullan, PT | 1 |
| Bridgman, P; Cawood, TJ; Cole, D; Hunter, L | 1 |
| Garcia-Velasco, JA | 1 |
| Ryan, FJ; Spinks, JJ | 1 |
| Bronstein, MD; Jallad, RS | 1 |
| Biller, BM; Grinspoon, S; Klibanski, A; Lawson, EA; Lo, J; McCarty, D; Miller, KK; Nachtigall, LB; Passeri, J; Utz, A; Valassi, E | 1 |
| Gorgulu, C; Ozkurt, H; Tufaner, O | 1 |
| Ata, B; Orhaner, S; Seyhan, A; Urman, B | 1 |
| Amols, MH; Coddington, CC; Hudson, SBA; Rollene, NL | 1 |
| Dastranj-Tabrizi, A; Farzadi, L; Gatrehsamani, F; Kazemi-Shishvan, M; Morteza, G; Ouladesahebmadarek, E; Sayyah-Melli, M; Tehrani-Gadim, S | 1 |
| Bhattacharyya, S; Davar, J; Mikhailidis, DP; Schapira, AH | 1 |
| Matsuno, A | 1 |
| Bahuleyan, B; Easwer, HV; Krishna, K; Menon, G; Nair, S; Rao, BR | 1 |
| Ballabio, R; Gelli, D; Milani, C; Mollo, A; Perin, S; Romagnoli, S; Stelletta, C | 1 |
| Arias, D; Barrena, JP; Blanco, PG; Corrada, Y; Gobello, C; Rube, A | 1 |
| Einspanier, A; Günzel-Apel, AR; Höftmann, T; Hoppen, HO; Knijn, HM; Meyer-Lindenberg, A; Mischke, R; Nottorf, S; Politt, E | 1 |
| Beyerbach, M; Eschricht, F; Günzel-Apel, AR; Hoppen, HO; Koivisto, MB; Oei, CH; Urhausen, C | 1 |
| Cho, EH; Cho, YH; Chung, JY; Kim, CJ; Kim, JH; Kim, MS; Koh, EH; Lee, SA | 1 |
| Mishra, AK; Mishra, P; Misra, A; Sharma, G | 1 |
| Hwang, JL; Lin, YH; Seow, KM | 1 |
| Schteingart, DE | 1 |
| Agra, R; Albuquerque, JL; Arahata, CM; Arruda, MJ; Azevedo, MF; Canadas, V; Montenegro, L; Moura E Silva, L; Naves, LA; Pontes, L; Vilar, L | 1 |
| Colao, A; Loche, S | 1 |
| Cervantes, CE; Da Costa, CV; Hernando, CA; Vargas, ML | 1 |
| Ambrosio, MR; Buratto, M; Degli Uberti, EC; Filieri, C; Lapparelli, M; Minoia, M; Scanarini, M; Tagliati, F; Zatelli, MC | 1 |
| Ajitkumar, G; Ghosh, KN; Mercy, KA; Praseeda, R; Sreekumaran, T | 1 |
| Serri, K; Serri, O; Vallette, S | 1 |
| Bélanger, N; Di Paolo, T; Hadj Tahar, A; Morissette, M; Samadi, P | 1 |
| Coiré, CI; Horvath, E; Kovacs, K; Rosso, D; Smyth, HS | 1 |
| Cramer, MJ; Lafeber, M; Stades, AM; Teding van Berkhout, F; Valk, GD; Zelissen, PM | 1 |
| Albuquerque, JL; Azevedo, MF; Boguszewski, CL; Bronstein, MD; Casulari, LA; de Oliveira, AR; Dos Santos Faria, M; Gadelha, MR; Montenegro, RM; Musolino, NR; Naves, LA; Pinho Barbosa, FR; Ramos, AJ; Serfaty, FM; Vilar, L | 1 |
| Boissevain, I | 1 |
| Arany, E; Becu-Villalobos, D; Chamson-Reig, A; García-Tornadú, I; Hill, DJ; Ornstein, AM; Rubinstein, M; Wheeler, MB | 1 |
| Atis, A; Aydin, Y; Goker, N; Kaleli, S; Uludağ, S | 1 |
| Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Hoyer, D; Morissette, M; Ouattara, B | 1 |
| Amano, K; Hori, T; Izumi, S; Kawamata, T; Makino, R; Miki, N; Okada, Y; Ono, M; Seki, T; Takano, K | 1 |
| Klibanski, A | 1 |
| Marinov, B | 1 |
| Chen, K; Fei, Z; Imachi, H; Ishida, T; Iwama, H; Murao, K; Tamiya, T; Zhang, W; Zhang, X | 1 |
| Arioz, DT; Dilek, H; Koken, T; Saylan, A; Saylan, F; Yilmazer, M | 1 |
| Bhadada, S; Bhansali, A; Dutta, P; Khandelwal, N; Sialy, R; Walia, R | 2 |
| Bernard, P; Hubinont, C; Lebbe, M; Maiter, D | 1 |
| Bahceci, M; Sismanoglu, A; Ulug, U | 1 |
| de Bruin, C; de Herder, WW; de Jong, FH; Feelders, RA; Hermus, AR; Hofland, LJ; Lamberts, SW; Netea-Maier, RT; Pereira, AM; Romijn, JA; van der Lely, AJ; van Heerebeek, R; Zelissen, PM | 1 |
| De La Peña Zarzuelo, E; Hernández Cañas, V; Llorente Abarca, C | 1 |
| Balasch, J; Castelo-Branco, C; Martinez, MJ | 1 |
| Babakhani, L; Fereshtehnejad, SM; Mojthahedi, K; Motazedian, S | 1 |
| Chiba, S; Kunugi, H; Ninomiya, M; Numakawa, T; Yoon, HS | 1 |
| Baynes, KC; Cabrita, IZ; Dhillo, WS; Eliahoo, J; Grogono, J; Hensman, D; Martin, NM; Meeran, K; Nihoyannopoulos, P; Robinson, S; Tan, T | 1 |
| Barbosa, FR; Domingues, RC; dos Santos Silva, CM; Fontes, R; Gadelha, MR; Lima, GA; Warszawski, L | 1 |
| Balcik, O; Buyukbayrak, EE; Karageyim Karsidag, AY; Kars, B; Pirimoglu, M; Turan, C; Unal, O | 1 |
| Carda, C; Garcia-Velasco, JA; Novella-Maestre, E; Pellicer, A; Ruiz-Sauri, A; Simon, C | 1 |
| Bidlingmaier, M; Gutt, B; Roemmler, J; Schneider, HJ; Schopohl, J; Sievers, C; Steffin, B | 1 |
| Balzaretti, M; Carrizo, A; Christiansen, S; Fainstein Day, P; Glerean, M; Kozak, A; Lovazzano, S; Pietrani, M | 1 |
| Gittoes, NJ; Harries, AM; Mitchell, RD | 1 |
| Alberiche Ruano, M; Boronat Cortés, M; Gracía Nuñez, M; Marrero Arencibia, D; Novoa Mogollón, FJ; Ojeda Pino, A; Rodriguez Perez, C | 1 |
| Bertrand, A; Marabelle, A; Marec-Berard, P; Raverot, G; Trouillas, J | 1 |
| Bosco, D; Bosco, F; Consoli, A; Plastino, M; Rotondo, A | 1 |
| Alfieri, A; Ballarino, MC; Boero, L; Chervin, A; Danilowicz, K; Diez, S; Fainstein-Day, P; García-Basavilbaso, N; Glerean, M; Gollan, V; Guitelman, M; Katz, D; Loto, MG; Mallea-Gil, MS; Manavela, M; Rogozinski, AS; Servidio, M; Stalldecker, G; Vitale, NM | 1 |
| Benjamin, J; Chawda, S; Nkonge, FM; Sharif, DA; Stojanović, ND | 1 |
| Beauregard, H; Bruno, OD; Danilowicz, K; Godbout, A; Lacroix, A; Manavela, M | 1 |
| Benbassat, C; Grozinsky-Glasberg, S; Shimon, I; Tzvetov, G | 1 |
| Abucham, J; Alves Martins, MR; Mattar, P | 1 |
| Beckers, A; Petrossians, P; Thonnard, AS | 1 |
| Burger, P; Menucci, M; Quiñones-Hinojosa, A; Salvatori, R | 1 |
| Albuquerque, JL; Azevedo, MF; Casulari, LA; Faria, MS; Figueiredo, P; Montenegro, RM; Nascimento, GC; Naves, LA; Vilar, L | 1 |
| Bianchi, A; Carrozza, C; D'Ercole, M; Della Pepa, GM; Doglietto, F | 1 |
| Beuls, EA; Cornips, EM; Kubben, PL; Looij, BJ | 1 |
| Freudenmann, RW; Gahr, M; Kölle, MA | 1 |
| Carroll, PV; Chambers, J; Gu, H; Luck, S; Powrie, J | 1 |
| Cevik, C; Feray, H; Izgi, C; Mansuroglu, D; Nugent, K; Saltan, Y | 1 |
| Boguszewski, CL; dos Santos Nunes, V; El Dib, R; Nogueira, CR | 1 |
| Chanson, P; Maison, P; Sandret, L | 1 |
| Harrisson, SE; Mathad, NV; Zaben, MJ | 1 |
| Bourdel, N; Delabaere, A; Jardon, K; Pouly, JL; Tran, X | 1 |
| Adamidou, F; Anagnostis, P; Efstathiadou, Z; Karathanassi, E; Kita, M; Polyzos, SA | 1 |
| Hornyak, M; Kohnen, R; Kriston, L; Riemann, D; Scholz, H; Trenkwalder, C | 1 |
| Kubota, K; Ooba, N; Yamaguchi, T | 1 |
| Alcázar, JL; Monedero, P; Nagore Setién, D | 1 |
| Agaoglu, AR; Aslan, S; Colak, A; Emre, B; Gultiken, N; Kaya, D; Kucukaslan, I; Mulazımoglu, BS; Schäfer-Somi, S | 1 |
| Boti, V; Ferraris, J; Pisera, D; Radl, DB; Sarkar, DK; Seilicovich, A | 1 |
| Ikeda, S; Ishizaki, T; Morikawa, K; Nakaoka, S; Nakayama, T; Satoh, T; Urushihara, H | 1 |
| Di Paolo, T; Morissette, M; Parent, M; Riahi, G | 1 |
| Gmeiner, P; Hübner, H; Kekewska, A; Pertz, HH | 1 |
| Bötzel, K; Levin, J; Näbauer, M; Neudert, J; Zwermann, L | 1 |
| Díez, JJ; Iglesias, P | 2 |
| Delgado-Rosas, F; Ferrero, H; Gaytan, F; Gaytan, M; Gómez, R; Morales, C; Pellicer, A; Simón, C; Zimmermann, RC | 1 |
| Astaf'eva, LI; Kadashev, BA; Kalinin, PL; Kutin, MA | 1 |
| Connemann, BJ; Gahr, M; Schönfeldt-Lecuona, CJ | 1 |
| Finestone, AJ | 1 |
| Azevedo, M; Boguszewski, CL; de Souza, AM; dos Santos, CM; Marini, LC; Sakamoto, KS | 1 |
| Barbieri, F; Culler, MD; Ferone, D; Florio, T; Gatti, M; Gatto, F; Giusti, M; Hofland, LJ; Minuto, F; Ravetti, JL; Saveanu, A; Schulz, S; Wurth, R; Zona, G | 1 |
| Delgado-Rosas, F; Ferrero, H; Garcia-Velasco, J; Gaytan, F; Gómez, R; Pellicer, A; Simón, C | 1 |
| DeCubellis, J; Donnelly, T; Kiupel, M; Mayer, J; Sato, A | 1 |
| Ceballos-Baumann, AO; Fietzek, UM; Riedl, L | 1 |
| Bernard, N; Descotes, J; Gillet, A; Gouraud, A; Mirkou, A; Suchovsky, D; Vial, T | 1 |
| Akutsu, H; Matsumura, A; Sato, H; Takano, S; Watanabe, S | 1 |
| Bruno, OD; Danilowicz, K; Manavela, MP | 1 |
| Gibson, CD; Karmally, W; Korner, J; McMahon, DJ; Wardlaw, SL | 1 |
| Annamalai, AK; Antoun, NM; Dash, S; Mannion, R; Sarkies, N; Simpson, HL | 1 |
| Brophy, JM; Dell'Aniello, S; Renoux, C; Suissa, S | 1 |
| Arlt, S; Drillich, M; Fischer-Tenhagen, C; Heuwieser, W; Reinecke, A | 1 |
| Hooijberg, E; Kirtz, G; Leidinger, E; Reinelt, B; Sick, K | 1 |
| Castro-Castro, J; Pastor-Zapata, A; Pinzón-Millán, A; Torre-Eiriz, JA | 1 |
| Brioschi, A; Mauro, A; Pignatti, R; Semenza, C; Wenter, J; Zamarian, L | 1 |
| Arabipoor, A; Aziminekoo, E; Bahmanabadi, A; Chehrazi, M; Hafezi, M; Tehraninejad, ES | 1 |
| Cottier, JP; François, P; Gilbert-Dussardier, B; Girard, JJ; Jan, M; Lecomte, P; Richard, S; Trouillas, J; Tudorancea, A | 1 |
| Atkinson, AB; Aylwin, S; Bidlingmaier, M; Drake, WM; Higham, CE; Lewis, A; Martin, NM; Moyes, V; Newell-Price, J; Trainer, PJ | 1 |
| de Bruin, C; de Herder, WW; de Jong, FH; de Maat, MP; Feelders, RA; Hermus, AR; Hofland, LJ; Lamberts, SW; Leebeek, FW; Netea-Maier, RT; Pereira, AM; Rijken, DC; Romijn, JA; van der Lely, AJ; van der Pas, R; Zelissen, PM | 1 |
| Albarran-Zeckler, R; Kern, A; Smith, RG; Walsh, HE | 1 |
| Abad, A; Aller, J; Batista, E; Doltra, A; García-Pavía, P; Halperin, I; Lucas, T; Mirelis, JG; Mora, M; Puig-Domingo, M; Santos, AE; Sitges, M; Varela, C | 1 |
| Chatziioannou, S; Filippopoulou, A; Lykouras, L; Peppa, M; Rizos, E; Tsigkaropoulou, E; Xelioti, I; Zompola, C | 1 |
| Hart, RJ; Hu, Y; Hunter, T; Sheng, X; Tang, H; Zhai, SD | 1 |
| Barlier, A; Couderc, B; Cuny, T; Defilles, C; Enjalbert, A; Figarella-Branger, D; Germanetti, AL; Graillon, T; Mohamed, A; Roche, C; Saveanu, A | 1 |
| Ambrosio, MR; Buratto, M; degli Uberti, E; Filieri, C; Frank, G; Gagliano, T; Lapparelli, M; Minoia, M; Tagliati, F; Zatelli, MC; Zoli, M | 1 |
| Fukuoka, S; Kawahara, S; Kimoto, N; Ogawa, N; Tanaka, K | 1 |
| Alvarez-Escolá, C; Bernabeu, I; Cabezas-Agrícola, JM; Casanueva, FF; Lucas, T; Marazuela, M; Paniagua, AE; Pavón, I | 1 |
| Malkani, S; Mehta, NK; Ockene, I | 1 |
| Cedersmyg, M; Eld, K; Ernholm, L; Hallgren, G; Holst, BS; Löfqvist, K | 1 |
| Maiter, D; Primeau, V | 1 |
| Nak, D; Nak, Y; Simsek, G | 1 |
| Elenkova, A; Kalinov, K; Shabani, R; Zacharieva, S | 1 |
| Utsumi, H | 1 |
| Bini, V; Bortolato, M; Cannas, A; Marrosu, F; Puligheddu, M; Solla, P | 1 |
| Berardini, A; Biagini, E; Graziosi, M; Pazzi, C; Rapezzi, C; Rosmini, S | 1 |
| Bilge, A; Kurtulmus, N; Yarman, S | 1 |
| Bussone, G; Moschiano, F; Usai, S | 1 |
| Athanasoulia, AP; Brockhaus, AC; Ising, M; Sievers, C; Stalla, GK; Uhr, M; Yassouridis, A | 1 |
| George, S; Jones, HB | 1 |
| Aleyasin, A; Bahmaee, F; Hosseini, MA; Mahdavi, A; Safdarian, L | 1 |
| Anholm, C; Baltzar, MT; Petersen, CD | 1 |
| Assayag, P; Bouchachi, A; Chanson, P; Garcia, C; Kallel, N; Maione, L; Maison, P; Salenave, S; Young, J | 1 |
| Giampietro, A; Iacovazzo, D; Lugli, F | 1 |
| Azevedo, MF; Casulari, LA; de Castro, LF; Garcia, EC; Naves, LA; Silva, AO | 1 |
| Ahmed, A; Furqan, S; Islam, N | 1 |
| Peregrin Abad, E; Salinas Botrán, A; Urgelés Puértolas, D | 1 |
| Machicado, JD; Orlander, PR; Varghese, JM | 1 |
| Aurora, RN; Bista, SR; Casey, KR; Kristo, DA; Lamm, CI; Rosenberg, RS; Rowley, JA; Tracy, SL; Zak, RS | 1 |
| Cobo, J; Coronas, R; Giménez-Palop, O; Márquez, M; Ortega, E | 1 |
| Beck-Peccoz, P; Beckers, A; Borson-Chazot, F; Brue, T; Caron, P; Chanson, P; Ciccarelli, E; Daly, AF; Delemer, B; Gatta, B; Jaffrain-Rea, ML; Naves, LA; Petrossians, P; Tamagno, G; Vilar, L; Vroonen, L | 1 |
| Carda, C; Herraiz, S; Novella-Maestre, E; Pellicer, A; Ruiz-Sauri, A; Vila-Vives, JM | 1 |
| Deukmedjian, AR; Hann, S; Morrison, AD; Shah, V; Vale, FL | 1 |
| Shaltout, A; Shohyab, A; Youssef, MA | 1 |
| Barahona Constanzo, MJ; del Pozo Picó, C | 1 |
| Bancroft, T; Burton, T; Le Nestour, E; Neary, M | 1 |
| Fatemi, SS; Rokni, H; Taghavi, SM | 1 |
| Creatsas, G; Kalampokas, E; Kalampokas, T | 1 |
| Shahzad, H; Sheikh, A; Sheikh, L | 1 |
| Ahtiainen, P; Calandra, RS; Di Giorgio, NP; Gonzalez, B; Huhtaniemi, IT; Poutanen, M; Ratner, LD; Rulli, SB | 1 |
| Auriemma, RS; Colao, A; Di Sarno, A; Gasperi, M; Grasso, LF; Guerra, E; Perone, Y; Pivonello, R | 1 |
| Bellgrove, MA; Dean, AJ; Hester, R; Honeysett, A; Messer, C; Nandam, LS; Nathan, PJ; Wagner, J | 1 |
| Alkabbani, A; Doshi, K; Hamrahian, A; Hatipoglu, B; Kennedy, L; Makin, V; Mon, SY; Olansky, L; Thorton, JN; Weil, R | 1 |
| Byrne, JV; Dobrescu, R; Grossman, AB; Karavitaki, N; Wass, JA | 1 |
| Bilal, L; Ching, C | 1 |
| de Bruin, C; de Herder, WW; de Jong, FH; Feelders, RA; Hermus, AR; Hofland, LJ; Lamberts, SW; Netea-Maier, RT; Pereira, AM; Romijn, JA; van der Lely, AJ; van der Pas, R; Webb, SM; Zelissen, PM | 1 |
| Bath, L; Cackett, P; Eunson, G; Mulvihill, A | 1 |
| Cakir, B; Caner, S; Ersoy, R; Inancli, SS; Tam, AA; Usluogullari, A; Ustu, Y | 1 |
| Fukuoka, H; Iguchi, G; Inoshita, N; Nishizawa, H; Suda, K; Takahashi, M; Takahashi, Y; Yamada, S; Yamamoto, M | 1 |
| Anand, KS; Dhikav, V | 1 |
| Bianchi, A; De Marinis, L; Doglietto, F; Giampietro, A; Iacovazzo, D; Lauriola, L; Lucci-Cordisco, E; Lugli, F; Milardi, D | 1 |
| Abaci, A; Altincik, A; Bober, E; Buyukgebiz, A; Can, S; Catli, G; Demir, K | 1 |
| Bhadada, SK; Bhansali, A; Dutta, P; Gupta, V; Rastogi, A; Sachdeva, N; Singh, P; Vijaivergiya, R; Walia, R | 1 |
| Hashida, H; Hattori, N; Iijima, M; Kano, O; Kubo, S; Matsumura, M; Murakami, H; Nanri, K; Okuma, Y; Suzuki, M; Suzuki, Y; Tomimitsu, H; Utsumi, H | 1 |
| Albiger, N; Barbot, M; Ceccato, F; Denaro, L; Frigo, AC; Mantero, F; Scaroni, C; Zilio, M | 1 |
| Ikeda, H; Tominaga, T; Watanabe, K; Yoshimoto, T | 1 |
| Barake, M; Biller, BM; Evins, AE; Klibanski, A; Miller, KK; Nachtigall, LB; Pachas, GN; Stoeckel, L; Tritos, NA | 1 |
| Amato, MC; Ciresi, A; Giordano, C; Guarnotta, V; Lo Castro, F | 1 |
| Agúndez, JA; Alonso-Navarro, H; García-Martín, E; Jiménez-Jiménez, FJ | 1 |
| Beuthien-Baumann, B; Grählert, X; Herting, B; Kotzerke, J; Löhle, M; Oehme, L; Perick, M; Reichmann, H; Schwanebeck, U; Storch, A; van den Hoff, J; Wolz, M | 1 |
| Chen, HJ; Hsieh, BC; Huang, LW; Huang, MZ; Hwang, JL; Lin, YH; Seow, KM; Tzeng, CR | 1 |
| Bai, CH; Chen, HJ; Hsieh, BC; Huang, LW; Hwang, JL; Lin, YH; Seow, KM; Tzeng, CR | 1 |
| Rettinger, G; Rotter, N; Scheithauer, M; v Bomhard, A | 1 |
| Gadelha, MR; Moraes, AB; Silva, CM; Vieira Neto, L | 1 |
| Bozdag, G; Esinler, I; Karakocsokmensuer, L | 1 |
| Cinar, O; Dilbaz, S; Duraker, R; Guvendag Guven, ES; Mentese, A; Ozdegirmenci, O | 1 |
| Ariano, C; De Vecchis, R; Esposito, C | 1 |
| Nakakuki, T; Nanba, K; Shimatsu, A; Usui, T | 1 |
| Benbassat, C; Shimon, I | 1 |
| Krysiak, R; Okopien, B | 2 |
| Anastasiou, A; Christoforidis, A; Dimitriadou, M; Pavlaki, A; Tsakalides, C | 1 |
| Fleseriu, M | 1 |
| Nieman, LK | 1 |
| Auriemma, RS; Colao, A; Ferreri, L; Gasperi, M; Grasso, LF; Iacuaniello, D; Perone, Y; Pivonello, R; Simeoli, C | 1 |
| Arvanitakis, P; Dimopoulou, K; Kalkavoura, CS; Lykouras, L; Michopoulos, I; Theodoropoulou, P; Tzebelikos, E | 1 |
| Deveer, R; Engin-Ustun, Y; Moraloglu, O; Timur, H; Ustun, Y; Yılmaz, N; Yılmaz, S | 1 |
| Ehsanipoor, RM; Woo, I | 1 |
| Husain, M; Manohar, S; Norbury, A; Rogers, RD | 1 |
| Andrés, M; Expósito, A; Matorras, R; Mendoza, R; Pijoan, JI; Prieto, B | 1 |
| Gürbüz, BB; Gürbüz, F; Kör, Y; Küpeli, S; Yağcı-Küpeli, B; Yüksel, B; Zorludemir, S | 1 |
| Bucolo, C; Drago, F; Leggio, GM; Platania, CB; Salomone, S | 1 |
| Castillo-Huerta, E; Garibay-Valencia, M; Mirabent-González, F | 1 |
| Arnez, L; Biagetti, B; Dalama, B; Mesa, J; Obiols, G; Valladares, S | 1 |
| Beckers, A; Daly, A; Vroonen, L | 1 |
| Góth, M | 1 |
| Baltacıoğlu, F; Cebeci, AN; Dursun, F; Güven, A; Kırmızıbekmez, H | 1 |
| Auriemma, RS; Colao, A; Kwancharoen, R; Salvatori, R; Wand, GS; Yenokyan, G | 1 |
| Chng, E; Dalan, R | 1 |
| Gadelha, MR; Vieira Neto, L | 1 |
| Cuevas, JL; Fernández, V; González, O; Rojas, D; Torche, E; Wohllk, N | 1 |
| Danser, AH; de Bruin, C; Feelders, RA; Hofland, LJ; Lamberts, SW; Netea-Maier, R; Pereira, AM; Sprij-Mooij, DM; van den Berg-Garrelds, IM; van den Meiracker, AH; van der Pas, R; van Esch, JH; van Schaik, RH; Zelissen, PM | 1 |
| Abreu, A; Albarrán, AA; Carrasco, CA; Espinosa de los Monteros, AL; Gadelha, M; Mercado, M | 1 |
| Chang, TJ; Huang, TS; Kao, YH | 1 |
| Bevan, JS; Drake, WM; Howlett, TA; Steeds, RP; Stiles, CE; Toogood, AA | 1 |
| Abucham, J; Boguszewski, C; Dias, M; Gadelha, M; Kasuki, L; Musolino, N; Vieira, JG | 1 |
| Hwang, JH; Hwang, SK; Kim, S; Park, KS; Park, SH | 1 |
| Hisanaga, R; Nakamura, M; Nomoto, S; Sato, T | 1 |
| Jensen, TS; Jørgensen, JO; Kallestrup, MM; Kasch, H; Nielsen, E; Østerby, T | 1 |
| Auriemma, RS; Colao, A; Galdiero, M; Gasperi, M; Giordano, C; Granieri, L; Mannarino, T; Negri, M; Perone, Y; Pivonello, C; Pivonello, R; Simeoli, C; Vitale, P | 1 |
| Leitao, VM; Martins, WP; Moroni, RM; Nastri, CO; Seko, LM | 1 |
| Camera, L; Carratù, A; Colao, A; de Luca di Roseto, C; Del Prete, M; Di Somma, C; Faggiano, A; Marciello, F; Marotta, V; Ramundo, V | 1 |
| Bakoto, N; Baleriaux, D; Boscolo, M; Corvilain, B; Devuyst, F | 1 |
| Canpolat, U; Elibol, B; Ozer, N; Yorgun, H | 1 |
| Descamps, P; Jeanneteau, P; Mercier, MB; Parot-Schinkel, E; Sentilhes, L | 1 |
| Gadelha, MR; Kasuki, L; Vieira Neto, L | 1 |
| Fuentes Uliaque, C; Fustero de Miguel, D; Moles Herbera, J; Montejo Gañan, I; Rivero Celada, D; Vela Marín, AC | 1 |
| Bernabeu, I; Marazuela, M; Ramos-Leví, A; Sampedro-Núñez, M | 1 |
| Chen, T; Feng, BS; Geng, XR; Liu, C; Liu, Z; Sun, M; Wu, R; Wu, W; Yang, G; Yang, PC; Zhang, HP | 1 |
| Aller, J; Alvarez-Escolá, C; Bernabeu, I; Biagetti, B; Blanco, C; Cámara, R; Castells, I; Fajardo, C; García, R; Gaztambide, S; Mora, M; Picó, A; Pozo, CD; Resmini, E; Salinas, I; Sesmilo, G; Soto, A; Torres, E; Villabona, C; Webb, SM | 1 |
| Andersen, M; Dal, J; Jørgensen, JO; Kistorp, C; Laurberg, P; Mægbæk, ML; Nørrelund, H; Steffensen, C | 1 |
| Du, Y; Lin, XM; Ma, YS; Ni, J; Tang, YY; Zhou, J | 1 |
| Benbassat, C; Lifshitz, A; Shimon, I; Tirosh, A | 1 |
| Barkan, A; Benbassat, C; Bronstein, MD; Shapiro, J; Shimon, I; Tsvetov, G | 1 |
| Macdonald, BK; Premaratne, VS; Saeger, I | 1 |
| Elzaher, MA; Hamid, AM; Madkour, WA; Moawad, A; Roberts, MP | 1 |
| Barambio-Ruíz, M; Córdoba-Soriano, JG; Hidalgo-Olivares, VM; Lamas-Oliveira, C; Salas-Nieto, J; Tercero-Martínez, A | 1 |
| Figueroa-Núñez, C; González, E; Gutierrez, M; Hernán Martínez, J; Mangual-García, M; Mansilla-Letelier, P; Miranda, Mde L; Palermo-Garofalo, C; Sánchez, A; Santiago, M; Torres, O; Trinidad, R | 1 |
| Bonadei, I; Curnis, A; D'Aloia, A; Metra, M; Piovanelli, B; Rovetta, R; Vizzardi, E | 1 |
| Ikeda, S; Ishizaki, T; Nakaoka, S; Nakayama, T; Satoh, T; Urushihara, H; Yamamoto, M | 1 |
| Adachi, N; Inoue, T; Katanuma, Y; Kunugi, H; Nakajima, S; Numakawa, T; Odaka, H; Ooshima, Y | 1 |
| Marek, J | 1 |
| Ezzat, S; Samson, SL | 1 |
| Bronstein, MD; Glezer, A | 1 |
| Hamrahian, AH; Hoffman, AR; Yuen, KC | 1 |
| Câmara, VL; Costa, EM; Cunha, FS; Domenice, S; Gooren, LJ; Mendonça, BB; Sircili, MH | 1 |
| Alhowsawi, G; Aljohani, N; Almalki, MH; Alshahrani, F; Alsherbeni, S; Alzahrani, S; Buhary, B | 1 |
| Schäfer-Somi, S; Schwendenwein, I; Sontas, BH | 1 |
| Beketić-Orešković, L; Ježek, D; Kasum, M; Orešković, S; Pekez, M; Stanić, P; Vrčić, H | 1 |
| Ehlen, JC; Jefferson, F; Montemarano, JJ; Paul, KN; Williams, NS | 1 |
| Asicioglu, O; Aydin, K; Kucur, S; Temizkan, O; Temizkan, S | 1 |
| Bogazzi, F; Cosottini, M; Lombardi, M; Lupi, I; Manetti, L; Martino, E; Raffaelli, V; Rossi, G; Sardella, C | 1 |
| Bianchini, E; Bramanti, P; Cilia, R; Ciurleo, R; de Luise, C; Di Lorenzo, G; Ilardi, M; Italiano, D; Pezzoli, G; Polimeni, G; Rijnbeek, P; Ross, D; Stocchi, F; Sturkenboom, M; Trifirò, G; Vacca, L; Zanettini, R | 1 |
| Abe, H; Ebihara, K; Funahashi, H; Ikeda, T; Ishida, Y; Koganemaru, G; Kuramashi, A; Matsuo, H; Nishimori, T; Yasuda, K | 1 |
| Ball, RL; Brown, JL; Morfeld, KA | 1 |
| Cleemann, L; Holm, K; Jarløv, AE; Lewis, A | 1 |
| Eglash, A | 1 |
| Bath, K; Cavanagh, JF; Frank, MJ; Masters, SE | 1 |
| Aydogan, U; Cengiz, M; Ercan, CM; Ergun, A; Ide, T; Kayaalp, O; Keskin, U; Yumusak, N | 1 |
| Fujii, S; Kambe, A; Kurosaki, M; Ogawa, T; Watanabe, T | 1 |
| Colli, LM; de Castro, M; Gadelha, MR; Gasparetto, EL; Kasuki, L; Marques, NV; Moraes, AB; Takiya, CM; Vieira Neto, L; Wildemberg, LE | 1 |
| Akbaba, G; Arduc, A; Aydin, Y; Berker, D; Gokay, F; Guler, S; Isik, S; Kucukler, FK; Ozuguz, U; Tutuncu, Y | 1 |
| Caputo, C; Inder, WJ; Prior, D | 1 |
| Amital, H; Jeandel, PY; Shoenfeld, Y; Versini, M; Watad, A | 1 |
| Colao, A; Faggiano, A; Modica, R | 1 |
| Hu, J; Yang, H; Zhang, W; Zheng, X | 1 |
| Angelova, M; Kacarova, P; Kozovski, G | 1 |
| Auriemma, RS; Cariati, F; Colao, A; Coppola, G; de Angelis, C; Ferreri, L; Galdiero, M; Granieri, L; Lo Calzo, F; Pivonello, C; Pivonello, R; Salzano, C; Vitale, P | 1 |
| Akdogan, A; Akman, L; Aktug, H; Erbas, O; Goker, EN; Sahin, G; Taskiran, D; Tavmergen, E | 1 |
| Elenkova, A; Gerenova, J; Hristozov, K; Kalinov, K; Kamenov, Z; Kirilov, G; Marinov, M; Natchev, E; Orbetzova, M; Tcharaktchiev, D; Tsinlikov, I; Vandeva, S; Yaneva, M; Zacharieva, S | 1 |
| Chanson, P | 1 |
| Cámara Gómez, R; Del Olmo García, M; Merino Torres, JF; Querol Ripoll, R; Simal Julián, JA | 1 |
| Auriemma, RS; Colao, A; Ferreri, L; Pivonello, R; Priscitelli, P | 1 |
| Evran, S; Hanimoglu, H; Ilhan, MM; Kaynar, MY; Tasan, E; Turgut, S | 1 |
| Bronstein, MD; Fleseriu, M; Greenman, Y; Jallad, RS; Shimon, I; Yedinak, CG | 1 |
| Gille, G; Meinel, J; Radad, K; Rausch, WD; Reichmann, H | 1 |
| Ahluwalia, A; Deng, X; Ostapchenko, L; Paunovic, B; Prysiazhniuk, A; Sandor, Z; Szabo, S; Tarnawski, A; Tolstanova, G | 1 |
| Baumgarten, E; Connemann, B; Feneberg, E; Gahr, M; Merger, S; Özpeynirci, Y; Schönfeldt-Lecuona, C | 1 |
| Couldwell, WT; Eloy, JA; Liu, JK; Wong, A | 1 |
| Benbassat, C; Shimon, I; Tirosh, A | 1 |
| Aris, A; Bach, A; De-Prado, A | 1 |
| Galofré, JC; Pascual-Corrales, E; Salvador, J; Tomás Velázquez, A; Zubieta, JL | 1 |
| Adali, E; Balcioğlu, E; Erken, G; Hismiogulları, AA; Taskin, MI; Topcu, O; Yay, A | 1 |
| Krysiak, R; Okopien, B; Okrzesik, J | 1 |
| Ferrero, H; García-Pascual, CM; Gómez, R; Pellicer, A; Pellicer, N; Simón, C | 1 |
| Assayag, P; Bouchachi, A; Brailly-Tabard, S; Chanson, P; Kamenicky, P; Kuhn, E; Maione, L; Rozière, M; Salenave, S; Young, J | 1 |
| Akan, Z; Cengiz, H; Eskicioğlu, F; Sahin, N; Sivrikoz, ON; Turan, GA; Vatansever, S; Yeşil, H; Yilmaz, O; Zafer, A | 1 |
| Cai, L; Cai, Y; Guo, YH; Le, WD; Leng, ZG; Li, N; Lin, SJ; Shang, HB; Wu, ZB; Zhao, WG | 1 |
| Ilhan, M; Kahraman, OT; Karaman, O; Shukurov, S; Tasan, E; Turan, S; Turgut, S; Yaylim, I; Zeybek, U | 1 |
| Anheim, M; Benabid, AL; Chabardès, S; Dowsey-Limousin, P; Krack, P; Pollak, P | 1 |
| Couldwell, WT; Eloy, JA; Hajart, AF; Jethwa, PR; Liu, JK; Patel, TD | 1 |
| Hiratochi, M; Ijiro, T; Kaidoh, K; Oana, F; Suzuki, T; Tsuchioka, A; Yamauchi, Y | 1 |
| Chatterjee, S; Das, A; Maiti, A | 1 |
| Burman, P; Edén-Engström, B; Ekman, B; Karlsson, FA; Schwarcz, E; Wahlberg, J | 1 |
| Broder, MS; Carmichael, JD; Chang, E; Ludlam, WH; Neary, MP | 1 |
| Ahuja, A; Bhardwaj, M; Dutta, D; Kulshreshtha, B; Sharma, L | 1 |
| Lamos, EM; Levitt, DL; Munir, KM | 1 |
| Arduç, A; Berker, D; Doğan, BA; Güler, S; Işık, S; Nasıroğlu, NI; Tuna, MM | 1 |
| Apaydın, N; Cengiz, H; Eskicioğlu, F; Genç, M; Şahin, N; Sivrikoz, ON; Töz, E; Turan, GA | 1 |
| Centini, G; Kashani, BN; Morelli, SS; Petraglia, F; Weiss, G | 1 |
| Dogansen, SC; Selcukbiricik, OS; Tanrikulu, S; Yarman, S | 1 |
| Auriemma, RS; Colao, A; Grasso, LF; Pivonello, R | 1 |
| Başer, H; Çakır, B; Ersoy, R; Kaya, C; Tam, AA | 1 |
| Alfieri, A; Ballarino, MC; Boero, L; Chervin, A; Danilowicz, K; Diez, S; Fainstein Day, P; García-Basavilbaso, N; Glerean, M; Guitelman, M; Katz, D; Loto, MG; Mallea-Gil, MS; Manavela, M; Martinez, M; Miragaya, K; Moncet, D; Rogozinski, AS; Servidio, M; Stalldecker, G; Vitale, M | 1 |
| D'Sylva, C; Fraser, LA; Khan, T; Van Uum, S | 1 |
| Arduc, A; Berker, D; Çiçekcioğlu, H; Demirci, N; Demirtaş, S; Doğan, BA; Güler, S; Tuna, MM | 1 |
| Cengiz, H; Eskicioğlu, F; Genc, M; Gur, EB; Kasap, E; Sivrikoz, ON; Turan, GA; Yılmaz, O | 1 |
| De Pue, A; Lutin, B; Paemeleire, K | 1 |
| Okazaki, K; Sugimoto, T; Takeno, A; Yamaguchi, T; Yamamoto, M | 1 |
| Albrecht, S; Barry, S; Bunce, B; Caswell, R; Ellard, S; Evanson, J; Iacovazzo, D; Jose, S; Korbonits, M; Millette, M; Rodd, C; Roncaroli, F; Sampson, J; Stiles, CE; Trouillas, J | 1 |
| Ishikura, R; Koyama, H; Kurajoh, M; Moriwaki, Y; Namba, M; Okazaki, H; Shiraishi, J; Shirakawa, M; Shoji, T; Yamamoto, T | 1 |
| Bronstein, MD; Espinosa, E; Glezer, A; Greenman, Y; Mendoza, V; Mercado, M; Popovic, V; Shimon, I; Sosa, E; Tirosh, A | 1 |
| Cooper, O; Gertych, A; Greenman, Y; Jonas-Kimchi, T; Melmed, S; Ram, Z; Robenshtok, E; Sagiv, N; Shimon, I; Stern, N; Yaish, I; Yuan, X | 1 |
| Bonaventura, MM; Calandra, RS; Huhtaniemi, IT; Lux-Lantos, VA; Poutanen, M; Ratner, LD; Rulli, SB; Stevens, G | 1 |
| Boutinaud, M; De Prado Taranilla, AI; Deflandre, A; Dessauge, F; Gandemer, E; Isaka, N; Lamberton, P; Lollivier, V; Sordillo, LM | 1 |
| Elsetohy, KA; Elshaer, HS; Fouda, UM; Hammad, BE; Sayed, AM; Shaban, MM; Youssef, MA | 1 |
| Bellaviti Buttoni, P; Carosi, G; Ferrante, E; Filopanti, M; Malchiodi, E; Mantovani, G; Profka, E; Rodari, G; Sala, E; Spada, A; Verrua, E | 1 |
| Gemmete, JJ; Hollon, TC; Khalsa, SS; Pandey, AS; Shastri, R; Trobe, JD | 2 |
| Blankley, G; Galbally, M; Power, J; Snellen, M | 1 |
| Bukowska, B; Domosławska, A; Janowski, T; Jurczak, A | 1 |
| Andrysiak-Mamos, E; Kaźmierczyk-Puchalska, A; Kojder, I; Sagan, L; Sowińska-Przepiera, E; Syrenicz, A; Zochowska, E | 1 |
| Ahmad, MS; Nakhleh, A; Pearl, IW; Reut, M; Saiegh, L; Shechner, C | 1 |
| Araujo Júnior, E; Carvalho, JS; Carvalho, RC; Costa Carvalho, FH; Feitosa, FE; Melo, MA; Peixoto, AB | 1 |
| Damiani, D; de F Presti, P; Faria, AM; Musolino, NR; Neto, MB | 1 |
| Bernabeu, I; Blanco, C; Casany, R; Cordido, F; Cuatrecasas, G; Fajardo, C; Gálvez, MÁ; Lucas, T; Maraver, S; Marazuela, M; Martín, T; Paja, M; Picó, A; Puig-Domingo, M; Resmini, E; Romero, E; Soto, A; Venegas, E; Vilchez, R | 1 |
| Díez, JJ; Iglesias, P; Villabona, C | 2 |
| Berriel, MR; Lima, GA; Melo, AS; Rahhal, H; Santos, ML; Taboada, GF | 1 |
| Altamura, AC; Cremaschi, L; Fiorentini, A; Lindenmayer, JP; Mauri, MC; Rovera, C; Serati, M; Thanju, A | 1 |
| Corn, HJ; Couldwell, WT; Eli, IM; Palmer, CA; Raheja, A; Simmons, DL | 1 |
| Fleseriu, M; Lim, DS | 1 |
| Librizzi, R; Obermayer-Pietsch, B; Pieber, TR; Pilz, S; Schwetz, V; Stiegler, C; Theiler, G; Trummer, C | 1 |
| Hide, T; Honda, Y; Kuratsu, JI; Mikami, Y; Uekawa, K; Yano, S | 1 |
| El Tokhy, O; El-Toukhy, T; Kopeika, J | 1 |
| Anyiam, S; Baldeweg, FC; Baldeweg, SE; Bevan, JS; Butt, N; Drake, WM; Han, TS; Karavitaki, N; Kyriakakis, N; Martin, NM; Murray, RD; Parasuraman, SK; Rees, DA; Richardson, TI; Sheikh, UE; Steeds, RP; Stiles, CE; Stojanovic, N; Taylor, L; Toogood, AA; Trainer, PJ; Vaidya, B | 1 |
| Chapman, IM; De Sousa, SM; Falhammar, H; Torpy, DJ | 1 |
| Abou-El-Ela Bourquin, B; Bhrugubanda, V; Fu, RZ; Schultz, SR; Seemungal, BM; Yousif, N | 1 |
| Ghaziani, N; Kashanian, M; Sheikhansari, N; Vahdat, M | 1 |
| Brue, T; Castinetti, F; Cebula, H; Goichot, B; Graillon, T; Képénékian, L | 1 |
| Akutsu, H; Ishikawa, E; Matsumura, A; Suzuki, H; Takano, S; Watanabe, S; Yamamoto, T | 1 |
| Atkinson, JL; Donegan, D; Erickson, B; Erickson, D; Jentoft, M; Meyer, F; Natt, N; Nippoldt, TB | 1 |
| Andereggen, L; Andres, RH; Beck, J; Christ, E; El-Koussy, M; Frey, J; Seiler, RW | 1 |
| Colao, A; De Martino, MC; Faggiano, A; Franco, R; Kaltsas, GA; Marino, FZ; Napolitano, M; Negri, M; Patalano, R; Pivonello, C; Pivonello, R; Rocco, G; Rousaki, P; Sarnataro, M; Sciammarella, C | 1 |
| Auriemma, R; Beckers, A; Daly, AF; Dulgheru, R; Garcia, MT; Lancellotti, P; Magne, J; Maiga, I; Petrossians, P; Rubio-Almanza, M; Vroonen, L | 1 |
| Akturk, HK; Nippoldt, TB | 1 |
| Akha, O; Ala, S; Bahar, A; Daneshpour, E; Kashi, Z | 1 |
| Beshyah, SA; Chentli, F; El-Fikki, M; Hamrahian, A; Jambart, S; Khalil, AB; Raef, H; Sherif, IH | 1 |
| Bronstein, MD; Bueno, C; Glezer, A; Trarbach, EB | 1 |
| Arslan, MS; Cakal, E; Caliskan, M; Demirci, T; Karakose, M; Ozbek, M; Ozdemir, S; Sahin, M; Topaloglu, O; Tutal, E; Ucan, B | 1 |
| Fallon, SJ; Husain, M; Manohar, SG; Norbury, A; Zokaei, N | 1 |
| Hart, RJ; Mourad, S; Tang, H; Zhai, SD | 1 |
| Bhadada, SK; Bhansali, A; Rastogi, A | 1 |
| Dhanjal, MK; Knight, M; Lambert, K; McCance, DR; Rees, K; Seed, PT; Williamson, C | 1 |
| Beckers, A; Bertherat, J; Briet, C; Caron, P; Castinetti, F; Cephise-Velayoudom, FL; Chabre, O; Chanson, P; Cortet, C; Delemer, B; Ferriere, A; Haissaguerre, M; Maiter, D; Nunes, ML; Raingeard, I; Reznik, Y; Rohmer, V; Tabarin, A; Vroonen, L | 1 |
| Abucham, J; Bronstein, MD; Casagrande, A; Jallad, RS; Mota, JI; Tabet, A | 1 |
| Chanson, P; Kuhn, E | 1 |
| Beckers, A; Bonneville, JF; Brue, T; Castinetti, F; Cuny, T; Dufour, H; Eroukhmanoff, J; Potorac, I; Tejedor, I; Touraine, P; Weryha, G | 1 |
| Gharabaghi, PM; Mobasseri, M; Ouladsahebmadarek, E; Rahmani, V; Sayyah-Melli, M | 1 |
| Brown, J; Farquhar, C; Mourad, S | 1 |
| Benedetto, C; Brossa, A; Bussolati, B; Canosa, S; Leoncini, S; Marchino, GL; Moggio, A; Pittatore, G; Revelli, A | 1 |
| Bertulat, S; de Prado, A; Hetreau, T; Heuwieser, W; Isaka, N; Lopez, A | 1 |
| Nachtigall, LB | 1 |
| Abdelsalam, EA; Elmahdy, M; Maghraby, HA | 1 |
| Hartmann, U; Jung, S; Kahl, KG; Keil, L; Krüger, THC; Leeners, B; Wittfoth, M | 1 |
| Banitaba, SH; Hasanpour, F; Heidari, M; Taei, M | 1 |
| Agostini, H; Arnoux, A; Brailly-Tabard, S; Chanson, P; Kuhn, E; Massart, C; Mavromati, M; Piketty, ML; Souberbielle, JC; Young, J | 1 |
| Carvalho, D; Souteiro, P; Teixeira, M | 1 |
| Amso, NN; D'Angelo, A; Hassan, R | 1 |
| Cai, L; Guo, YH; Le, WD; Leng, ZG; Lin, SJ; Lou, MQ; Shang, HB; Tang, H; Wu, ZB; Wu, ZR; Xue, YJ; Zhang, X; Zhao, W; Zhao, WG | 1 |
| Ayala, A; Biller, BMK; Bonert, V; Broder, MS; Carmichael, JD; Cherepanov, D; Eagan, M; Geer, EB; Gordon, MB; Hannoush, Z; Katznelson, L; Lalazar, Y; Lee, J; Manuylova, E; Neary, MP; Pulaski-Liebert, KJ; Said, Q; Shafiq, I; Surampudi, V; Swerdloff, RS | 1 |
| Clevenger, CV; Costa, R; Flaum, L; Gradishar, WJ; Jain, S; Kaklamani, VG; Santa-Maria, CA; Scholtens, DM | 1 |
| Seow, CJ; Young, WF | 1 |
| Araujo, B; Belo, S; Carvalho, D | 1 |
| Deepak, DS; Lee, KO; Sek, KS | 1 |
| Ji, MJ; Kim, JH; Kim, SY; Kim, YH; Lee, JH; Paek, SH; Shin, CS | 1 |
| Ayaseh, M; Jalali, P; Mogheiseh, A; Vara, N | 1 |
| Bandarian, E; Mogheiseh, A; Mosavi Ghiri, MJ | 1 |
| Croxson, MS; Holdaway, I; Kunasegaran, S; Murphy, R | 1 |
| Cosio, C; Fracassi, F; Garatti, M; Grinwis, GCM; Kooistra, HS; Luccardini, L; Sartori, E | 1 |
| Jamor, J; Tayae, M | 1 |
| Shimatsu, Y | 1 |
| Cha, HJ; Kim, JH; Kim, SW; Kim, YH; Lee, JH; Lee, SY; Paek, SH; Shin, CS | 1 |
| Bredella, MA; Dichtel, LE; Gerweck, AV; Miller, KK; Schorr, M; Swearingen, B; Woodmansee, WW; Young, BJ | 1 |
| Casulari, LA; de Castro, LF; Luiz Mendonça, J; Magalhães Gonzaga, MF; Naves, LA; Oton de Lima, B | 1 |
| Boutinaud, M; Gandemer, E; Isaka, N; Lamberton, P; Lollivier, V; Sordillo, LM; Taranilla, AIP; Wiart, S | 1 |
| Cao, L; Guo, YH; Leng, ZG; Lin, SJ; Shang, HB; Wu, ZB; Wu, ZR; Zhang, X; Zhang, Y; Zhao, WG | 1 |
| Bassiouny, YA; Bayoumi, YA; Dakhly, DMR; Gouda, HM; Hassan, AA; Salaheldin, NM | 1 |
| Groß, U; Iacovazzo, D; Jungheim, K; Koehler, VF; Korbonits, M; Mann, A | 1 |
| Demidowich, AP; Hannah-Shmouni, F; Lodish, M; Rowell, J; Stratakis, CA | 1 |
| Chia, YY; Goh, GH; Mohan, N; Teo, K; Ting, E; Yeo, TT | 1 |
| Čehić, E; Franulić, D; Grgić, F; Kasum, M; Lila, A; Orešković, S; Vujić, G | 1 |
| Bilbao, I; Egaña, N; García, C; Olaizola, I | 1 |
| Brau, R; de Lourdes Miranda, M; Gutierrez, M; Hernán Martínez, J; Laboy-Ortiz, IE; Mangual, M; Mansilla, P; Palermo, C; Rivera, C; Sanchez, A; Trinidad, R; Velez-Maymí, S | 1 |
| Ciebiera, M; Jakiel, G; Męczekalski, B; Słabuszewska-Jóźwiak, A; Wojtyła, C; Łukaszuk, K | 1 |
| Hefzy, E; Seyam, E | 1 |
| Ciresi, A; Giordano, C; Guarnotta, V; Radellini, S | 1 |
| Akinduro, OO; Akinduro, OT; Gupta, V; Olomu, O; Reimer, R | 1 |
| Berger, M; Cobb, MIH; Codd, P; Crowson, M; Husain, AM; Jang, D; Mintz-Cole, R | 1 |
| Díaz-Gimeno, P; Faus, A; Ferrero, H; Gómez, R; Pellicer, A; Sebastián-León, P | 1 |
| Bettendorf, M; Breil, T; Choukair, D; Inta, I; Jesser, J; Klose, D; Lorz, C; Mittnacht, J; Schulze, E | 1 |
| Kaya, S; Ogul, H; Ogul, Y | 1 |
| Akirov, A; Eizenberg, Y; Glaser, B; Greenman, Y; Mansiterski, Y; S'chigol, I; Shimon, I; Shraga-Slutzky, I | 1 |
| Arlt, W; Ayuk, J; Fountas, A; Gittoes, N; Karavitaki, N; Santharam, S; Tampourlou, M; Toogood, A | 1 |
| Akbari, H; Alaei-Shahmiri, F; Asadi, P; Ghorbani, M; Honardoost, M; Imani, M; Kaynama, MR; Khamseh, ME; Malek, M | 1 |
| Drake, WM; Steeds, RP; Stiles, CE | 1 |
| Caputo, C; Inder, WJ | 1 |
| Harris, K; Horn, D; MacGilivray, J; Murphy, KE; Yudin, MH | 1 |
| Anokhin, PK; Pavshintsev, VV; Shamakina, IY; Veretinskaya, AG | 1 |
| Espinosa-Cárdenas, E; Mendoza-Zubieta, V; Mercado, M; Ramírez-Rentería, C; Sánchez-García, M; Sosa-Eroza, E | 2 |
| Andereggen, L; Christ, E; Frey, J | 1 |
| Astafyeva, LI; Kadashev, BA; Kalinin, PL; Melnichenko, GA; Sharipov, OI; Shishkina, LV; Sidneva, JG | 1 |
| Akın, Ş; Candemir, B | 1 |
| Beckers, A; Daly, AF | 1 |
| Autmizguine, J; Boucher, M; Boucoiran, I; Elwood, C; Ferreira, E; Kakkar, F; Money, D; Poliquin, V; Roy, M; Sheehan, NL; Thibaudeau, R; Tulloch, K | 1 |
| Hart, RJ; Mourad, SM; Tang, H; Wang, A; Zhai, SD | 1 |
| Akirov, A; Duskin-Bitan, H; Manisterski, Y; Masri-Iraqi, H; Pertzov, B; Rudman, Y; Shimon, I | 1 |
| Barbot, M; Ceccato, F; Lizzul, L; Scaroni, C; Voltan, G | 1 |
| Cohen, D; Eshkoli, T; Fraenkel, M; Goldbart, A; Gorshtein, A; Greenman, Y; Shimon, I; Tsvetov, G; Yoel, U; Zaid, D | 1 |
| Barranco-Trabi, J; Elegino-Steffens, DU; Hussain, A; Minns, RM; Yiu, AC | 1 |
| Han, C; Lin, S; Lou, X; Wu, ZB | 1 |
| Aral, F; Bilgic, B; Gul, N; Hacisahinogullari, H; Selcukbiricik, OS; Tanakol, R; Uzum, AK; Yalin, GY | 1 |
| Arastu, MI; Curiale, AM; Lipton, BA; Longo, S; Nanda, S; Tessier, S | 1 |
| Bueno, CBF; de Castro Moreira, AR; Glezer, A; Grande, IPP; Maciel, GAR; Monteiro, ALS; Padula, M; Trarbach, E | 1 |
| Aung, AT; Teo, AE; Tng, EL | 1 |
| Auriemma, RS; Colao, A; Garifalos, F; Pirchio, R; Pivonello, C; Pivonello, R | 1 |
| Cescato, VAS; Cunha-Neto, MBC; Glezer, A; Musolino, NRC; Pinheiro, FMM; Silva, GO; Stumpf, MAM | 1 |
| Attanasio, R; Basile, M; Bozzao, A; Cappabianca, P; Caputo, M; Cozzi, R; Cruciani, F; De Menis, E; Doglietto, F; Esposito, F; Ferrante, E; Ferraù, F; Grimaldi, F; Iatì, G; Lania, AG; Laureti, S; Lello, S; Locatelli, D; Maffei, P; Mazzatenta, D; Minniti, G; Mitrova, Z; Paoletta, A; Papini, E; Peri, A; Persichetti, A; Poggi, M; Rudà, R; Ruini, C; Samperi, I; Saulle, R; Scoppola, A; Settanni, F; Silvani, A; Simona Auriemma, R; Tortora, F; Vecchi, S; Veronese, N | 1 |
| Gulsen Coban, P; Haltas, H; Inal, HA; Timur, H; Yilmaz, N; Yilmaz, S | 1 |
126 review(s) available for cabergoline and ergoline
| Article | Year |
|---|---|
New drugs for hyperprolactinaemia.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Clinical Trials as Topic; Ergolines; Hormone Antagonists; Humans; Hyperprolactinemia | 1995 |
Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Hyperprolactinemia; Lactation; Prolactin; Tissue Distribution | 1995 |
Cabergoline: a new drug for the treatment of hyperprolactinaemia.
Topics: Bromocriptine; Cabergoline; Clinical Trials as Topic; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Ergolines; Female; Humans; Hyperprolactinemia; Lactation; Postpartum Period; Randomized Controlled Trials as Topic | 1995 |
A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.
Topics: Aminoquinolines; Animals; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Lactation; Male; Pregnancy | 1996 |
Second generation of dopamine agonists: pros and cons.
Topics: Antiparkinson Agents; Benzothiazoles; Cabergoline; Dopamine Agonists; Drugs, Investigational; Ergolines; Humans; Indoles; Parkinson Disease; Pramipexole; Thiazoles | 1995 |
Newer therapies for Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Indoles; Parkinson Disease | 1996 |
New pharmacotherapy for Parkinson's disease.
Topics: Benzophenones; Benzothiazoles; Cabergoline; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Enzyme Inhibitors; Ergolines; Humans; Indoles; Nitriles; Nitrophenols; Parkinson Disease; Pramipexole; Receptors, Dopamine D2; Thiazoles; Tolcapone | 1997 |
New options for treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Benzothiazoles; Cabergoline; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Enzyme Inhibitors; Ergolines; Guidelines as Topic; Humans; Indoles; Nitriles; Nitrophenols; Parkinson Disease; Pramipexole; Thiazoles; Tolcapone; Treatment Outcome | 1997 |
Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Area Under Curve; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Levodopa; Male; Parkinson Disease; Rats; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1998 |
Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa.
Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic | 1998 |
Hyperprolactinemia; etiology, diagnosis and treatment alternatives.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Pergolide; Prolactin; Receptors, Prolactin | 1998 |
[Prolactinoma in the male. Physiopathological, clinical, and therapeutic features].
Topics: Cabergoline; Cranial Irradiation; Dopamine Agonists; Erectile Dysfunction; Ergolines; Galactorrhea; Gynecomastia; Humans; Hyperprolactinemia; Hypophysectomy; Infertility, Male; Libido; Male; Pituitary Neoplasms; Prolactinoma; Treatment Outcome | 1998 |
Growth-hormone and prolactin excess.
Topics: Acromegaly; Cabergoline; Dopamine Agonists; Ergolines; Hormone Antagonists; Human Growth Hormone; Humans; Hyperprolactinemia; Somatostatin | 1998 |
Clinical pharmacology of dopamine agonists in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Benzothiazoles; Cabergoline; Dopamine Agonists; Ergolines; Ergot Alkaloids; Humans; Indoles; Neuroprotective Agents; Parkinson Disease; Pramipexole; Thiazoles | 1998 |
Ergoline derivatives: receptor affinity and selectivity.
Topics: Animals; Cabergoline; Dopamine Agents; Ergolines; Humans; Prolactin; Receptors, Dopamine; Receptors, Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists | 1999 |
Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature.
Topics: Adult; Cabergoline; Cushing Syndrome; Dopamine Agonists; Ergolines; Female; Humans; Ketoconazole; Pregnancy; Pregnancy Complications; Pregnancy Outcome | 1999 |
Treatment of Parkinson's disease should begin with a dopamine agonist.
Topics: Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Humans; Indoles; Levodopa; Lisuride; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D2; Thiazoles | 1999 |
Clinical pharmacology of dopamine agonists.
Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Drug Interactions; Ergolines; Humans; Indoles; Parkinson Disease; Pramipexole; Thiazoles | 2000 |
New drugs for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Benzothiazoles; Cabergoline; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Synergism; Enzyme Inhibitors; Ergolines; Humans; Indoles; Levodopa; Nitrophenols; Parkinson Disease; Pramipexole; Thiazoles; Tolcapone | 2000 |
CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas.
Topics: Adult; Bromocriptine; Cabergoline; Cerebrospinal Fluid Rhinorrhea; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Tomography, X-Ray Computed | 2000 |
Ectopic macroprolactinoma mimicking a chordoma: a case report.
Topics: Aged; Aged, 80 and over; Amnesia, Retrograde; Antineoplastic Agents; Cabergoline; Chordoma; Cranial Fossa, Posterior; Diagnosis, Differential; Dopamine Agonists; Ergolines; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Headache; Humans; Hyperprolactinemia; Luteinizing Hormone; Magnetic Resonance Imaging; Prolactinoma; Skull Base Neoplasms | 1999 |
A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature.
Topics: Cabergoline; Dopamine Agonists; Ergolines; Exophthalmos; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma | 2000 |
Clinical management of prolactinomas.
Topics: Bone Density; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Female; Humans; Hypogonadism; Male; Pituitary Neoplasms; Pregnancy; Prolactinoma | 1999 |
Cabergoline for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2001 |
Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2001 |
[Pharmacological effects of cabergoline against parkinsonism].
Topics: Animals; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Haplorhini; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 2001 |
Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.
Topics: Age Factors; Antipsychotic Agents; Cabergoline; Child; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Male; Retrospective Studies; Risperidone | 2001 |
Bait-delivered cabergoline for the reproductive control of the red fox (Vulpes vulpes): estimating mammalian non-target risk in south-eastern Australia.
Topics: Abortifacient Agents; Abortion, Induced; Abortion, Veterinary; Animals; Australia; Cabergoline; Embryo Implantation; Ergolines; Female; Foxes; Lactation; Mammals; Population Control; Pregnancy; Prolactin; Reproduction | 2001 |
Dopamine receptor agonists for treating prolactinomas.
Topics: Aminoquinolines; Animals; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Ergot Alkaloids; Female; Humans; Pergolide; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma | 2002 |
[Novel pharmacologic therapies in acromegaly].
Topics: Acromegaly; Adenoma; Aminoquinolines; Antineoplastic Agents, Hormonal; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Hormones; Human Growth Hormone; Humans; Octreotide; Peptides, Cyclic; Pituitary Neoplasms; Prolactin; Receptors, Somatotropin; Somatostatin | 2002 |
DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.
Topics: Benzophenones; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Enzyme Inhibitors; Ergolines; Ergot Alkaloids; Humans; Levodopa; Lisuride; Nitrophenols; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic; Tolcapone | 2002 |
DA agonists -- ergot derivatives: cabergoline: management of Parkinson's disease.
Topics: Cabergoline; Dopamine Agonists; Ergolines; Ergot Alkaloids; Humans; Parkinson Disease | 2002 |
[Use of dopamine agonists in the treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Controlled Clinical Trials as Topic; Dopamine Agonists; Ergolines; Humans; Indoles; Lisuride; Parkinson Disease; Pergolide; Piribedil; Placebos; Pramipexole; Serotonin Receptor Agonists; Thiazoles; Time Factors | 2002 |
Use of the dopamine agonist cabergoline in the treatment of movement disorders.
Topics: Antiparkinson Agents; Cabergoline; Disease Models, Animal; Dopamine Agonists; Ergolines; Humans; Movement Disorders; Neuroprotective Agents; Parkinson Disease | 2002 |
Dopamine agonist monotherapy in Parkinson's disease.
Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Ergolines; Humans; Indoles; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Randomized Controlled Trials as Topic; Thiazoles; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2002 |
Hyperprolactinemia: etiology, diagnosis, and management.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Neurosurgical Procedures; Prevalence | 2002 |
Dopamine agonist therapy for hyperprolactinemia.
Topics: Aminoquinolines; Benzothiazoles; Bromocriptine; Cabergoline; Clinical Trials as Topic; Dopamine Agonists; Ergolines; Ergoloid Mesylates; Female; Humans; Hyperprolactinemia; Indoles; Pergolide; Pramipexole; Thiazoles | 2003 |
Clinical pharmacokinetics of cabergoline.
Topics: Age Factors; Antiparkinson Agents; Cabergoline; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Ergolines; Female; Food-Drug Interactions; Humans; Kidney Diseases; Levodopa; Liver Diseases; Male; Selegiline; Sex Factors | 2003 |
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
Topics: Age of Onset; Benzothiazoles; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Evidence-Based Medicine; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Thiazoles | 2003 |
Hair loss induced by dopamine agonist: case report and review of the literature.
Topics: Aged; Alopecia; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Parkinson Disease | 2003 |
Dopamine resistance of prolactinomas.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Humans; Pituitary Neoplasms; Prolactinoma | 2003 |
Contemporary management of prolactinomas.
Topics: Bromocriptine; Cabergoline; Contraindications; Diagnosis, Differential; Ergolines; Female; Humans; Hypophysectomy; Magnetic Resonance Imaging; Male; Pituitary Diseases; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactin; Prolactinoma; Radiosurgery; Remission Induction | 2004 |
Pharmacological approach to the treatment of acromegaly.
Topics: Acromegaly; Algorithms; Cabergoline; Dopamine Agonists; Ergolines; Health Care Costs; Human Growth Hormone; Humans; Octreotide; Peptides, Cyclic; Receptors, Somatotropin; Somatostatin; Treatment Outcome | 2004 |
Cabergoline : a review of its use in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Cabergoline; Clinical Trials as Topic; Dose-Response Relationship, Drug; Ergolines; Humans; Parkinson Disease | 2004 |
[Prolactinoma and pregnancy].
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactinoma | 2004 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.
Topics: Apomorphine; Benzophenones; Cabergoline; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Ergolines; Humans; Levodopa; Movement Disorders; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2005 |
Hyperprolactinemia: pathophysiology and management.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Estrogens; Female; Humans; Hyperprolactinemia; Male; Pergolide; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma; Radiotherapy; Surgical Procedures, Operative | 2003 |
Current treatment issues in female hyperprolactinaemia.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms; Pregnancy; Prolactinoma | 2006 |
Treatment of pituitary tumors: dopamine agonists.
Topics: Adenoma; Bromocriptine; Cabergoline; Dopamine; Dopamine Agonists; Ergolines; Humans; Pituitary Neoplasms; Receptors, Dopamine | 2005 |
Prolactinomas and pregnancy.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Child; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactinoma | 2005 |
PRL secreting adenomas in male patients.
Topics: Age Factors; Cabergoline; Dopamine Agonists; Ergolines; Humans; Libido; Male; Pituitary Neoplasms; Prevalence; Prolactin; Prolactinoma; Prostatic Hyperplasia; Semen; Sex Factors; Spermatogenesis; Testis | 2005 |
Pharmacologic resistance in prolactinoma patients.
Topics: Bromocriptine; Cabergoline; Cell Proliferation; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Resistance; Ergolines; Estrogens; Female; Humans; Male; Pergolide; Pituitary Neoplasms; Prolactin; Prolactinoma; Receptors, Dopamine D2 | 2005 |
Quinagolide--a valuable treatment option for hyperprolactinaemia.
Topics: Administration, Oral; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Patient Compliance | 2006 |
Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.
Topics: Adenoma; Antineoplastic Agents; Bromocriptine; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Male; Prolactin; Prolactinoma; Sex Characteristics | 2006 |
[Treatment of Parkinson disease: therapeutic reserve of the dopaminergic agonist].
Topics: Benzothiazoles; Cabergoline; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Humans; Parkinson Disease; Pramipexole | 2006 |
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
Topics: Animals; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Heart Valve Diseases; Humans; Indoles; Pergolide; Pulmonary Fibrosis; Receptors, Dopamine | 2006 |
Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.
Topics: Antiparkinson Agents; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Drug Combinations; Echocardiography; Ergolines; Ergot Alkaloids; Heart Valve Diseases; Humans; Parkinson Disease; Pergolide; Product Surveillance, Postmarketing | 2007 |
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
Topics: Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Parkinson Disease; Pergolide | 2007 |
Restless legs syndrome in older adults.
Topics: Aged, 80 and over; Benzothiazoles; Cabergoline; Circadian Rhythm; Cognition Disorders; Comorbidity; Diagnosis, Differential; Dopamine Agonists; Ergolines; Humans; Indoles; Polysomnography; Pramipexole; Prevalence; Restless Legs Syndrome; Sleep Wake Disorders | 2008 |
[Some possibilities for application of "Pfizer" medicines--Prostin 15m, Prostin E2, Prepidil gel, Dostinex, Synarel--in the obstetrician practice].
Topics: Cabergoline; Carboprost; Dinoprostone; Drug Combinations; Ergolines; Female; Humans; Nafarelin; Obstetrics; Tromethamine | 2007 |
Pharmacologic prevention of aspiration pneumonia: a systematic review.
Topics: Aged; Amantadine; Angiotensin-Converting Enzyme Inhibitors; Cabergoline; Capsaicin; Cilostazol; Controlled Clinical Trials as Topic; Ergolines; Humans; Pneumonia, Aspiration; Risk Factors; Sensory System Agents; Tetrazoles; Theophylline | 2007 |
Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
Topics: Adenoma; Antineoplastic Agents, Hormonal; Cabergoline; Cell Proliferation; Dopamine; Ergolines; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Octreotide; Pituitary Neoplasms; Protein Multimerization; Receptors, Dopamine D2; Receptors, Somatostatin; Somatostatin; Tumor Cells, Cultured | 2008 |
Pituitary-targeted medical therapy of Cushing's disease.
Topics: Adrenocorticotropic Hormone; Animals; Cabergoline; Dopamine Agonists; Ergolines; Humans; Neurotransmitter Agents; Oligopeptides; Pituitary ACTH Hypersecretion; Pituitary Gland; Somatostatin | 2008 |
Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required.
Topics: Cabergoline; Clinical Trials as Topic; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Pituitary Neoplasms; Prolactinoma | 2008 |
Management of aggressive pituitary adenomas: current treatment strategies.
Topics: Cabergoline; Dacarbazine; Dopamine Agonists; Ergolines; Female; Humans; Male; Pituitary Neoplasms; Somatostatin; Temozolomide | 2009 |
Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review.
Topics: Antineoplastic Agents; Cabergoline; Drug Resistance, Neoplasm; Drug Tolerance; Ergolines; Female; Humans; Middle Aged; Pituitary Neoplasms; Prolactinoma | 2011 |
Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies.
Topics: Aortic Valve; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Mental Disorders; Mitral Valve; Risk Factors; Tricuspid Valve | 2008 |
How to avoid ovarian hyperstimulation syndrome: a new indication for dopamine agonists.
Topics: Cabergoline; Clinical Protocols; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Randomized Controlled Trials as Topic | 2009 |
Drug-induced fibrotic valvular heart disease.
Topics: Antiparkinson Agents; Appetite Depressants; Cabergoline; Dexfenfluramine; Dopamine Agonists; Drug Monitoring; Ergolines; Ergotamine; Fenfluramine; Fibrosis; Heart Valve Diseases; Heart Valves; Humans; Methysergide; Migraine Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Patient Selection; Pergolide; Receptors, Serotonin; Serotonin Agents; Serotonin Plasma Membrane Transport Proteins; Vasoconstrictor Agents | 2009 |
[Recent trends in the pathophysiology and treatment of pituitary adenomas].
Topics: Adenoma; Antineoplastic Agents; Cabergoline; Corticotropin-Releasing Hormone; Dacarbazine; Ergolines; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hypothalamic Hormones; Incidental Findings; Neurosurgical Procedures; Octreotide; Pituitary Neoplasms; Prolactinoma; Receptors, Neuropeptide; Receptors, Pituitary Hormone-Regulating Hormone; Temozolomide | 2009 |
Drugs in the medical treatment of Cushing's syndrome.
Topics: Adrenal Cortex Neoplasms; Adrenocorticotropic Hormone; Antiparkinson Agents; Cabergoline; Cushing Syndrome; Ergolines; Human Growth Hormone; Humans; Hydrocortisone; Ketoconazole; Metyrapone; Pituitary Hormones; Pituitary Neoplasms | 2009 |
Prolactinomas in children and adolescents.
Topics: Adolescent; Antineoplastic Agents; Cabergoline; Child; Combined Modality Therapy; Ergolines; Growth; Growth Disorders; Humans; Pituitary Neoplasms; Prolactinoma | 2010 |
[Cabergoline in hyperprolactinemia and valvular heart disease].
Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactin; Prolactinoma; Ultrasonography | 2009 |
Clinical practice. Prolactinomas.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Neoplastic; Prolactin; Prolactinoma; Visual Fields | 2010 |
Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature.
Topics: Adult; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Female; Gestational Age; Humans; Hyperprolactinemia; Middle Aged; Pregnancy; Pregnancy Complications; Premature Birth; Prolactin; Retrospective Studies; Young Adult | 2010 |
Medical treatment in Cushing's syndrome: dopamine agonists and cabergoline.
Topics: Cabergoline; Cushing Syndrome; Dopamine Agonists; Ergolines; Humans | 2010 |
Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Randomized Controlled Trials as Topic | 2011 |
Place of cabergoline in acromegaly: a meta-analysis.
Topics: Acromegaly; Adult; Antineoplastic Agents; Cabergoline; Data Interpretation, Statistical; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Hormone Antagonists; Human Growth Hormone; Humans; Hyperprolactinemia; Insulin-Like Growth Factor I; Male; Middle Aged; Somatostatin; Treatment Outcome | 2011 |
Dopamine agonists for restless legs syndrome.
Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Ergolines; Humans; Levodopa; Pergolide; Pramipexole; Randomized Controlled Trials as Topic; Restless Legs Syndrome; Severity of Illness Index | 2011 |
Prolactinoma in pregnancy.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Fetus; Humans; Hyperprolactinemia; Infertility, Female; Pregnancy; Pregnancy Complications, Neoplastic; Prolactinoma | 2011 |
Cabergoline for preventing ovarian hyperstimulation syndrome.
Topics: Abortion, Spontaneous; Administration, Oral; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Reproductive Techniques, Assisted | 2012 |
2012 update in the treatment of prolactinomas.
Topics: Cabergoline; Contraindications; Dopamine Agonists; Endocrinology; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Neurosurgical Procedures; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma | 2012 |
How to investigate and treat: headache and hyperprolactinemia.
Topics: Adult; Amenorrhea; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Tension-Type Headache; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline.
Topics: Academies and Institutes; Benzothiazoles; Cabergoline; Carbamates; Dopamine Agents; Ergolines; Evidence-Based Medicine; gamma-Aminobutyric Acid; Humans; Indoles; Levodopa; Nocturnal Myoclonus Syndrome; Pergolide; Peripheral Nervous System Diseases; Pramipexole; Restless Legs Syndrome; Sleep Medicine Specialty; United States; Venous Insufficiency | 2012 |
New prospects for drug treatment in Cushing disease.
Topics: Adenoma; Adrenocorticotropic Hormone; Animals; Cabergoline; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Ergolines; Etomidate; Humans; Hydrocortisone; Imidazoles; Ketoconazole; Metyrapone; Mice; Mifepristone; Mitotane; Multicenter Studies as Topic; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; PPAR gamma; Pyridines; Rats; Somatostatin; Therapies, Investigational; Tretinoin | 2012 |
[Optimization of the medical treatment for acromegaly].
Topics: Acromegaly; Cabergoline; Combined Modality Therapy; Dopamine Agonists; Dosage Forms; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ergolines; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Octreotide; Peptides, Cyclic; Pituitary Neoplasms; Randomized Controlled Trials as Topic; Receptors, Somatotropin; Somatostatin; Treatment Outcome | 2013 |
Cabergoline as treatment of ovarian hyperstimulation syndrome: a review.
Topics: Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Ergolines; Evidence-Based Medicine; Female; Fertility Agents, Female; Gene Expression Regulation; Humans; Ovarian Hyperstimulation Syndrome; Ovary; Phosphorylation; Protein Processing, Post-Translational; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Double pituitary adenomas.
Topics: Adenoma; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Comorbidity; Ergolines; Humans; Male; Middle Aged; Neoplasms, Multiple Primary; Neurosurgical Procedures; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Treatment Outcome | 2013 |
Anti-Parkinson's disease drugs and pharmacogenetic considerations.
Topics: Aryl Hydrocarbon Hydroxylases; Benzothiazoles; Benztropine; Bromocriptine; Cabergoline; Catechols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Ergolines; Genetic Markers; Humans; Indans; Indoles; Levodopa; Lisuride; Nitriles; Parkinson Disease; Pergolide; Pharmacogenetics; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Reproducibility of Results; Selegiline | 2013 |
Giant prolactinomas: the therapeutic approach.
Topics: Cabergoline; Combined Modality Therapy; Dopamine Agonists; Ergolines; Humans; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma; Treatment Outcome; Tumor Burden | 2013 |
Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.
Topics: Cabergoline; Dopamine Agonists; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Male; Myocardium; Observational Studies as Topic; Prevalence; Risk Factors | 2013 |
The role of combination medical therapy in acromegaly: hope for the nonresponsive patient.
Topics: Acromegaly; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Human Growth Hormone; Humans; Ligands; Receptors, Somatostatin | 2013 |
Update in the medical therapy of Cushing's disease.
Topics: Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Humans; Hydrocortisone; Pituitary ACTH Hypersecretion; Somatostatin | 2013 |
[Drug therapy for acromegaly].
Topics: Acromegaly; Aminoquinolines; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Interdisciplinary Communication; Membrane Proteins; Octreotide; Patient Care Team; Peptides, Cyclic; Pituitary Neoplasms; Somatostatin | 2013 |
Pituitary apoplexy associated with cabergoline therapy.
Topics: Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Humans; Male; Pituitary Apoplexy; Pituitary Neoplasms; Prolactinoma; Young Adult | 2013 |
Efficacy of medical treatment in Cushing's disease: a systematic review.
Topics: Cabergoline; Ergolines; Female; Humans; Ketoconazole; Male; Metyrapone; Mitotane; Pituitary ACTH Hypersecretion; Somatostatin | 2014 |
Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials.
Topics: Cabergoline; Ergolines; Female; Humans; Oocyte Retrieval; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Randomized Controlled Trials as Topic; Reproductive Techniques, Assisted | 2014 |
Acute aseptic meningitis as the initial presentation of a macroprolactinoma.
Topics: Adult; Anti-Bacterial Agents; Blindness; Cabergoline; Combined Modality Therapy; Ergolines; Fever; Headache; Hormone Replacement Therapy; Humans; Hydrocortisone; Hypophysectomy; Hypopituitarism; Male; Meningitis, Aseptic; Neoplasm Invasiveness; Pituitary Neoplasms; Prolactinoma; Sella Turcica; Third Ventricle; Thyroxine | 2014 |
[Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients].
Topics: Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Parkinson Disease; Ultrasonography | 2014 |
Prolactinomas, cabergoline, and pregnancy.
Topics: Animals; Antineoplastic Agents; Cabergoline; Ergolines; Female; Fetal Development; Humans; Hyperprolactinemia; Infertility, Female; Pituitary Neoplasms; Pregnancy; Prolactinoma | 2014 |
AACE/ACE Disease State Clinical Review: Medical Management of Cushing Disease.
Topics: Adrenocorticotropic Hormone; Cabergoline; Drug Therapy, Combination; Ergolines; Humans; Ketoconazole; Mifepristone; Pituitary ACTH Hypersecretion; Somatostatin | 2014 |
Dopamine agonists in prevention of ovarian hyperstimulation syndrome.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction | 2014 |
The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data.
Topics: Adult; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma | 2015 |
Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
Topics: Biomarkers, Tumor; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactin; Prolactinoma; Recurrence; Time Factors; Treatment Outcome; Tumor Burden | 2015 |
Medical Treatment of Acromegaly with Dopamine Agonists or Somatostatin Analogs.
Topics: Acromegaly; Cabergoline; Dopamine Agonists; Ergolines; Growth Hormone; Human Growth Hormone; Humans; Somatostatin | 2016 |
Cabergoline use for pituitary tumors and valvular disorders.
Topics: Acromegaly; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Pituitary Neoplasms; Prolactinoma | 2015 |
Update on prolactinomas. Part 2: Treatment and management strategies.
Topics: Bromocriptine; Cabergoline; Disease Management; Dopamine Agonists; Drug Administration Schedule; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neuroendoscopy; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactin; Prolactinoma; Radiosurgery; Sphenoid Sinus | 2015 |
A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters.
Topics: Animals; Biomarkers; Blood Glucose; Bromocriptine; Cabergoline; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dopamine Agonists; Ergolines; Humans; Hypoglycemic Agents; Risk Factors; Treatment Outcome | 2016 |
Role of Medical Management for Uterine Leiomyomas.
Topics: Antifibrinolytic Agents; Aromatase Inhibitors; Cabergoline; Cholecalciferol; Contraceptive Agents, Female; Contraceptives, Oral, Hormonal; Contraceptives, Oral, Synthetic; Danazol; Dopamine Agonists; Ergolines; Estrenes; Estrogen Antagonists; Female; Gestrinone; Gonadotropin-Releasing Hormone; Humans; Intrauterine Devices, Medicated; Leiomyoma; Levonorgestrel; Mifepristone; Norpregnadienes; Oximes; Patient Care Planning; Selective Estrogen Receptor Modulators; Somatostatin; Tranexamic Acid; Uterine Neoplasms; Vitamins | 2016 |
The safety of treatments for prolactinomas.
Topics: Animals; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Drug-Related Side Effects and Adverse Reactions; Ergolines; Humans; Pituitary Neoplasms; Prolactinoma; Safety | 2016 |
Osteoporotic fractures in patients with untreated hyperprolactinemia vs. those taking dopamine agonists: A systematic review and meta-analysis.
Topics: Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Hypogonadism; Male; Odds Ratio; Osteoporotic Fractures; Pituitary Neoplasms; Prevalence; Prolactinoma; Sex Factors; Spinal Fractures | 2015 |
Pharmacological lactation suppression with D2 receptor agonists and risk of postpartum psychosis: A systematic review.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Lactation; Psychoses, Substance-Induced; Receptors, Dopamine D2; Risk Factors | 2016 |
The role of combination medical therapy in the treatment of acromegaly.
Topics: Acromegaly; Cabergoline; Combined Modality Therapy; Ergolines; Humans; Receptors, Somatostatin; Receptors, Somatotropin | 2017 |
Dopamine agonists for preventing ovarian hyperstimulation syndrome.
Topics: Abortion, Spontaneous; Administration, Oral; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Reproductive Techniques, Assisted | 2016 |
Cabergoline in acromegaly.
Topics: Acromegaly; Cabergoline; Dopamine Agonists; Ergolines; Human Growth Hormone; Humans; Pituitary Neoplasms; Receptors, Somatostatin | 2017 |
Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews.
Topics: Cabergoline; Ergolines; Female; Gonadotropin-Releasing Hormone; Humans; Metformin; Ovarian Hyperstimulation Syndrome; Pregnancy; Progesterone; Reproductive Techniques, Assisted; Review Literature as Topic | 2017 |
Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.
Topics: Abortion, Spontaneous; Cabergoline; Chorionic Gonadotropin; Ergolines; Female; Fertilization in Vitro; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Live Birth; Ovarian Hyperstimulation Syndrome; Pregnancy; Pregnancy Rate; Pregnancy, Multiple; Randomized Controlled Trials as Topic; Withholding Treatment | 2017 |
Current Medical Strategies in the Prevention of Ovarian Hyperstimulation Syndrome
Topics: Aminoquinolines; Bromocriptine; Buserelin; Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Ergolines; Estradiol; Estrogens; Female; Fertility Agents, Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Oocyte Retrieval; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Pregnancy Rate; Progesterone; Progestins; Triptorelin Pamoate | 2017 |
Alternative Oral Agents in Prophylaxis and Therapy of Uterine Fibroids-An Up-to-Date Review.
Topics: Administration, Oral; Antineoplastic Agents; Aromatase Inhibitors; Cabergoline; Catechin; Ergocalciferols; Ergolines; Female; Humans; Hydrocarbons, Fluorinated; Leiomyoma; Pyrimidines; Quality of Life; Uterine Neoplasms; Vitamin D | 2017 |
Clinical Features and Response to Treatment of Prolactinomas in Children and Adolescents: A Retrospective Single-Centre Analysis and Review of the Literature.
Topics: Adolescent; Antineoplastic Agents; Cabergoline; Child; Ergolines; Female; Germany; Humans; Male; Pituitary Neoplasms; Prolactinoma; Retrospective Studies | 2018 |
Safety of Cabergoline for Postpartum Lactation Inhibition or Suppression: A Systematic Review.
Topics: Administration, Oral; Adolescent; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Lactation; Middle Aged; Postpartum Period; Young Adult | 2020 |
Dopamine agonists for preventing ovarian hyperstimulation syndrome.
Topics: Abortion, Spontaneous; Administration, Oral; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Fertilization in Vitro; Humans; Live Birth; Ovarian Hyperstimulation Syndrome; Placebos; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Sperm Injections, Intracytoplasmic | 2021 |
Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature.
Topics: Cabergoline; Dopamine Agonists; Ergolines; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma | 2023 |
Approach to the Patient With Prolactinoma.
Topics: Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hypogonadism; Male; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma | 2023 |
How to manage intolerance to dopamine agonist in patients with prolactinoma.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactinoma | 2023 |
164 trial(s) available for cabergoline and ergoline
| Article | Year |
|---|---|
Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group.
Topics: Adolescent; Adult; Cabergoline; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged; Prospective Studies | 1992 |
Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study. European Multicentre Study Group for Cabergoline in Lactation Inhibition.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agents; Double-Blind Method; Drug Administration Schedule; Ergolines; Female; Humans; Lactation; Pregnancy; Prospective Studies | 1991 |
Oral cabergoline. Single-dose inhibition of puerperal lactation.
Topics: Administration, Oral; Breast; Cabergoline; Dopamine Agents; Double-Blind Method; Drug Tolerance; Ergolines; Female; Humans; Lactation; Placebos; Postpartum Period; Prolactin; Prospective Studies; Regression Analysis | 1991 |
Cabergoline versus bromocriptine in suppression of lactation after cesarean delivery.
Topics: Administration, Oral; Adult; Bromocriptine; Cabergoline; Cesarean Section; Ergolines; Female; Humans; Lactation; Postpartum Period; Prolactin; Single-Blind Method | 1991 |
Clinical experience with cabergoline, a new ergoline derivative, in the treatment of Parkinson's disease.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Cabergoline; Dose-Response Relationship, Drug; Drug Administration Schedule; Ergolines; Female; Humans; Male; Neurologic Examination; Parkinson Disease | 1990 |
Cabergoline: long-acting oral treatment of hyperprolactinemic disorders.
Topics: Administration, Oral; Adolescent; Adult; Cabergoline; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged; Pituitary Neoplasms; Placebos; Prolactin; Prolactinoma; Radiography | 1989 |
Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients.
Topics: Acromegaly; Adult; Animals; Cabergoline; Chick Embryo; Dopamine; Dopamine Agents; Ergolines; Female; Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Prolactin | 1988 |
Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients.
Topics: Adolescent; Adult; Amenorrhea; Bromocriptine; Cabergoline; Clinical Trials as Topic; Ergolines; Female; Humans; Hyperprolactinemia; Kinetics; Male; Middle Aged; Prolactin | 1988 |
Prevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug, cabergoline.
Topics: Administration, Oral; Adult; Cabergoline; Clinical Trials as Topic; Ergolines; Female; Humans; Lactation; Postpartum Period; Pregnancy; Prolactin; Random Allocation | 1988 |
Selective and extremely long inhibition of prolactin release in man by 1-ethyl-3-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta- carbonyl)-urea-diphosphate (FCE 21336).
Topics: Adult; Antineoplastic Agents; Cabergoline; Double-Blind Method; Ergolines; Growth Hormone; Hemodynamics; Humans; Hydrocortisone; Luteinizing Hormone; Male; Prolactin; Thyrotropin | 1987 |
[Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study].
Topics: Adolescent; Adult; Amenorrhea; Bromocriptine; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Female; France; Humans; Hyperprolactinemia; Middle Aged; Prolactin; Prospective Studies | 1995 |
Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers.
Topics: Adult; Antineoplastic Agents; Biological Availability; Cabergoline; Chemistry, Pharmaceutical; Cross-Over Studies; Dopamine Agonists; Ergolines; Female; Humans; Solutions; Tablets | 1994 |
The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group.
Topics: Adult; Cabergoline; Dopamine Agents; Drug Administration Schedule; Ergolines; Female; Humans; Hyperprolactinemia; Pregnancy; Prospective Studies; Time Factors | 1993 |
Luteotrophic action of prolactin in dogs and the effects of a dopamine agonist, cabergoline.
Topics: Abortifacient Agents; Abortion, Induced; Animals; Cabergoline; Corpus Luteum Maintenance; Dog Diseases; Dogs; Dopamine Agents; Ergolines; Female; Fetal Resorption; Pregnancy; Pregnancy, Animal; Progesterone; Prolactin | 1993 |
A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients.
Topics: Administration, Oral; Adult; Aminoquinolines; Cabergoline; Dopamine Agents; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged; Prolactin | 1994 |
A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.
Topics: Adolescent; Adult; Amenorrhea; Bromocriptine; Cabergoline; Dopamine Agents; Double-Blind Method; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged; Prolactin | 1994 |
Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline.
Topics: Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1994 |
Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.
Topics: Adult; Aged; Cabergoline; Carbidopa; Dopamine Agents; Drug Combinations; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Receptors, Dopamine | 1993 |
Abortion induction in the cat using prostaglandin F2 alpha and a new anti-prolactinic agent, cabergoline.
Topics: Abortifacient Agents; Abortion, Induced; Animals; Cabergoline; Cats; Dinoprost; Drug Evaluation; Ergolines; Female; Fetal Resorption; Pregnancy; Pregnancy, Animal; Progesterone; Prolactin | 1993 |
Reproduction in a feral cat population and its control with a prolactin inhibitor, cabergoline.
Topics: Abortifacient Agents; Abortion, Induced; Animals; Animals, Wild; Cabergoline; Cats; Dog Diseases; Dogs; Ergolines; Female; Fertility; Male; Mammary Glands, Animal; Obstetric Labor, Premature; Pregnancy; Pregnancy, Animal; Prolactin; Reproduction | 1993 |
Controlled study of the antiparkinsonian activity and tolerability of cabergoline.
Topics: Adult; Aged; Cabergoline; Double-Blind Method; Ergolines; Female; Humans; Male; Middle Aged; Parkinson Disease | 1993 |
Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Prolactinoma | 1996 |
Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect.
Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1996 |
Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline.
Topics: Aged; Amphetamine; Amphetamines; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Drug Interactions; Ergolines; Female; Humans; Male; Methamphetamine; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 1995 |
Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Cabergoline; Dopamine Agonists; Double-Blind Method; Drug Administration Schedule; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Patient Dropouts; Placebos; Treatment Outcome | 1996 |
Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Bromocriptine; Cabergoline; Double-Blind Method; Ergolines; Female; Humans; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1996 |
The chronic administration of cabergoline normalizes androgen secretion and improves menstrual cyclicity in women with polycystic ovary syndrome.
Topics: Adult; Androgens; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Menstrual Cycle; Polycystic Ovary Syndrome | 1996 |
The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers.
Topics: Adult; Analysis of Variance; Blood Chemical Analysis; Blood Pressure; Cabergoline; Cross-Over Studies; Dopamine Agonists; Eating; Electrocardiography; Ergolines; Fasting; Half-Life; Heart Rate; Humans; Male; Radioimmunoassay | 1996 |
Fluoxetine in Parkinson's disease.
Topics: Aged; Cabergoline; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Ergolines; Female; Humans; Male; Middle Aged; Parkinson Disease; Placebos; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1996 |
Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations.
Topics: Adult; Aged; Blood Pressure; Cabergoline; Dose-Response Relationship, Drug; Double-Blind Method; Ergolines; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Placebos; Severity of Illness Index; Time Factors | 1996 |
Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group.
Topics: Aged; Antiparkinson Agents; Cabergoline; Double-Blind Method; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1997 |
Cabergoline for hyperprolactinemia.
Topics: Abnormalities, Drug-Induced; Bromocriptine; Cabergoline; Costs and Cost Analysis; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Ergolines; Female; Humans; Intestinal Absorption; Prolactin | 1997 |
Beneficial effect of cabergoline, new long-lasting D2 agonist in the treatment of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine D2 | 1994 |
Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cabergoline; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 1997 |
Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
Topics: Adolescent; Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Time Factors; Treatment Outcome; Visual Field Tests | 1997 |
Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients.
Topics: Acromegaly; Adenoma; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Hyperprolactinemia; Insulin-Like Growth Factor I; Middle Aged; Pituitary Neoplasms; Pregnancy; Prolactin | 1997 |
[Cabergoline in the inhibition of lactogenesis and suppression of lactopoiesis].
Topics: Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Infant, Newborn; Lactation; Pregnancy; Prolactin; Puerperal Disorders | 1997 |
Cabergoline in the treatment of acromegaly: a study in 64 patients.
Topics: Acromegaly; Adenoma; Adolescent; Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prospective Studies | 1998 |
Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
Topics: Activities of Daily Living; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1998 |
Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.
Topics: Adult; Aminoquinolines; Biomarkers; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Remodeling; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Male; Middle Aged; Prospective Studies | 1998 |
Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine.
Topics: Adult; Bromocriptine; Cabergoline; Cohort Studies; Dopamine Agonists; Ergolines; Follow-Up Studies; Hormones; Humans; Hyperprolactinemia; Libido; Male; Penile Erection; Prolactin; Semen; Time Factors | 1998 |
[Treatment of hyperprolactinemic amenorrhea with cabergoline].
Topics: Adolescent; Adult; Amenorrhea; Bromocriptine; Cabergoline; Dopamine Agonists; Double-Blind Method; Drug Tolerance; Ergolines; Female; Humans; Hyperprolactinemia; Prolactin; Treatment Outcome | 1997 |
Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?
Topics: Acromegaly; Adenoma; Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Pituitary Neoplasms; Prolactin | 1998 |
Effect of chronic administration of cabergoline on uterine perfusion in women with polycystic ovary syndrome.
Topics: Administration, Oral; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Polycystic Ovary Syndrome; Prospective Studies; Pulsatile Flow; Time Factors; Uterus; Vascular Resistance | 1999 |
A study of the aetiology of pseudopregnancy in the bitch and the effect of cabergoline therapy.
Topics: Aggression; Animals; Cabergoline; Dogs; Dopamine Agonists; Ergolines; Female; Lactation; Prolactin; Pseudopregnancy; Treatment Outcome | 1999 |
Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactin; Prolactinoma; Treatment Outcome | 1999 |
Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Topics: Adenoma; Adult; Aminoquinolines; Benzamides; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Iodine Radioisotopes; Magnetic Resonance Imaging; Male; Middle Aged; Patient Selection; Pituitary Neoplasms; Predictive Value of Tests; Prolactin; Prolactinoma; Radionuclide Imaging | 2000 |
Cabergoline, prolactin and melatonin release at night in healthy men.
Topics: Adult; Cabergoline; Circadian Rhythm; Ergolines; Humans; Male; Melatonin; Prolactin | 2000 |
Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline--an open clinical trial.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Polysomnography; Quality of Life; Receptors, Dopamine D2; Restless Legs Syndrome; Severity of Illness Index | 2000 |
Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
Topics: Adolescent; Adult; Aged; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies; Treatment Outcome | 2000 |
The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Topics: Adult; Aminoquinolines; Cabergoline; Cross-Over Studies; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Receptors, Dopamine D2; Treatment Outcome | 2000 |
Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas.
Topics: Adolescent; Adult; Antineoplastic Agents; Cabergoline; Child; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Time Factors; Visual Fields | 2000 |
Study of the change of prolactin and progesterone during dopaminergic agonist treatments in pseudopregnant bitches.
Topics: Animals; Bromocriptine; Cabergoline; Dog Diseases; Dogs; Dopamine Agonists; Ergolines; Female; Placebos; Progesterone; Prolactin; Pseudopregnancy | 2001 |
Control of red fox (Vulpes vulpes) fertility with cabergoline: dose response and timing of intervention.
Topics: Abortion, Induced; Abortion, Veterinary; Animals; Animals, Newborn; Cabergoline; Dose-Response Relationship, Drug; Ergolines; Female; Foxes; Gestational Age; Lactation; Litter Size; Placebos; Pregnancy; Time Factors | 2001 |
Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Topics: Adult; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Treatment Outcome | 2001 |
Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
Topics: Adenoma; Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Hypopituitarism; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Radioimmunoassay; Retrospective Studies | 2001 |
Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dyskinesias; Ergolines; Female; Humans; Male; Motor Activity; Parkinson Disease; Quality of Life; Sleep; Time | 2001 |
Clinical data on restless legs syndrome: a dose-finding study with cabergoline.
Topics: Adult; Aged; Cabergoline; Dopamine Agents; Dose-Response Relationship, Drug; Double-Blind Method; Ergolines; Female; Humans; Male; Restless Legs Syndrome; Surveys and Questionnaires | 2001 |
Effectiveness of cabergoline for termination of pregnancy in silver fox (Vulpes vulpes fulva).
Topics: Abortifacient Agents; Abortion, Induced; Abortion, Veterinary; Administration, Oral; Animals; Cabergoline; Dose-Response Relationship, Drug; Ergolines; Female; Foxes; Pregnancy; Progesterone; Prolactin | 2001 |
Control of fertility in the red fox (Vulpes vulpes): effect of a single oral dose of cabergoline in early pregnancy.
Topics: Abortion, Induced; Abortion, Veterinary; Administration, Oral; Animals; Cabergoline; Dopamine Agonists; Ecosystem; Ergolines; Female; Fertility; Foxes; Litter Size; Male; Population Control; Pregnancy; Pregnancy, Animal | 2002 |
Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline.
Topics: Adenoma; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Treatment Outcome; Visual Acuity | 2001 |
Combination of two different dopamine agonists in the management of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Prospective Studies; Thiazoles; Treatment Outcome | 2002 |
Circulating nitric oxide changes throughout the menstrual cycle in healthy women and women affected by pathological hyperprolactinemia on dopamine agonist therapy.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Estradiol; Female; Humans; Hyperprolactinemia; Luteal Phase; Menstrual Cycle; Nitric Oxide; Ovulation; Pituitary Neoplasms; Progesterone; Prolactinoma; Reference Values | 2002 |
Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cabergoline; Ergolines; Female; Follow-Up Studies; Galactose; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies; Sex Characteristics; Sexual Dysfunction, Physiological; Treatment Outcome; Visual Fields; Weight Gain | 2003 |
[Arrest of lactation after 2nd trimester abortion with a single dose of cabergoline in comparison with 10-day administration of teguride].
Topics: Abortion, Induced; Adolescent; Adult; Cabergoline; Drug Administration Schedule; Ergolines; Female; Humans; Lactation; Lisuride; Pregnancy; Pregnancy Trimester, Second; Prospective Studies | 2003 |
The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cabergoline; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Male; Middle Aged; Motor Activity; Nocturnal Myoclonus Syndrome; Parkinson Disease; Polysomnography; Sleep; Treatment Outcome | 2003 |
Coat colour changes associated with cabergoline administration in bitches.
Topics: Animals; Bromocriptine; Cabergoline; Dog Diseases; Dogs; Dopamine Agonists; Ergolines; Estrous Cycle; Female; Hair Color; Melanocyte-Stimulating Hormones; Pedigree; Pigmentation; Pseudopregnancy | 2003 |
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
Topics: Age of Onset; Benzothiazoles; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Evidence-Based Medicine; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Thiazoles | 2003 |
Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function.
Topics: Adrenocorticotropic Hormone; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Follicle Stimulating Hormone; Humans; Hypopituitarism; Luteinizing Hormone; Male; Middle Aged; Pergolide; Pituitary Function Tests; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma; Testosterone; Thyrotropin | 2002 |
Evaluation of cabergoline and buserelin efficacy for oestrous induction in the bitch.
Topics: Administration, Oral; Animals; Buserelin; Cabergoline; Dogs; Drug Administration Schedule; Ergolines; Estrus; Female; Fertility Agents, Female; Injections, Subcutaneous; Pregnancy; Prolactin; Treatment Outcome | 2003 |
Cabergoline is an effective single-drug treatment for restless legs syndrome: clinical and actigraphic evaluation.
Topics: Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Polysomnography; Restless Legs Syndrome; Single-Blind Method | 2003 |
Cabergoline and silent aspiration in elderly patients with stroke.
Topics: Aged; Cabergoline; Deglutition Disorders; Dopamine Agonists; Ergolines; Female; Humans; Male; Pneumonia, Aspiration; Stroke | 2003 |
Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence.
Topics: Adult; Cabergoline; Case-Control Studies; Circadian Rhythm; Dopamine Agonists; Drug Administration Schedule; Erectile Dysfunction; Ergolines; Humans; Hyperprolactinemia; Longitudinal Studies; Male; Middle Aged; Penile Erection; Testosterone; Treatment Outcome | 2004 |
The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Topics: Adult; Cabergoline; Dopamine Agonists; Drug Tolerance; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2 | 2003 |
Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
Topics: Adolescent; Adult; Aged; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma; Semen; Treatment Outcome | 2004 |
Usefulness of switching to cabergoline from other dopamine agonists in patients with advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Cabergoline; Ergolines; Humans; Parkinson Disease; Pergolide; Prospective Studies; Treatment Outcome | 2004 |
Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma.
Topics: Adult; Cabergoline; Case-Control Studies; Dihydrotestosterone; Dopamine Agonists; Ergolines; Humans; Male; Middle Aged; Pilot Projects; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies; Prostate; Prostatic Hyperplasia; Testosterone; Ultrasonography | 2004 |
Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
Topics: Acromegaly; Adult; Aged; Aged, 80 and over; Cabergoline; Delayed-Action Preparations; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Gastrointestinal Agents; Human Growth Hormone; Humans; Immunohistochemistry; Insulin-Like Growth Factor I; Male; Maximum Tolerated Dose; Middle Aged; Octreotide; Peptides, Cyclic; Prolactin; Prospective Studies; Somatostatin | 2004 |
Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial.
Topics: Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Restless Legs Syndrome; Severity of Illness Index; Time; Time Factors | 2004 |
The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Case-Control Studies; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease; Risk Factors; Time Factors; Treatment Outcome | 2004 |
Effective cabergoline treatment in idiopathic restless legs syndrome.
Topics: Aged; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Ergolines; Female; Gastrointestinal Diseases; Hallucinations; Humans; Male; Middle Aged; Nervous System Diseases; Prospective Studies; Restless Legs Syndrome; Severity of Illness Index; Treatment Outcome | 2004 |
Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST).
Topics: Adult; Cabergoline; Carbidopa; Cocaine-Related Disorders; Dopamine Agents; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Pilot Projects | 2005 |
Cocaine Rapid Efficacy Screening Trial (CREST): a paradigm for the controlled evaluation of candidate medications for cocaine dependence.
Topics: Adolescent; Adult; Antipsychotic Agents; Cabergoline; Cocaine-Related Disorders; Dopamine Agonists; Double-Blind Method; Ergolines; Female; Humans; Male; Neurotransmitter Uptake Inhibitors; Nipecotic Acids; Prospective Studies; Reproducibility of Results; Reserpine; Tiagabine | 2005 |
Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome?
Topics: Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Treatment Outcome | 2005 |
[Suppression of hyperprolactinemia in pituitary microadenoma with cabergoline (Dostinex)].
Topics: Adenoma; Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged; Pituitary Neoplasms; Prolactin; Treatment Outcome; Tumor Burden | 2005 |
Efficacy and safety of high-dose cabergoline in Parkinson's disease.
Topics: Adolescent; Adult; Aged; Amantadine; Antiparkinson Agents; Cabergoline; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Ergolines; Humans; Levodopa; Middle Aged; Nitriles; Parkinson Disease; Piperidines; Prospective Studies; Quality of Life; Selegiline; Severity of Illness Index; Treatment Outcome | 2006 |
Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cabergoline; Clarithromycin; Dopamine Agonists; Drug Interactions; Ergolines; Female; Humans; Male; Middle Aged; Parkinson Disease | 2006 |
The effect of administering a dopamine agonist (Cabergoline) on follicular and luteal development during pro-estrus and estrus in the female greyhound.
Topics: Animals; Cabergoline; Corpus Luteum; Dogs; Dopamine Agonists; Ergolines; Estrous Cycle; Female; Luteinizing Hormone; Male; Ovarian Follicle; Ovulation; Progesterone; Prolactin; Ultrasonography | 2006 |
The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy.
Topics: Adult; Biomarkers; Blood Glucose; C-Reactive Protein; Cabergoline; Cardiovascular Diseases; E-Selectin; Enzyme-Linked Immunosorbent Assay; Ergolines; Female; Humans; Hyperprolactinemia; Inflammation; Insulin; Insulin Resistance; Interleukin-6; Linear Models; Lipids; Male; Middle Aged; Obesity; Risk Factors; Tumor Necrosis Factor-alpha | 2006 |
Treatment of Japanese restless legs syndrome patients with cabergoline: an open clinical preliminary trial.
Topics: Aged; Aged, 80 and over; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Restless Legs Syndrome; Treatment Outcome | 2006 |
A mechanistic account of striatal dopamine function in human cognition: psychopharmacological studies with cabergoline and haloperidol.
Topics: Adolescent; Adult; Attention; Cabergoline; Choice Behavior; Cognition; Computer Simulation; Corpus Striatum; Dopamine; Dopamine Agonists; Dopamine Antagonists; Ergolines; Female; Generalization, Psychological; Haloperidol; Humans; Male; Memory, Short-Term; Models, Neurological; Neuropsychological Tests; Probability Learning; Prolactin; Young Adult | 2006 |
Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR).
Topics: Adolescent; Adult; Aged; Cabergoline; Case-Control Studies; Dopamine Agonists; Double-Blind Method; Drug Administration Schedule; Ergolines; Female; Humans; Male; Middle Aged; Psychometrics; Restless Legs Syndrome; Severity of Illness Index; Statistics, Nonparametric | 2006 |
Cabergoline reverses cortical hyperexcitability in patients with restless legs syndrome.
Topics: Adult; Aged; Brain Diseases; Cabergoline; Dopamine; Dopamine Agonists; Ergolines; Female; Humans; Male; Membrane Potentials; Middle Aged; Motor Cortex; Neural Conduction; Neural Inhibition; Neurons; Pyramidal Tracts; Reaction Time; Restless Legs Syndrome; Synaptic Transmission; Transcranial Magnetic Stimulation; Treatment Outcome | 2006 |
Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Topics: Adenoma; Adult; Antineoplastic Agents, Hormonal; Cabergoline; Dopamine; Drug Screening Assays, Antitumor; Ergolines; Female; Human Growth Hormone; Humans; Ligands; Male; Octreotide; Pituitary Neoplasms; Receptors, Dopamine D2; Receptors, Somatostatin; Recombinant Fusion Proteins; RNA, Messenger; Somatostatin; Tumor Cells, Cultured | 2006 |
Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.
Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Double-Blind Method; Echocardiography; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Hypertrophy, Left Ventricular; Indoles; Male; Middle Aged; Mitral Valve Insufficiency; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Tricuspid Valve Insufficiency | 2007 |
Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial.
Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Ergolines; Europe; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Restless Legs Syndrome | 2007 |
[Comparative evaluation of effectiveness of treatment of hyperprolactinemia].
Topics: Adenoma; Adolescent; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Female; Humans; Hyperprolactinemia; Ovulation; Pituitary Neoplasms; Treatment Outcome | 2007 |
Comparison of the effect of gonadotropin-releasing hormone analog (Diphereline) and Cabergoline (Dostinex) treatment on uterine myoma regression.
Topics: Adult; Biopsy, Needle; Cabergoline; Dose-Response Relationship, Drug; Drug Administration Schedule; Ergolines; Female; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Infusions, Intravenous; Leiomyoma; Middle Aged; Neoplasm Staging; Prospective Studies; Risk Assessment; Treatment Outcome; Uterine Neoplasms | 2007 |
Treatment of spontaneous pyometra in 22 bitches with a combination of cabergoline and cloprostenol.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cabergoline; Cloprostenol; Dog Diseases; Dogs; Drug Therapy, Combination; Endometrial Hyperplasia; Ergolines; Female; Severity of Illness Index; Treatment Outcome; Ultrasonography | 2007 |
Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction.
Topics: Adult; Ascites; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Extracellular Space; Female; Fertilization in Vitro; Granulosa Cells; Hematocrit; Hemoglobins; Humans; Image Processing, Computer-Assisted; Luteal Cells; Magnetic Resonance Imaging; Ovarian Hyperstimulation Syndrome; Ovary; Pregnancy; Prospective Studies; Receptors, Dopamine D2; Regional Blood Flow; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Cabergoline; Catechols; Double-Blind Method; Drug Administration Schedule; Drug Tolerance; Dyskinesias; Ergolines; Female; Humans; Male; Medical Records; Middle Aged; Nitriles; Parkinson Disease; Psychiatric Status Rating Scales; Surveys and Questionnaires | 2007 |
Follicular development and plasma concentrations of LH and prolactin in anestrous female dogs treated with the dopamine agonist cabergoline.
Topics: Anestrus; Animals; Cabergoline; Dogs; Dopamine Agonists; Ergolines; Female; Luteinizing Hormone; Ovarian Follicle; Ovulation Induction; Prolactin | 2007 |
Repeated induction of abortion in bitches and the effect on plasma concentrations of relaxin, progesterone and estradiol-17beta.
Topics: Abortifacient Agents; Abortion, Induced; Abortion, Veterinary; Animals; Cabergoline; Dogs; Drug Combinations; Ergolines; Estradiol; Estrenes; Female; Pregnancy; Progesterone; Relaxin | 2007 |
Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study.
Topics: Abortion, Spontaneous; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Pregnancy; Pregnancy Outcome; Prospective Studies | 2008 |
Cushing's disease in dogs: cabergoline treatment.
Topics: Adrenocorticotropic Hormone; alpha-MSH; Animals; Cabergoline; Dog Diseases; Dogs; Dopamine Agonists; Ergolines; Female; Ketoconazole; Male; Pituitary ACTH Hypersecretion; Time Factors | 2008 |
Augmentation in restless legs syndrome is associated with low ferritin.
Topics: Adult; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Female; Ferritins; Humans; Levodopa; Male; Patient Dropouts; Prospective Studies; Restless Legs Syndrome; Retrospective Studies; Risk Factors | 2008 |
Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Cabergoline; Cross-Sectional Studies; Denmark; Dopamine Agonists; Electrocardiography; Ergolines; Ergot Alkaloids; Female; Heart Valve Diseases; Humans; Logistic Models; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Ultrasonography | 2008 |
Influence of cabergoline on motor excitability in patients with restless legs syndrome.
Topics: Aged; Cabergoline; Dopamine Agonists; Electromyography; Ergolines; Evoked Potentials, Motor; Humans; Middle Aged; Motor Cortex; Muscle Contraction; Muscle, Skeletal; Neural Inhibition; Restless Legs Syndrome; Sensory Thresholds; Severity of Illness Index; Time Factors; Transcranial Magnetic Stimulation; Treatment Outcome | 2007 |
Quality of life in women with microprolactinoma treated with dopamine agonists.
Topics: Adult; Antineoplastic Agents; Brazil; Bromocriptine; Cabergoline; Case-Control Studies; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Female; Health Status Indicators; Humans; Hyperprolactinemia; Middle Aged; Multivariate Analysis; Pituitary Neoplasms; Prolactin; Prolactinoma; Quality of Life; Reproducibility of Results; Surveys and Questionnaires; Treatment Outcome | 2008 |
Cabergoline for suppression of puerperal lactation in a prevention of mother-to-child HIV-transmission programme in rural Malawi.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lactation; Malawi; Postpartum Period; Prolactin; Rural Population | 2008 |
Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson's disease patients. An ambulatory polysomnographic study.
Topics: Aged; Antiparkinson Agents; Cabergoline; Case-Control Studies; Ergolines; Female; Humans; Male; Middle Aged; Outpatients; Parkinson Disease; Polysomnography; Severity of Illness Index; Sleep; Wakefulness | 2008 |
Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas.
Topics: Adult; Cabergoline; Case-Control Studies; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Prolactinoma | 2009 |
Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.
Topics: Adult; Aged; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Resistance; Ergolines; Female; Humans; Male; Middle Aged; Neurosurgical Procedures; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies; Young Adult | 2008 |
Long-term experience of pegvisomant therapy as a treatment for acromegaly.
Topics: Acromegaly; Adult; Aged; Cabergoline; Drug-Related Side Effects and Adverse Reactions; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Retrospective Studies; Somatostatin; Treatment Outcome | 2009 |
Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study.
Topics: Adult; Albumins; Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Ergolines; Estradiol; Female; Fertilization in Vitro; Humans; Oocytes; Ovarian Hyperstimulation Syndrome; Prospective Studies; Risk; Sperm Injections, Intracytoplasmic; Treatment Outcome | 2008 |
Effect of cabergoline on parkinsonian tremor assessed by long-term actigraphy.
Topics: Aged; Antiparkinson Agents; Cabergoline; Ergolines; Female; Humans; Linear Models; Male; Monitoring, Ambulatory; Motor Activity; Parkinson Disease; Pilot Projects; Severity of Illness Index; Tremor | 2009 |
Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: an open preliminary trial in Japan.
Topics: Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Ergolines; Humans; Japan; Outcome Assessment, Health Care; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide.
Topics: Acromegaly; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Cabergoline; Delayed-Action Preparations; Drug Therapy, Combination; Ergolines; Female; Growth Hormone; Humans; Immunohistochemistry; Male; Middle Aged; Octreotide; Prospective Studies; Time Factors; Treatment Outcome | 2009 |
Comparison of the effect of gonadotropin-releasing hormone agonist and dopamine receptor agonist on uterine myoma growth. Histologic, sonographic, and intra-operative changes.
Topics: Adult; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Gonadotropin-Releasing Hormone; Humans; Leiomyoma; Middle Aged; Treatment Outcome; Ultrasonography; Uterine Neoplasms | 2009 |
Follicular dynamics, ovulation and conception rates in bitches.
Topics: Animals; Cabergoline; Dogs; Dopamine Agonists; Ergolines; Estrous Cycle; Female; Fertilization; Gonadotropins; Male; Ovarian Follicle; Ovulation; Pregnancy | 2009 |
Effect of an injectable cabergoline formulation on serum prolactin (PRL) and milk secretion in early postpartum Beagle bitches.
Topics: Animals; Cabergoline; Dogs; Dopamine Agonists; Ergolines; Female; Lactation; Postpartum Period; Pregnancy; Prolactin; Time Factors | 2009 |
Effects of short-term hyper- and hypoprolactinaemia on hormones of the pituitary, gonad and -thyroid axis and on semen quality in male Beagles.
Topics: Animals; Cabergoline; Dogs; Dopamine Agonists; Dopamine Antagonists; Ergolines; Luteinizing Hormone; Male; Metoclopramide; Pituitary Gland; Prolactin; Semen; Testis; Testosterone; Thyroid Gland; Thyrotropin; Thyrotropin-Releasing Hormone; Thyroxine | 2009 |
Cabergoline versus bromocriptine for symptomatic treatment of premenstrual mastalgia: a randomised, open-label study.
Topics: Adult; Analysis of Variance; Breast; Bromocriptine; Cabergoline; Drug Administration Schedule; Ergolines; Female; Hormone Antagonists; Humans; Middle Aged; Pain; Pain Measurement; Premenstrual Syndrome; Prolactin; Quality of Life; Severity of Illness Index; Treatment Outcome | 2010 |
Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.
Topics: Adult; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Hydrocortisone; Ketoconazole; Male; Middle Aged; Pituitary ACTH Hypersecretion; Prospective Studies; Receptors, Dopamine D2; Receptors, Somatostatin; Somatostatin | 2010 |
A comparison of bromocriptine & cabergoline on fertility outcome of hyperprolactinemic infertile women undergoing intrauterine insemination.
Topics: Adult; Bromocriptine; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Infertility, Female; Insemination, Artificial | 2010 |
Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia.
Topics: Adolescent; Adult; Cabergoline; Chi-Square Distribution; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Young Adult | 2010 |
Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly.
Topics: Acromegaly; Adult; Aged; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Insulin-Like Growth Factor I; Middle Aged; Octreotide; Somatostatin | 2010 |
Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias?
Topics: Adult; Antineoplastic Agents; Artifacts; Bias; Cabergoline; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Mitral Valve Insufficiency; Pituitary Neoplasms; Prolactinoma; Tricuspid Valve Insufficiency | 2011 |
The intravaginal application of misoprostol improves induction of abortion with aglepristone.
Topics: Abortifacient Agents; Abortion, Induced; Abortion, Veterinary; Animals; Cabergoline; Cloprostenol; Dogs; Ergolines; Estrenes; Estrogens; Female; Misoprostol; Pregnancy; Progesterone; Time Factors | 2011 |
Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults.
Topics: Adolescent; Adult; Blood Glucose; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Female; Glucose Tolerance Test; Humans; Hyperprolactinemia; Male; Middle Aged; Obesity; Pilot Projects; Prolactin; Weight Loss; Young Adult | 2012 |
Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial.
Topics: Adult; Cabergoline; Dopamine Agents; Ergolines; Female; Fertilization in Vitro; Humans; Incidence; Infertility; Infusions, Intravenous; Iran; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Pregnancy Outcome; Pregnancy Rate; Risk Factors; Serum Albumin; Serum Albumin, Human; Severity of Illness Index; Sperm Injections, Intracytoplasmic; Young Adult | 2012 |
Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
Topics: Acromegaly; Adult; Aged; Aged, 80 and over; Cabergoline; Dopamine Agonists; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Patient Dropouts; Receptors, Somatotropin; United Kingdom | 2012 |
The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy.
Topics: Adult; Aged; Blood Coagulation; Blood Coagulation Factors; Cabergoline; Dopamine Agonists; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Ergolines; Fibrinolysis; Humans; Hydrocortisone; Ketoconazole; Male; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Hormones, Anterior; Remission Induction; Somatostatin; Thrombophilia; Young Adult | 2012 |
Long-term effects of cabergoline and levodopa in Japanese patients with early Parkinson's disease: a 5-year prospective study.
Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Time; Treatment Outcome | 2012 |
Treatment of ovarian hyperstimulation syndrome using gonadotropin releasing hormone antagonist: a pilot study.
Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Ovarian Hyperstimulation Syndrome; Pilot Projects; Young Adult | 2012 |
Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Pregnancy; Sperm Injections, Intracytoplasmic | 2012 |
Cabergoline effect on blood sugar in type 2 diabetic patients with oral agent failure.
Topics: Adult; Blood Glucose; Cabergoline; Diabetes Mellitus, Type 2; Dopamine Agonists; Ergolines; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Treatment Failure | 2012 |
Dopamine D₂ receptor modulation of human response inhibition and error awareness.
Topics: Adolescent; Adult; Awareness; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Humans; Inhibition, Psychological; Male; Motor Activity; Neuropsychological Tests; Psychomotor Performance; Reaction Time; Receptors, Dopamine D2; Signal Detection, Psychological; Time Factors; Young Adult | 2013 |
Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hypopituitarism; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies | 2013 |
Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Hormonal; Biomarkers; Cabergoline; Carotid Intima-Media Thickness; Ergolines; Female; Glucose Tolerance Test; Humans; Inflammation; Insulin Resistance; Middle Aged; Pituitary Neoplasms; Prolactinoma; Young Adult | 2013 |
A comparison between intensive and conventional cabergoline treatment of newly diagnosed patients with macroprolactinoma.
Topics: Adult; Antineoplastic Agents; Cabergoline; Drug Administration Schedule; Echocardiography; Ergolines; Female; Humans; Luminescence; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Prospective Studies; ROC Curve; Treatment Outcome; Young Adult | 2013 |
Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2013 |
Combination therapy for Cushing's disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole?
Topics: Adult; Aged; Biomarkers; Cabergoline; Circadian Rhythm; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Female; Humans; Hydrocortisone; Ketoconazole; Male; Middle Aged; Pituitary ACTH Hypersecretion; Prospective Studies; Saliva; Treatment Outcome | 2014 |
Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cabergoline; Corpus Striatum; Dopamine; Dopamine Agonists; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Single-Blind Method; Treatment Outcome | 2013 |
Clinical outcome according to timing of cabergoline initiation for prevention of OHSS: a randomized controlled trial.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Pregnancy; Treatment Outcome | 2013 |
The effect of cabergoline on folicular microenviroment profile in patients with high risk of OHSS.
Topics: Adult; Anti-Mullerian Hormone; Cabergoline; Cellular Microenvironment; Cohort Studies; Ergolines; Female; Fertilization in Vitro; Follicular Fluid; Hepatocyte Growth Factor; Humans; Inhibins; Insulin-Like Growth Factor I; Ovarian Follicle; Ovarian Hyperstimulation Syndrome; Polycystic Ovary Syndrome; Risk Factors; Young Adult | 2013 |
Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.
Topics: Adult; Antineoplastic Agents; Cabergoline; Cohort Studies; Dopamine Agonists; Drug Monitoring; Early Diagnosis; Ergolines; Female; Follow-Up Studies; Heart Valve Diseases; Heart Valves; Humans; Italy; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Severity of Illness Index; Time Factors; Ultrasonography | 2013 |
Dopamine modulates risk-taking as a function of baseline sensation-seeking trait.
Topics: Adult; Analysis of Variance; Cabergoline; Choice Behavior; Decision Making; Domperidone; Dopamine; Dopamine Agonists; Dopamine Antagonists; Double-Blind Method; Ergolines; Female; Games, Experimental; Humans; Individuality; Memory, Short-Term; Probability; Risk-Taking; Self Report; Sensation; Young Adult | 2013 |
Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch.
Topics: Adult; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Humans; Hydroxyethyl Starch Derivatives; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Plasma Substitutes; Pregnancy; Pregnancy Rate; Prospective Studies; Secondary Prevention; Triptorelin Pamoate | 2013 |
[Clinical comparision of alpha dihydroergocryptine against cabergoline in the treatment of the fibrocystic mastopathy].
Topics: Adolescent; Adult; Cabergoline; Dihydroergocryptine; Ergolines; Female; Fibrocystic Breast Disease; Galactorrhea; Gastrointestinal Diseases; Headache; Humans; Mastodynia; Middle Aged; Prolactin; Prospective Studies; Treatment Outcome; Young Adult | 2013 |
Second attempt to withdraw cabergoline in prolactinomas: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Male; Middle Aged; Pilot Projects; Prolactinoma; Prospective Studies; Young Adult | 2014 |
Does cabergoline help in decreasing endometrioma size compared to LHRH agonist? A prospective randomized study.
Topics: Administration, Oral; Adult; Cabergoline; Dopamine Agonists; Endometriosis; Ergolines; Female; Genital Diseases, Female; Gonadotropin-Releasing Hormone; Humans; Injections, Subcutaneous; Luteolytic Agents; Magnetic Resonance Imaging; Prospective Studies; Triptorelin Pamoate; Ultrasonography | 2014 |
Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
Topics: Adult; Blood Glucose; Bromocriptine; Cabergoline; Cardiovascular Diseases; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Insulin Resistance; Insulin-Like Growth Factor I; Lipids; Middle Aged; Prolactin; Risk Factors | 2015 |
Color Doppler analysis of uterine, spiral, and intraovarian artery blood flow before and after treatment with cabergoline in hyperprolactinemic patients.
Topics: Adolescent; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Ovary; Pilot Projects; Regional Blood Flow; Ultrasonography; Uterine Artery; Uterus; Young Adult | 2015 |
Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome.
Topics: Animals; Cabergoline; Capillary Permeability; Chorionic Gonadotropin; Ergolines; Eye Proteins; Female; Gonadotropins, Equine; Humans; Letrozole; Nerve Growth Factors; Nitriles; Ovarian Hyperstimulation Syndrome; Ovary; Pregnancy; Prospective Studies; Rats; Rats, Wistar; Serpins; Triazoles; Vascular Endothelial Growth Factor A | 2016 |
GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial.
Topics: Adult; Antineoplastic Agents; Cabergoline; Chorionic Gonadotropin; Ergolines; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Gonadotropins; Humans; Incidence; Outcome Assessment, Health Care; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Young Adult | 2016 |
Evaluation of the effects of cabergoline (Dostinex) on women with symptomatic myomatous uterus: a randomized trial.
Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Leiomyoma; Single-Blind Method; Treatment Outcome; Uterine Hemorrhage; Uterine Neoplasms; Young Adult | 2016 |
Effects of cabergoline on blood glucose levels in type 2 diabetic patients: A double-blind controlled clinical trial.
Topics: Blood Glucose; Cabergoline; Diabetes Mellitus, Type 2; Dopamine Agonists; Double-Blind Method; Ergolines; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged | 2016 |
Comparing the effect of aromatase inhibitor (letrozole) + cabergoline (Dostinex) and letrozole alone on uterine myoma regression,a randomized clinical trial.
Topics: Adult; Antineoplastic Agents; Aromatase Inhibitors; Cabergoline; Drug Therapy, Combination; Ergolines; Female; Humans; Leiomyoma; Letrozole; Middle Aged; Nitriles; Triazoles; Uterine Neoplasms; Uterus | 2017 |
Lack of Increase in Sexual Drive and Function After Dopaminergic Stimulation in Women.
Topics: Adult; Arousal; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Female; Humans; Sexual Behavior; Sexual Dysfunction, Physiological | 2018 |
A pilot study of cabergoline for the treatment of metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Cabergoline; Disease Progression; Ergolines; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pilot Projects; Retreatment; Treatment Outcome | 2017 |
Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Estradiol; Female; Gonadotropin-Releasing Hormone; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Pregnancy Rate; Sperm Injections, Intracytoplasmic | 2018 |
Laparoscopic ovarian drilling versus GnRH antagonist combined with cabergoline as a prophylaxis against the re-development of ovarian hyperstimulation syndrome.
Topics: Adult; Cabergoline; Chemoprevention; Clomiphene; Drug Resistance; Ergolines; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Gynecologic Surgical Procedures; Hormone Antagonists; Humans; Infertility, Female; Laparoscopy; Ovarian Hyperstimulation Syndrome; Ovary; Ovulation Induction; Polycystic Ovary Syndrome; Pregnancy; Secondary Prevention; Treatment Failure | 2018 |
COMPARISON OF CABERGOLINE VERSUS RALOXIFENE ADD-ON THERAPY TO LONG-ACTING SOMATOSTATIN ANALOGUE IN PATIENTS WITH INADEQUATELY CONTROLLED ACROMEGALY: A RANDOMIZED OPEN LABEL CLINICAL TRIAL.
Topics: Acromegaly; Adult; Blood Pressure; Cabergoline; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Logistic Models; Male; Middle Aged; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Somatostatin | 2018 |
680 other study(ies) available for cabergoline and ergoline
| Article | Year |
|---|---|
Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.
Topics: Bromocriptine; Cabergoline; Dopamine Agents; Ergolines; Humans; Lung Diseases; Male; Middle Aged; Parkinson Disease; Pleural Effusion | 1992 |
Determination of cabergoline in plasma and urine by high-performance liquid chromatography with electrochemical detection.
Topics: Cabergoline; Chromatography, High Pressure Liquid; Dopamine Agents; Electrochemistry; Ergolines; Humans; Prolactin; Quality Control | 1992 |
Radioimmunoassay for the synthetic ergoline derivative cabergoline in biological fluids.
Topics: Aged; Cabergoline; Cross Reactions; Dopamine Agents; Ergolines; Evaluation Studies as Topic; Humans; Male; Parkinson Disease; Radioimmunoassay; Reference Standards; Sensitivity and Specificity | 1992 |
Excretion balance and urinary metabolic pattern of [3H]cabergoline in man.
Topics: Adult; Cabergoline; Drug Stability; Ergolines; Feces; Humans; Male; Prolactin; Scintillation Counting; Tritium | 1992 |
Cabergoline in the long-term therapy of hyperprolactinemic disorders.
Topics: Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Drug Resistance; Ergolines; Female; Humans; Hyperprolactinemia; Male; Menstruation Disturbances; Middle Aged; Ovulation; Pituitary Neoplasms; Prolactinoma | 1992 |
Cardiopressor effects of short-term treatment with cabergoline in L-dopa stable responder parkinsonian patients: relevance of postprandial hypotension.
Topics: Aged; Blood Pressure; Cabergoline; Dopamine Agents; Ergolines; Female; Food; Heart Rate; Humans; Hypotension; Hypotension, Orthostatic; Male; Middle Aged; Parkinson Disease; Time Factors | 1991 |
Pleuropulmonary disease associated with dopamine agonist therapy.
Topics: Aged; Cabergoline; Dopamine Agents; Ergolines; Female; Humans; Lisuride; Lung Diseases; Male; Middle Aged; Parkinson Disease; Pleural Diseases; Radiography | 1991 |
Osteocalcin levels in patients with microprolactinoma before and during medical treatment.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Density; Cabergoline; Dihydroergotoxine; Dopamine Agents; Ergolines; Estradiol; Female; Humans; Hyperprolactinemia; Osteocalcin; Pituitary Neoplasms; Prolactin; Prolactinoma | 1990 |
In vivo interaction of cabergoline with rat brain dopamine receptors labelled with [3H]N-n-propylnorapomorphine.
Topics: Administration, Oral; Animals; Apomorphine; Brain Chemistry; Bromocriptine; Cabergoline; Dopamine Agents; Dose-Response Relationship, Drug; Ergolines; Female; In Vitro Techniques; Injections, Intravenous; Kinetics; Rats; Rats, Inbred Strains; Receptors, Dopamine | 1990 |
Cabergoline: a long-acting dopamine agonist in Parkinson's disease.
Topics: Administration, Oral; Antiparkinson Agents; Cabergoline; Drug Evaluation; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 1990 |
New perspectives in medical management of hyperprolactinemia.
Topics: Adenoma; Bromocriptine; Cabergoline; Delayed-Action Preparations; Empty Sella Syndrome; Ergolines; Female; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms | 1990 |
Reduction in the size of prolactin-producing pituitary tumor after Cabergoline administration.
Topics: Adolescent; Adult; Antineoplastic Agents; Cabergoline; Dopamine Agents; Ergolines; Female; Humans; Pituitary Neoplasms; Prolactin; Prolactinoma; Time Factors; Tomography, X-Ray Computed | 1989 |
Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients.
Topics: Adenoma; Adult; Amenorrhea; Bromocriptine; Cabergoline; Dopamine Agents; Ergolines; Female; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactin | 1989 |
Effect of subacute cabergoline treatment on prolactin, thyroid stimulating hormone and growth hormone response to simultaneous administration of thyrotrophin-releasing hormone and growth hormone-releasing hormone in hyperprolactinaemic women.
Topics: Adult; Cabergoline; Dopamine Agents; Ergolines; Female; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hyperprolactinemia; Middle Aged; Prolactin; Stimulation, Chemical; Thyrotropin; Thyrotropin-Releasing Hormone; Time Factors | 1989 |
Effects on pseudopregnancy, pregnancy and interoestrous intervals of pharmacological suppression of prolactin secretion in female dogs and cats.
Topics: Abortion, Spontaneous; Animals; Birth Weight; Cabergoline; Cats; Dogs; Dose-Response Relationship, Drug; Ergolines; Estrus; Female; Lactation; Pregnancy; Pregnancy, Animal; Progesterone; Prolactin; Pseudopregnancy | 1989 |
[Possibilities for estrus induction in the bitch with an ergoline derivative].
Topics: Animals; Cabergoline; Dogs; Ergolines; Estrus; Female; Prolactin | 1988 |
Inhibitory effect of cabergoline on the development of estrogen-induced prolactin-secreting adenomas of the pituitary.
Topics: Adenoma; Animals; Antineoplastic Agents; Body Weight; Bromocriptine; Cabergoline; DNA, Neoplasm; Ergolines; Estrogens; Female; Mitosis; Pituitary Neoplasms; Prolactin; Rats | 1988 |
Dose-related prolactin inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal, and hyperprolactinemic women.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cabergoline; Delayed-Action Preparations; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Hyperprolactinemia; Menstrual Cycle; Middle Aged; Postpartum Period; Pregnancy; Prolactin; Receptors, Dopamine | 1987 |
Inhibition of basal and metoclopramide-induced prolactin release by cabergoline, an extremely long-acting dopaminergic drug.
Topics: Adult; Cabergoline; Dopamine; Ergolines; Humans; Male; Metoclopramide; Prolactin; Stimulation, Chemical; Time Factors | 1987 |
Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients.
Topics: Adult; Aged; Blood Pressure; Bromocriptine; Cabergoline; Ergolines; Female; Growth Hormone; Humans; Hyperprolactinemia; Male; Middle Aged; Time Factors | 1986 |
Antitumor activity of FCE 21336, a new prolactin lowering drug, on the MXT mouse mammary carcinoma.
Topics: Animals; Antineoplastic Agents; Bromocriptine; Cabergoline; Dose-Response Relationship, Drug; Ergolines; Female; Mammary Neoplasms, Experimental; Mice; Prolactin | 1985 |
Effect of octreotide on circulating IGF-I chromatographic profile: evidence for an inhibitory action on the formation of the 150-kDa ternary complex.
Topics: Acromegaly; Adult; Bromocriptine; Cabergoline; Carrier Proteins; Ergolines; Growth Hormone; Humans; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Middle Aged; Octreotide | 1995 |
In vivo effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors.
Topics: Animals; Antineoplastic Agents; Bromocriptine; Cabergoline; Cytoplasmic Granules; Dopamine Agonists; Endoplasmic Reticulum; Ergolines; Estradiol; Female; Microscopy, Electron; Organ Size; Pituitary Neoplasms; Prolactin; Rats; Rats, Inbred F344 | 1995 |
Cabergoline in Parkinson's disease.
Topics: Cabergoline; Dopamine Agonists; Ergolines; Humans; Parkinson Disease | 1995 |
Effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors: in vitro culture studies.
Topics: Animals; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Estradiol; Female; Pituitary Neoplasms; Prolactin; Rats; Rats, Inbred F344; Tumor Cells, Cultured | 1995 |
X-ray crystal structure and conformational analysis of N-(3-dimethylaminopropyl)-N-(ethylaminocarbonyl)-6-(2-propenyl)er goline -8 beta-carboxamide (Cabergoline): comparison with bromocriptine and lisuride and a hypothesis for its high dopaminergic activi
Topics: Bromocriptine; Cabergoline; Crystallography, X-Ray; Dopamine Agonists; Ergolines; Lisuride; Molecular Conformation; Structure-Activity Relationship | 1995 |
Drenching sweats as an off phenomenon in Parkinson's disease: treatment and relation to plasma levodopa profile.
Topics: Aged; Bromocriptine; Cabergoline; Chorea; Dopamine Agonists; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Monitoring, Physiologic; Parkinson Disease; Pergolide; Sweating | 1995 |
Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers.
Topics: Adult; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Humans; Male; Prolactin | 1995 |
Cabergoline: an advance in dopaminergic therapy.
Topics: Cabergoline; Dopamine Agents; Ergolines; Female; Humans; Hyperprolactinemia; Patient Compliance; Pregnancy; Prolactin | 1994 |
Cabergoline in Parkinson's disease: long-term follow-up.
Topics: Adult; Aged; Cabergoline; Dopamine Agents; Drug Therapy, Combination; Ergolines; Female; Follow-Up Studies; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 1993 |
Disposition and urinary metabolic pattern of cabergoline, a potent dopaminergic agonist, in rat, monkey and man.
Topics: Administration, Oral; Adult; Animals; Bile; Biotransformation; Cabergoline; Dopamine Agents; Ergolines; Feces; Female; Humans; Hydrolysis; Macaca fascicularis; Male; Rats; Rats, Sprague-Dawley; Species Specificity | 1993 |
Cabergoline treated hyperprolactinaemia results in pregnancy in a bromocriptine intolerant patient after seventeen years of infertility.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agents; Ergolines; Female; Humans; Hyperprolactinemia; Infertility, Female; Pregnancy | 1994 |
Progress in the management of hyperprolactinemia.
Topics: Amenorrhea; Bromocriptine; Cabergoline; Dopamine Agents; Ergolines; Female; Humans; Hyperprolactinemia | 1994 |
Effectiveness of cabergoline in reducing follicle-stimulating hormone and prolactin hypersecretion from pituitary macroadenoma in an infertile woman.
Topics: Adenoma; Adult; Amenorrhea; Cabergoline; Dopamine Agonists; Ergolines; Female; Follicle Stimulating Hormone; Humans; Infertility, Female; Pituitary Neoplasms; Pregnancy; Prolactin | 1994 |
Regulation of progesterone during pregnancy in the cat: studies on the roles of corpora lutea, placenta and prolactin secretion.
Topics: Animals; Cabergoline; Cats; Corpus Luteum; Ergolines; Female; Megestrol; Megestrol Acetate; Ovariectomy; Placenta; Pregnancy; Pregnancy, Animal; Progesterone; Prolactin; Pseudopregnancy | 1993 |
No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Brain; Cabergoline; Carbidopa; Diabetes Mellitus; Ergolines; Female; Free Radicals; Humans; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Oxidative Stress; Parkinson Disease; Selegiline; Vitamin E | 1995 |
Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease.
Topics: Aged; Cabergoline; Dopamine Agonists; Drug Tolerance; Dyskinesia, Drug-Induced; Edema; Ergolines; Female; Humans; Male; Middle Aged; Parkinson Disease | 1995 |
Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Vagina | 1996 |
Differential effects of three dopamine receptor agonists in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Macaca fascicularis; Parkinson Disease, Secondary; Pergolide | 1995 |
Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.
Topics: Animals; Bacterial Proteins; Base Sequence; Benzazepines; Blotting, Western; Cabergoline; Corpus Striatum; Denervation; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Ergolines; Female; Gene Expression Regulation; Genes, fos; Haloperidol; Indoles; Macaca fascicularis; Male; Molecular Weight; MPTP Poisoning; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease, Secondary; Phenanthridines; Polymerase Chain Reaction; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Receptors, Dopamine D1; RNA, Messenger; Species Specificity; Time Factors; Transcription Factors | 1996 |
Practical use of a combination of a dopamine agonist and a synthetic prostaglandin analogue to terminate unwanted pregnancy in dogs.
Topics: Abortion, Induced; Abortion, Veterinary; Administration, Oral; Animals; Cabergoline; Cloprostenol; Dogs; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Injections, Subcutaneous; Pregnancy; Pregnancy Outcome; Progesterone | 1996 |
Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients.
Topics: Analysis of Variance; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Treatment Outcome | 1995 |
Cabergoline in Parkinson's disease complicated by motor fluctuations.
Topics: Aged; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Ergolines; Humans; Middle Aged; Parkinson Disease; Receptors, Dopamine D2 | 1996 |
Dopamine receptor affinities in vitro and stereotypic activities in vivo of cabergoline in rats.
Topics: Animals; Benzazepines; Binding, Competitive; Bromocriptine; Cabergoline; Dopamine Agonists; Dopamine Antagonists; Ergolines; In Vitro Techniques; Male; Pergolide; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Stereotyped Behavior | 1996 |
Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Cabergoline; Catecholamines; Dopamine Agonists; Ergolines; Female; Macaca fascicularis; Motor Activity; Movement Disorders; Putamen; Stereotyped Behavior | 1996 |
Effect of cabergoline, a long-acting dopamine D2 agonist, on reserpine-treated rodents.
Topics: Animals; Cabergoline; Dopamine Agonists; Ergolines; Levodopa; Male; Mice; Motor Activity; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Reserpine | 1996 |
Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.
Topics: Adenoma; Adolescent; Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Gonads; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Visual Fields | 1996 |
In vivo investigation of luteal function in dogs: effects of cabergoline, a dopamine agonist, and prolactin on progesterone secretion during mid-pregnancy and -diestrus.
Topics: Animals; Cabergoline; Corpus Luteum; Diestrus; Dogs; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Injections, Intravenous; Injections, Subcutaneous; Luteal Phase; Luteinizing Hormone; Pregnancy; Pregnancy, Animal; Progesterone; Prolactin; Radioimmunoassay; Random Allocation; Time Factors | 1997 |
Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Cabergoline; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Hyperkinesis; Levodopa; Macaca fascicularis; Movement; Parkinson Disease, Secondary | 1996 |
Effect of different dopaminergic agents in the treatment of acromegaly.
Topics: Acromegaly; Adult; Aminoquinolines; Bromocriptine; Cabergoline; Delayed-Action Preparations; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Male; Middle Aged; Prolactin | 1997 |
Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
Topics: Adolescent; Adult; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Drug Resistance; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma | 1997 |
Prevention and termination of pregnancy in rats by cabergoline, a dopamine agonist.
Topics: Animals; Cabergoline; Contraceptive Agents, Female; Dopamine Agonists; Embryo Implantation; Ergolines; Estradiol; Female; Male; Pregnancy; Pregnancy, Animal; Progesterone; Prolactin; Rats; Rats, Sprague-Dawley | 1997 |
Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Infertility, Male; Male; Menstruation Disturbances; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma | 1997 |
Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy.
Topics: Aminoquinolines; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Humans; Pituitary Neoplasms; Prolactinoma | 1997 |
Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy.
Topics: Aminoquinolines; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Humans; Pituitary Neoplasms; Prolactinoma | 1997 |
Cabergoline treatment of acromegaly: a preliminary dose finding study.
Topics: Acromegaly; Adult; Aged; Cabergoline; Depression, Chemical; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Ergolines; Female; Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Prolactin | 1997 |
Effect and mechanisms of the anti-prolactin drug cabergoline on pseudopregnancy in the bitch.
Topics: Animals; Behavior, Animal; Cabergoline; Dog Diseases; Dogs; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Hysterectomy; Ovariectomy; Progesterone; Prolactin; Pseudopregnancy | 1997 |
Metastatic prolactinoma: effect of octreotide, cabergoline, carboplatin and etoposide; immunocytochemical analysis of proto-oncogene expression.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Carboplatin; Ergolines; Etoposide; Female; Gene Expression; Humans; Immunohistochemistry; Indium Radioisotopes; Magnetic Resonance Imaging; Middle Aged; Octreotide; Pituitary Neoplasms; Prolactinoma; Proto-Oncogene Mas; Proto-Oncogenes; Somatostatin; Treatment Failure | 1997 |
Effects of cabergoline in a pituitary adenoma secreting follicle-stimulating hormone.
Topics: Adenoma; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Follicle Stimulating Hormone; Humans; Male; Middle Aged; Pituitary Neoplasms | 1997 |
Termination of dioestrus and induction of oestrus in dioestrous nonpregnant bitches by the prolactin antagonist cabergoline.
Topics: Animals; Breeding; Cabergoline; Diestrus; Dogs; Dopamine Agonists; Ergolines; Estrus; Female; Infertility, Female; Pregnancy; Progesterone; Prolactin; Uterus; Vaginal Smears | 1997 |
Termination of pregnancy in cats using a combination of cabergoline, a new dopamine agonist, and a synthetic PGF2 alpha, cloprostenol.
Topics: Abortion, Induced; Administration, Oral; Animals; Cabergoline; Cats; Cloprostenol; Dopamine Agonists; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Female; Injections, Subcutaneous; Pregnancy; Progesterone | 1997 |
[Therapy of Parkinson disease. Continuous physiologic dopaminergic stimulation with carbergoline].
Topics: Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Humans; Parkinson Disease | 1997 |
Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy.
Topics: Adenoma; Adolescent; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Kinetics; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactin | 1997 |
Quantitative determination of cabergoline in human plasma using liquid chromatography combined with tandem mass spectrometry.
Topics: Cabergoline; Calibration; Chromatography, Liquid; Dopamine Agonists; Ergolines; Humans; Indicators and Reagents; Mass Spectrometry; Reference Standards; Solutions | 1998 |
Effects of acute or prolonged administration of cabergoline on parkinsonism induced by MPTP in common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cabergoline; Callithrix; Dopamine Agents; Dopamine Agonists; Ergolines; Female; Male; Motor Activity; Parkinson Disease, Secondary | 1998 |
Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients.
Topics: Acromegaly; Administration, Oral; Adult; Aged; Cabergoline; Data Interpretation, Statistical; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Growth Hormone; Hormones; Humans; Injections, Subcutaneous; Male; Middle Aged; Octreotide | 1997 |
[Administration of combination therapy with synthetic pgf2alpha analogs and a dopamine agonist for the termination of unwanted pregnancy in pregnant dogs. A study of six cases].
Topics: Abortifacient Agents; Abortion, Induced; Animals; Cabergoline; Cloprostenol; Dinoprost; Dogs; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Injections, Subcutaneous; Pregnancy | 1998 |
Late development of resistance to bromocriptine in a patient with macroprolactinoma.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma | 1998 |
Treatment of lactating sows with the dopamine agonist Cabergoline: effects on LH and prolactin secretion and responses to challenges with naloxone and morphine.
Topics: Analysis of Variance; Animals; Cabergoline; Dopamine Agonists; Ergolines; Estradiol; Female; Lactation; Luteinizing Hormone; Morphine; Naloxone; Narcotic Antagonists; Narcotics; Prolactin; Radioimmunoassay; Random Allocation; Swine | 1998 |
Effects of cabergoline on reproduction in three families of Australian marsupials.
Topics: Administration, Oral; Animals; Animals, Newborn; Body Weight; Cabergoline; Dopamine Agonists; Ergolines; Female; Injections, Intramuscular; Lactation; Macropodidae; Marsupialia; Pregnancy; Pregnancy, Animal; Prolactin; Reproduction | 1998 |
In vitro production of progesterone and estradiol by rat granulosa cells regulated by cabergoline and prolactin.
Topics: Animals; Cabergoline; Cells, Cultured; Culture Media, Serum-Free; Dopamine Agonists; Ergolines; Estradiol; Female; Follicle Stimulating Hormone; Granulosa Cells; Progesterone; Prolactin; Radioimmunoassay; Rats; Rats, Sprague-Dawley | 1998 |
[Cabergolin: new horizons in the therapy of Parkinson diseases].
Topics: Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Humans; Parkinson Disease; Restless Legs Syndrome | 1998 |
[Cabergoline].
Topics: Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Pregnancy; Prolactin | 1998 |
Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Benzazepines; Brain Chemistry; Cabergoline; Corpus Striatum; Denervation; Dopamine Agents; Dopamine Agonists; Enkephalins; Ergolines; Female; Gene Expression; Macaca fascicularis; Movement Disorders; Protein Precursors; Pulsatile Flow; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger; Tachykinins | 1999 |
New hyperprolactinemia and anovulation model in common marmoset (Callithrix jacchus) and effect of cabergoline.
Topics: Animals; Anovulation; Bromocriptine; Cabergoline; Callithrix; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Ergolines; Estradiol; Female; Hyperprolactinemia; Menstrual Cycle; Progesterone; Prolactin; Sulpiride; Time Factors | 1999 |
Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Humans; Lung Diseases; Male; Parkinson Disease, Secondary; Pericarditis, Constrictive; Pleural Diseases; Tomography, X-Ray Computed | 1999 |
Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline.
Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Magnetic Resonance Imaging; Pituitary Neoplasms; Prolactin; Time Factors | 1999 |
Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Basal Ganglia; Benzazepines; Cabergoline; Denervation; Dopamine Agonists; Ergolines; Female; Flunitrazepam; gamma-Aminobutyric Acid; Macaca fascicularis; Ovariectomy; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, GABA-A; Tritium | 1999 |
Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Topics: Adenoma; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Drug Tolerance; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Retrospective Studies; Sex Characteristics | 1999 |
Low dose cabergoline induced interstitial pneumonitis.
Topics: Aged; Biopsy; Bronchoalveolar Lavage Fluid; Cabergoline; Diagnosis, Differential; Dopamine Agonists; Ergolines; Humans; Lung Diseases, Interstitial; Male; Parkinson Disease; Radiography, Thoracic; Tomography, X-Ray Computed | 1999 |
Toward the establishment of a clinical prediction rule for response of prolactinomas to cabergoline.
Topics: Antineoplastic Agents; Cabergoline; Ergolines; Humans; Pituitary Neoplasms; Prolactinoma | 1999 |
Toward the establishment of a clinical prediction rule for response of prolactinomas to cabergoline.
Topics: Antineoplastic Agents; Cabergoline; Ergolines; Humans; Pituitary Neoplasms; Prolactinoma | 1999 |
Cabergoline and gallbladder motility in healthy men.
Topics: Adult; Cabergoline; Cholelithiasis; Ergolines; Gallbladder; Gallbladder Emptying; Humans; Male; Ultrasonography | 1999 |
Giant prolactinoma presented as unilateral exophthalmos in a prepubertal boy: response to cabergoline.
Topics: Antineoplastic Agents; Cabergoline; Child; Ergolines; Exophthalmos; Humans; Male; Pituitary Neoplasms; Prolactin; Prolactinoma | 1999 |
Dopamine agonist therapy in hyperprolactinemia.
Topics: Aminoquinolines; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Female; Humans; Hyperprolactinemia; Male; Pregnancy; Pregnancy Complications | 1999 |
Complete remission of Nelson's syndrome after 1-year treatment with cabergoline.
Topics: Adenoma; Adrenalectomy; Adrenocorticotropic Hormone; Adult; Antineoplastic Agents; Cabergoline; Cushing Syndrome; Dopamine Agonists; Ergolines; Humans; Magnetic Resonance Imaging; Male; Nelson Syndrome; Pituitary Neoplasms; Remission Induction | 1999 |
Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.
Topics: Adolescent; Adult; Aminoquinolines; Analysis of Variance; Biomarkers; Bone Density; Bone Remodeling; Bromocriptine; Cabergoline; Case-Control Studies; Collagen; Collagen Type I; Dopamine Agonists; Ergolines; Female; Femur Neck; Humans; Longitudinal Studies; Lumbar Vertebrae; Male; Middle Aged; Osteocalcin; Osteoporosis; Peptides; Pituitary Neoplasms; Prolactinoma; Regression Analysis | 2000 |
Effect of stage of anestrus on the induction of estrus by the dopamine agonist cabergoline in dogs.
Topics: Anestrus; Animals; Behavior, Animal; Cabergoline; Dogs; Dopamine Agonists; Ergolines; Estradiol; Female; Fertility; Luteinizing Hormone; Male; Pregnancy; Progesterone; Prolactin; Vagina | 1999 |
Osteopenia in children and adolescents with hyperprolactinemia.
Topics: Adolescent; Antineoplastic Agents; Bone Density; Bone Diseases, Metabolic; Cabergoline; Child; Empty Sella Syndrome; Ergolines; Female; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms; Prolactinoma; Puberty, Delayed | 2000 |
125I-CGP 64213 binding to GABA(B) receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Autoradiography; Basal Ganglia; Benzazepines; Benzoates; Binding Sites; Brain; Cabergoline; Corpus Striatum; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Ergolines; Female; GABA Antagonists; GABA-B Receptor Antagonists; Injections, Subcutaneous; Iodine Radioisotopes; Macaca fascicularis; Organophosphorus Compounds; Parkinson Disease, Secondary; Receptors, GABA-B; Substantia Nigra; Thalamus | 2000 |
Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-monkeys.
Topics: Animals; Antiparkinson Agents; Binding Sites; Cabergoline; Disease Models, Animal; Ergolines; Female; In Situ Hybridization; Macaca fascicularis; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2000 |
Reduction of lipid peroxidation in different rat brain areas after cabergoline treatment.
Topics: Animals; Antioxidants; Cabergoline; Catalase; Corpus Striatum; Ergolines; Glutathione Peroxidase; Hippocampus; Lipid Peroxidation; Male; Oxidative Stress; Rats; Rats, Wistar; Superoxide Dismutase | 2000 |
Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma.
Topics: Adenoma, Acidophil; Adolescent; Antineoplastic Agents, Hormonal; Cabergoline; Delayed-Action Preparations; Dopamine Agonists; Ergolines; Female; Gigantism; Hormones; Humans; Magnetic Resonance Imaging; Octreotide; Pituitary Neoplasms; Receptors, Dopamine D2; Receptors, Somatostatin; Reverse Transcriptase Polymerase Chain Reaction; Stem Cells | 2000 |
Images in thyroidology. Left exophthalmos of endocrine nonthyroid origin in a seven-year-old boy.
Topics: Antineoplastic Agents; Cabergoline; Child; Ergolines; Exophthalmos; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma | 2000 |
Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients.
Topics: Acromegaly; Adult; Aminoquinolines; Cabergoline; Dopamine Agonists; Drug Synergism; Drug Therapy, Combination; Ergolines; Female; Hormones; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Octreotide; Peptides, Cyclic; Somatostatin; Time Factors | 1999 |
Cabergoline and quinagolide therapy for prolactinomas.
Topics: Aminoquinolines; Cabergoline; Cross-Over Studies; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Pituitary Neoplasms; Prolactinoma; Research Design; Treatment Outcome | 2000 |
Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas.
Topics: Adolescent; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Hydrocortisone; Hypopituitarism; Insulin-Like Growth Factor I; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Recovery of Function; Treatment Outcome | 2000 |
Comparative effects of repeated administration of dopamine agonists on circling behavior in rats.
Topics: Animals; Benzothiazoles; Brain; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Indoles; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pergolide; Pramipexole; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Dopamine D1; Receptors, Dopamine D2; Thiazoles | 2000 |
In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Hormonal; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; Octreotide; Pituitary Neoplasms; Prognosis; Thyrotropin | 2001 |
Tumour shrinkage and chiasmal herniation after successful cabergoline treatment for a macroprolactinoma.
Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Hernia; Humans; Magnetic Resonance Imaging; Male; Optic Chiasm; Optic Nerve Diseases; Pituitary Neoplasms; Prolactinoma | 2001 |
ACTH silent adenoma shrinking under cabergoline.
Topics: Adenoma; Adrenocorticotropic Hormone; Aged; Antineoplastic Agents; Autoradiography; Cabergoline; Ergolines; Humans; In Situ Hybridization; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2; RNA, Messenger | 2001 |
Long-term treatment of thyrotropin-secreting microadenoma with lanreotide and cabergoline.
Topics: Adenoma; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Ergolines; Female; Humans; Peptides, Cyclic; Somatostatin; Thyrotropin; Time Factors | 2001 |
[Dostinex (cabergoline)- a significant advance in prolactin control].
Topics: Administration, Oral; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Luteinizing Hormone; Receptors, Dopamine D2; Time Factors; Treatment Outcome | 2000 |
Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.
Topics: Adult; Antipsychotic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Hypogonadism; Male; Middle Aged; Prolactin; Psychotic Disorders; Risperidone | 2000 |
Treatment versus no treatment of transient hyperprolactinemia in patients undergoing intracytoplasmic sperm injection programs.
Topics: Adult; Bromocriptine; Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Embryo Transfer; Ergolines; Estradiol; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Hyperprolactinemia; Luteolytic Agents; Oocytes; Prolactin; Retrospective Studies; Sperm Injections, Intracytoplasmic; Treatment Outcome; Triptorelin Pamoate | 2000 |
Cabergoline.
Topics: Animals; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Pregnancy | 2000 |
Control of unremitting rheumatoid arthritis by the prolactin antagonist cabergoline.
Topics: Adult; Arthritis, Rheumatoid; Cabergoline; Ergolines; Female; Humans; Prolactin; Treatment Failure | 2001 |
A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzothiazoles; Cabergoline; Disorders of Excessive Somnolence; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Retrospective Studies; Thiazoles | 2001 |
Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases.
Topics: Acromegaly; Adenoma; Adolescent; Amenorrhea; Bromocriptine; Cabergoline; Child; Ergolines; Female; Headache; Human Growth Hormone; Humans; Male; Neoplasm Recurrence, Local; Octreotide; Pituitary Neoplasms; Prolactinoma; Puberty, Delayed; Radiotherapy; Treatment Outcome; Vision Disorders; Visual Fields | 2001 |
Cabergoline-induced CSF rhinorrhea in patients with macroprolactinoma. Report of three cases.
Topics: Adult; Cabergoline; Cerebrospinal Fluid Rhinorrhea; Endoscopy; Ergolines; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Tomography, X-Ray Computed | 2001 |
In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Topics: Acromegaly; Adrenocorticotropic Hormone; Adult; Aminoquinolines; Analysis of Variance; Antineoplastic Agents, Hormonal; Cabergoline; Dopamine Agonists; Ergolines; Female; Follicle Stimulating Hormone; Growth Hormone; Humans; Immunohistochemistry; Indium Radioisotopes; Insulin-Like Growth Factor I; Iodine Radioisotopes; Luteinizing Hormone; Male; Octreotide; Pituitary Neoplasms; Prolactin; Prolactinoma; Receptors, Dopamine; Receptors, Somatostatin; Thyrotropin; Tumor Cells, Cultured | 2001 |
Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method.
Topics: Adult; Bromocriptine; Cabergoline; Cohort Studies; Ergolines; Female; Fertility; Headache; Humans; Magnetic Resonance Imaging; Medical Records; Menstruation; Menstruation Disturbances; Middle Aged; Pituitary Gland; Polyethylene Glycols; Prolactin; Tomography, X-Ray Computed | 2001 |
Regulation of dopamine receptors and motor behavior following pulsatile and continuous dopaminergic replacement strategies in the MPTP primate model.
Topics: Aminoquinolines; Animals; Behavior, Animal; Benzazepines; Cabergoline; Disease Models, Animal; Dopamine Agonists; Ergolines; Female; Gene Expression; Imidazoles; Infusion Pumps, Implantable; Macaca fascicularis; Motor Activity; Parkinsonian Disorders; Pulse Therapy, Drug; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger | 2001 |
Cabergoline, a hopeful medicine for prolactinomas and non-tumoral hyperprolactinemia.
Topics: Antineoplastic Agents, Hormonal; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactinoma; Treatment Outcome | 2001 |
Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome.
Topics: Adult; Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Ergolines; Estradiol; Female; Follicle Stimulating Hormone; Humans; Hyperprolactinemia; Infertility, Female; Ovarian Follicle; Ovarian Hyperstimulation Syndrome; Ovary; Ovulation Induction; Polycystic Ovary Syndrome; Pregnancy; Recombinant Proteins; Time Factors; Ultrasonography | 2001 |
Determination of cabergoline by electrospray ionization tandem mass spectrometry: picogram detection via column focusing sample introduction.
Topics: Animals; Cabergoline; Carnivora; Ergolines; Flow Injection Analysis; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2001 |
Actigraph analysis of diurnal motor fluctuations during dopamine agonist therapy.
Topics: Aged; Antiparkinson Agents; Cabergoline; Circadian Rhythm; Electrophysiology; Ergolines; Female; Humans; Male; Middle Aged; Monitoring, Physiologic; Motor Activity; Parkinson Disease | 2001 |
Hepatolithiasis (intrahepatic stone) during octreotide therapy for acromegaly: a case report.
Topics: Abdominal Pain; Acromegaly; Adenoma; Adult; Anti-Bacterial Agents; Bile Ducts, Intrahepatic; Bilirubin; Cabergoline; Chemical and Drug Induced Liver Injury; Cholangiopancreatography, Endoscopic Retrograde; Cholelithiasis; Cholesterol; Ergolines; Gram-Negative Bacterial Infections; Hepatectomy; Humans; Insulin-Like Growth Factor I; Liver; Liver Diseases; Male; Octreotide; Pituitary Neoplasms; Postoperative Complications; Sepsis; Surgical Wound Infection | 2000 |
[Dostinex - the most effective medicine for inhibition of postpartal lactation].
Topics: Cabergoline; Dopamine Agents; Drug Administration Schedule; Ergolines; Female; Humans; Lactation; Pregnancy; Prolactin | 2001 |
Is cabergoline a better drug to inhibit lactation in patients with psychotic symptoms?
Topics: Cabergoline; Depression, Postpartum; Dopamine Agonists; Ergolines; Female; Humans; Lactation; Psychotic Disorders | 2002 |
Effects of short- and long-acting dopamine agonists on sensitized dopaminergic neurotransmission in rats with unilateral 6-OHDA lesions.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Drug Antagonism; Ergolines; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Synaptic Transmission | 2002 |
Cabergoline can increase penile erections and libido.
Topics: Aged; Animals; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Humans; Libido; Male; Parkinson Disease; Penile Erection | 2002 |
Giant prolactinomas presenting as skull base tumors.
Topics: Adult; Cabergoline; Diagnosis, Differential; Dopamine Agonists; Ergolines; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Pituitary Neoplasms; Prolactin; Prolactinoma; Skull Base Neoplasms | 2002 |
Macroprolactinoma associated with Cushing's disease, successfully treated with cabergoline.
Topics: Adrenocorticotropic Hormone; Adult; Antineoplastic Agents; Cabergoline; Cushing Syndrome; Dexamethasone; Ergolines; Glucocorticoids; Humans; Hydrocortisone; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Thyrotropin-Releasing Hormone; Treatment Outcome | 2002 |
Use of cabergoline to treat primary and secondary anestrus in dogs.
Topics: Anestrus; Animals; Cabergoline; Dogs; Dopamine Agonists; Ergolines; Female; Fertility; Ovarian Follicle; Ovulation Induction; Pregnancy; Progesterone; Prospective Studies; Safety; Treatment Outcome; Vagina; Vaginal Smears | 2002 |
The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals.
Topics: Aminoacyltransferases; Animals; Cabergoline; Corpus Striatum; Dopamine Agonists; Drug Administration Schedule; Ergolines; Free Radical Scavengers; Glutathione; Glutathione Reductase; Glutathione Transferase; Male; Mice; Mice, Inbred ICR; Neuroprotective Agents; RNA, Messenger | 2002 |
Successful treatment of a large macroprolactinoma with cabergoline during pregnancy.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactinoma | 2001 |
Antioxidant properties of cabergoline: inhibition of brain auto-oxidation and superoxide anion production of microglial cells in rats.
Topics: Animals; Animals, Newborn; Antioxidants; Brain; Cabergoline; Cells, Cultured; Dose-Response Relationship, Drug; Ergolines; Male; Microglia; Oxidation-Reduction; Rats; Rats, Wistar; Superoxides; Vitamin E | 2002 |
Assessment of cabergoline as a reproductive inhibitor in coyotes (Canis latrans).
Topics: Abortifacient Agents, Steroidal; Administration, Oral; Animals; Animals, Zoo; Cabergoline; Carnivora; Dose-Response Relationship, Drug; Drug Administration Schedule; Ergolines; Female; Litter Size; Male; Pregnancy; Progesterone; Prolactin; Time Factors | 2002 |
A practical synthesis of cabergoline.
Topics: Cabergoline; Catalysis; Chemistry, Organic; Dopamine Agents; Ergolines; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Prolactin; Stereoisomerism; Urea | 2002 |
Microstructure of the non-rapid eye movement sleep electroencephalogram in patients with newly diagnosed Parkinson's disease: effects of dopaminergic treatment.
Topics: Aged; Brain; Cabergoline; Delta Rhythm; Dopamine Agonists; Drug Therapy, Combination; Electroencephalography; Electromyography; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Sleep, REM; Wakefulness | 2002 |
The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.
Topics: Adult; Anastrozole; Aromatase Inhibitors; Bromocriptine; Cabergoline; Dopamine Agonists; Enzyme Inhibitors; Ergolines; Hormone Replacement Therapy; Humans; Magnetic Resonance Imaging; Male; Nitriles; Pituitary Neoplasms; Prolactin; Prolactinoma; Sexual Dysfunction, Physiological; Testosterone; Treatment Outcome; Triazoles | 2002 |
Effect of cabergoline on thyroid function in hyperprolactinaemia.
Topics: Cabergoline; Dopamine Agonists; Ergolines; Humans; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Thyrotropin; Thyroxine | 2002 |
Long term tolerability of high dose ergoline derived dopamine agonist therapy for the treatment of Parkinson's disease.
Topics: Adult; Aged; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Drug Tolerance; Ergolines; Female; Humans; Male; Middle Aged; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic; Time | 2002 |
Detecting dose-response using contrasts: asymptotic power and sample size determination for binomial data.
Topics: Cabergoline; Computer Simulation; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Humans; Hyperprolactinemia; Monte Carlo Method; Randomized Controlled Trials as Topic; Research Design; Sample Size | 2002 |
Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome.
Topics: Adenoma; Antineoplastic Agents; Body Height; Cabergoline; DNA Mutational Analysis; Ergolines; Fibrous Dysplasia, Polyostotic; GTP-Binding Protein alpha Subunits, Gs; Human Growth Hormone; Insulin-Like Growth Factor I; Magnetic Resonance Imaging; Octreotide; Pituitary Neoplasms | 2002 |
Cabergoline prevents necrotic neuronal death in an in vitro model of oxidative stress.
Topics: Cabergoline; Cell Death; Cell Survival; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Ergolines; Free Radicals; Haloperidol; Humans; Lipid Peroxidation; Models, Neurological; Necrosis; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Receptors, Dopamine D2; tert-Butylhydroperoxide; Tumor Cells, Cultured | 2002 |
Cabergoline plasma concentration is increased during concomitant treatment with itraconazole.
Topics: Adult; Aged; Antifungal Agents; Antiparkinson Agents; Cabergoline; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Ergolines; Female; Humans; Itraconazole; Male; Neurologic Examination; Onychomycosis; Parkinson Disease; Treatment Outcome | 2002 |
Alopecia induced by dopamine agonists.
Topics: Aged; Alopecia; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Humans; Male; Parkinson Disease | 2002 |
Selective control of the estrous cycle of the dog through suppression of estrus and reduction of the length of anestrus.
Topics: Anestrus; Animals; Cabergoline; Dogs; Ergolines; Estrus; Female; Hormone Antagonists; Progesterone; Prolactin; Random Allocation; Testosterone | 2003 |
Radioimmunoassay of prolactin for the meerkat (Suricata suricatta), a cooperatively breeding carnivore.
Topics: Animals; Cabergoline; Carnivora; Dogs; Dose-Response Relationship, Drug; Ergolines; Female; Hormone Antagonists; Male; Pituitary Gland; Prolactin; Radioimmunoassay; Reference Values; Reproducibility of Results; Restraint, Physical; Stress, Psychological; Sulpiride | 2003 |
Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia.
Topics: Anti-Obesity Agents; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Male; Weight Loss | 2003 |
Prolactinomas, dopamine agonists and headache: two case reports.
Topics: Adult; Amenorrhea; Anti-Inflammatory Agents, Non-Steroidal; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Headache; Humans; Indomethacin; Magnetic Resonance Imaging; Pituitary Neoplasms; Prolactin; Prolactinoma; Radiography | 2003 |
Involvement of PI3'-K, mitogen-activated protein kinase and protein kinase B in the up-regulation of the expression of nNOSalpha and nNOSbeta splicing variants induced by PRL-receptor activation in GH3 cells.
Topics: Alternative Splicing; Animals; Antibodies; Cabergoline; Cell Line; Enzyme Inhibitors; Ergolines; Exons; Isoenzymes; Mitogen-Activated Protein Kinases; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Pituitary Gland; Prolactin; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Receptors, Prolactin; Signal Transduction; Up-Regulation | 2003 |
Accurate mass measurement at enhanced mass-resolution on a triple quadrupole mass-spectrometer for the identification of a reaction impurity and collisionally-induced fragment ions of cabergoline.
Topics: Cabergoline; Drug Contamination; Ergolines; Ions; Molecular Structure; Pharmaceutical Preparations; Spectrometry, Mass, Electrospray Ionization | 2003 |
[Efficacy of cabergoline in the treatment of macroprolactinoma].
Topics: Adult; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma; Time Factors | 2003 |
[Macroadenoma of the pituitary gland with moderate hyperprolactinaemia].
Topics: Cabergoline; Diagnosis, Differential; Ergolines; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Middle Aged; Neoplasm, Residual; Pituitary Gland; Pituitary Neoplasms; Postoperative Complications; Prolactinoma | 2003 |
Giant prolactinomas in men: efficacy of cabergoline treatment.
Topics: Adrenal Glands; Adult; Aged; Antineoplastic Agents; Cabergoline; Erectile Dysfunction; Ergolines; Humans; Hypothyroidism; Libido; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma; Vision Disorders | 2003 |
[Cabergoline in the treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Brain; Cabergoline; Drug Tolerance; Ergolines; Humans; Parkinson Disease; Randomized Controlled Trials as Topic | 2003 |
Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Astrocytes; Blotting, Northern; Brain-Derived Neurotrophic Factor; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Ergolines; Glial Cell Line-Derived Neurotrophic Factor; Mice; Mice, Inbred ICR; Nerve Growth Factor; Nerve Growth Factors; Pergolide; Receptors, Dopamine D1; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors | 2003 |
Determination of cabergoline and L-dopa in human plasma using liquid chromatography-tandem mass spectrometry.
Topics: Adult; Cabergoline; Case-Control Studies; Chromatography, Liquid; Dopamine Agonists; Ergolines; Humans; Levodopa; Middle Aged; Reproducibility of Results; Schizophrenia; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2003 |
[Three patients with Parkinson's disease whose therapeutic levels were successfully improved after administration of quetiapine for suppression of psychosis].
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Cabergoline; Dibenzothiazepines; Ergolines; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Quetiapine Fumarate | 2003 |
Paraquat leads to dopaminergic neural vulnerability in organotypic midbrain culture.
Topics: 1-Methyl-4-phenylpyridinium; Analysis of Variance; Animals; Animals, Newborn; Azepines; Cabergoline; Caspases; Cell Count; Cycloheximide; Dizocilpine Maleate; Dopamine Agonists; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Ergolines; Excitatory Amino Acid Antagonists; Herbicides; Immunohistochemistry; Mesencephalon; NADPH Dehydrogenase; Neuroprotective Agents; NG-Nitroarginine Methyl Ester; Organ Culture Techniques; Paraquat; Piperazines; Protein Synthesis Inhibitors; Quinoxalines; Rats; Rats, Wistar; Selegiline; Tyrosine 3-Monooxygenase | 2003 |
Cabergoline versus levodopa monotherapy: a decision analysis.
Topics: Antiparkinson Agents; Cabergoline; Cost-Benefit Analysis; Decision Making; Disease Progression; Ergolines; Female; Humans; Levodopa; Male; Markov Chains; Middle Aged; Parkinson Disease; Severity of Illness Index | 2003 |
High-sensitivity quantitation of cabergoline and pergolide using a triple-quadrupole mass spectrometer with enhanced mass-resolution capabilities.
Topics: Animals; Cabergoline; Cattle; Chromatography, High Pressure Liquid; Dopamine Agonists; Ergolines; Pergolide; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2003 |
Restless legs syndrome.
Topics: Apomorphine; Cabergoline; Dopamine Agonists; Ergolines; Europe; Humans; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes | 2003 |
Falsely low serum prolactin in two cases of invasive macroprolactinoma.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; False Negative Reactions; Headache; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Pituitary Function Tests; Pituitary Neoplasms; Prolactin; Prolactinoma; Skull Base Neoplasms; Vision Disorders | 2002 |
Bedtime cabergoline in Parkinson's disease patients with excessive daytime sleepiness induced by dopamine agonists.
Topics: Aged; Antiparkinson Agents; Cabergoline; Disorders of Excessive Somnolence; Dopamine Agonists; Drug Administration Schedule; Drug Interactions; Ergolines; Female; Humans; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Pilot Projects; Prospective Studies; Psychomotor Performance; Time Factors | 2003 |
Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies; Recurrence; Withholding Treatment | 2003 |
Effects of acute prolactin manipulation on sexual drive and function in males.
Topics: Adult; Blood Pressure; Cabergoline; Cross-Over Studies; Dopamine Agonists; Epinephrine; Ergolines; Erotica; Heart Rate; Humans; Male; Norepinephrine; Orgasm; Prolactin; Psychometrics; Sexual Behavior; Single-Blind Method; Thyrotropin; Thyrotropin-Releasing Hormone | 2003 |
Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Cabergoline; Disease Models, Animal; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Ergolines; Female; Locomotion; Macaca fascicularis; Parkinson Disease; Posture | 2003 |
Improvement of sleep hypopnea by antiparkinsonian drugs in a patient with Parkinson's disease: a polysomnographic study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Cabergoline; Ergolines; Humans; Levodopa; Male; Parkinson Disease; Polysomnography; Sleep Apnea Syndromes | 2003 |
[Clinical and therapeutic aspects of prolactinoma in men].
Topics: Adolescent; Adult; Age of Onset; Biomarkers; Bromocriptine; Cabergoline; Chi-Square Distribution; Dopamine Agonists; Ergolines; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Pituitary Neoplasms; Prolactin; Prolactinoma; Statistics, Nonparametric; Treatment Outcome | 2003 |
The treatment of polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; Diabetes Complications; Dopamine Agonists; Ergolines; Female; Finasteride; Flutamide; Follicle Stimulating Hormone; Gonadotropins; Hirsutism; Humans; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metformin; Mineralocorticoid Receptor Antagonists; Obesity; Ovulation Induction; Polycystic Ovary Syndrome; Risk Factors; Spironolactone; Weight Loss | 2004 |
Prolactinomas.
Topics: Antineoplastic Agents; Cabergoline; Ergolines; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactin; Prolactinoma; Withholding Treatment | 2004 |
Prolactinomas.
Topics: Antineoplastic Agents; Cabergoline; Ergolines; Follow-Up Studies; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactin; Prolactinoma; Recurrence; Withholding Treatment | 2004 |
[Pharmacologic cure of a pituitary macroprolactinoma].
Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma | 2003 |
Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study.
Topics: Adult; Antipsychotic Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Prolactin; Receptors, Dopamine D2; Risperidone; Schizophrenia; Schizophrenic Psychology | 2004 |
Increased serum concentration of nerve growth factor in patients with microprolactinoma.
Topics: Adult; Cabergoline; Dopamine Antagonists; Ergolines; Female; Humans; Immunoenzyme Techniques; Nerve Growth Factor; Pituitary Neoplasms; Prolactin; Prolactinoma; Stimulation, Chemical; Thyrotropin-Releasing Hormone | 2004 |
Induction of abortion in queens by administration of cabergoline (Galastop) solely or in combination with the PGF2alpha analogue Alfaprostol (Gabbrostim).
Topics: Abortion, Induced; Abortion, Veterinary; Animals; Cabergoline; Cats; Ergolines; Female; Pregnancy; Progesterone; Prostaglandins F; Time Factors | 2004 |
Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment.
Topics: Adult; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Protein Isoforms; Protein Subunits; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Dopamine D4; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Tumor Cells, Cultured; Visual Fields | 2004 |
Cabergoline protects SH-SY5Y neuronal cells in an in vitro model of ischemia.
Topics: Animals; Antioxidants; Cabergoline; Cell Death; Cell Hypoxia; Cell Line, Transformed; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Ergolines; Free Radical Scavengers; Free Radicals; Gene Expression; Genes, bcl-2; Glucose; Haloperidol; Humans; Ischemia; Neurons; Thiobarbituric Acid Reactive Substances; Time Factors; Tretinoin; Vitamin E | 2004 |
Prolactinoma presenting as painful postganglionic Horner syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Bromocriptine; Cabergoline; Carotid Arteries; Dopamine Agonists; Ergolines; Horner Syndrome; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Migraine Disorders; Neoplasm Recurrence, Local; p-Hydroxyamphetamine; Pituitary Neoplasms; Prolactin; Prolactinoma; Remission Induction | 2004 |
Dopamine receptor expression and function in corticotroph pituitary tumors.
Topics: Adenoma; Adrenocorticotropic Hormone; Adult; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Immunoblotting; Immunohistochemistry; Male; Middle Aged; Pituitary Neoplasms; Radioligand Assay; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2004 |
Resolution of macroprolactinoma-induced symptomatic hydrocephalus following cabergoline therapy.
Topics: Adenoma; Aged; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hydrocephalus; Male; Pituitary Neoplasms; Prolactinoma | 2004 |
Cabergoline stimulates synthesis and secretion of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor by mouse astrocytes in primary culture.
Topics: Animals; Astrocytes; Brain-Derived Neurotrophic Factor; Cabergoline; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Ergolines; Glial Cell Line-Derived Neurotrophic Factor; Mice; Mice, Inbred ICR; Nerve Growth Factor; Nerve Growth Factors; Neuroprotective Agents; Receptors, Dopamine D1; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction | 2004 |
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.
Topics: Adult; Aged; Cabergoline; Carbidopa; Dopamine Agonists; Drug Combinations; Echocardiography, Transesophageal; Ergolines; Ergot Alkaloids; Female; Heart Valve Diseases; Humans; Levodopa; Male; Parkinson Disease; Pergolide | 2004 |
Cabergoline versus levodopa monotherapy.
Topics: Antiparkinson Agents; Cabergoline; Cost-Benefit Analysis; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease | 2004 |
Re: Cabergoline versus levodopa monotherapy: a decision analysis.
Topics: Age Factors; Antiparkinson Agents; Cabergoline; Cost-Benefit Analysis; Decision Support Techniques; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease; Prospective Studies; Surveys and Questionnaires | 2004 |
Synergistic inhibition of lipid peroxidation by vitamin E and a dopamine agonist, cabergoline.
Topics: Antioxidants; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Ergolines; In Vitro Techniques; Kinetics; Lipid Peroxidation; Liposomes; Time Factors; Vitamin E | 2004 |
Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease.
Topics: Antiparkinson Agents; Cabergoline; Ergolines; Fibrosis; Humans; Male; Middle Aged; Parkinson Disease; Pericarditis, Constrictive; Pleura; Pulmonary Fibrosis | 2004 |
Massive reduction of tumour load and normalisation of hyperprolactinaemia after high dose cabergoline in metastasised prolactinoma causing thoracic syringomyelia.
Topics: Adult; Antineoplastic Agents; Brain Stem Neoplasms; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Pituitary Neoplasms; Prolactinoma; Treatment Outcome | 2004 |
Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Domperidone; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Ergot Alkaloids; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Therapeutic Equivalency; Thiazoles | 2004 |
Lifecorder: a new device for the long-term monitoring of motor activities for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cabergoline; Circadian Rhythm; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Monitoring, Ambulatory; Motor Activity; Parkinson Disease | 2004 |
A fatal overdose of the ergot derivative cabergoline.
Topics: Aged; Antiparkinson Agents; Cabergoline; Chromatography, Ion Exchange; Drug Overdose; Ergolines; Female; Gas Chromatography-Mass Spectrometry; Humans; Liver; Molecular Structure; Parkinson Disease; Spectrometry, Mass, Electrospray Ionization | 2004 |
Cardiopulmonary complications of ergot-derivative dopamine agonists.
Topics: Antipsychotic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Pergolide; Pulmonary Fibrosis; Risperidone | 2004 |
Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared.
Topics: Aortic Valve; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Fibrosis; Heart Valve Diseases; Humans; Parkinson Disease; Pergolide | 2004 |
[Recurrence of prolactinoma surveyed. Hormone therapy can safely be withdrawn for a long time in patients with normalized prolactin levels and invisible tumor].
Topics: Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma | 2004 |
Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment.
Topics: Adenoma; Adrenalectomy; Adrenocorticotropic Hormone; Adult; Bromocriptine; Cabergoline; Cyproheptadine; Dopamine Agonists; Ergolines; Female; Hormone Replacement Therapy; Humans; Magnetic Resonance Imaging; Nelson Syndrome; Pituitary Neoplasms | 2004 |
Dopamine agonist cabergoline inhibits levodopa-induced caspase activation in 6-OHDA-lesioned mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Cabergoline; Carbidopa; Caspases; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Agonists; Drug Combinations; Drug Interactions; Enzyme Activation; Ergolines; Glutathione; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred ICR; Neurotoxicity Syndromes; Oxidopamine; Thiobarbituric Acid Reactive Substances | 2005 |
Restless legs: do they keep you awake?
Topics: Adult; Aged; Cabergoline; Dopamine; Dopamine Agonists; Ergolines; Humans; Middle Aged; Nocturnal Myoclonus Syndrome; Restless Legs Syndrome; Sleep Deprivation | 2004 |
Relief in sight for restless legs syndrome.
Topics: Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Genetic Predisposition to Disease; Humans; Restless Legs Syndrome; Treatment Outcome | 2004 |
Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors.
Topics: Acromegaly; Adult; Antineoplastic Agents; Biomarkers; Cabergoline; Ergolines; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Magnetic Resonance Imaging; Male; Pituitary Gland; Pituitary Neoplasms; Prolactin | 2004 |
Dopamine agonist treatment before and after the birth reduces prolactin concentration but does not impair paternal responsiveness in Djungarian hamsters, Phodopus campbelli.
Topics: Animals; Bromocriptine; Cabergoline; Cricetinae; Dopamine Agonists; Ergolines; Female; Male; Parturition; Paternal Behavior; Phodopus; Pregnancy; Prolactin; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2005 |
Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma.
Topics: Adenoma; Adrenocorticotropic Hormone; Cabergoline; Dopamine Agonists; Ergolines; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Receptors, Dopamine D2; Treatment Outcome | 2004 |
Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma.
Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Hypopituitarism; Magnetic Resonance Imaging; Male; Pituitary Diseases; Pituitary Neoplasms; Prolactin; Prolactinoma; Stroke | 2004 |
Cabergoline decreases somatotroph adenoma size: a case report.
Topics: Adenoma; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cabergoline; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Pituitary Neoplasms; Treatment Outcome | 2004 |
Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson's disease patients treated with cabergoline.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cabergoline; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Male; Middle Aged; Parkinson Disease; Pulmonary Fibrosis; Retroperitoneal Fibrosis; Retrospective Studies | 2005 |
Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly.
Topics: Acromegaly; Adult; Aged; Aged, 80 and over; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Prolactin; Retrospective Studies; Somatostatin | 2005 |
The clinical characteristics of headache in patients with pituitary tumours.
Topics: Adenoma; Adult; Aminoquinolines; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Disability Evaluation; Dopamine Agonists; Ergolines; Female; Headache; Humans; Male; Migraine Disorders; Octreotide; Peptides, Cyclic; Pituitary Neoplasms; Severity of Illness Index; Somatostatin; Time Factors | 2005 |
Prolactin in the brushtail possum (Trichosurus vulpecula): development of homologous radioimmunoassay using recombinant possum prolactin.
Topics: Animals; Biological Assay; Blotting, Western; Cabergoline; Dopamine Agonists; Ergolines; Female; Granulosa Cells; Male; New Zealand; Opossums; Progesterone; Prolactin; Radioimmunoassay; Radioligand Assay; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA; Thyrotropin-Releasing Hormone | 2005 |
Cabergoline plus lanreotide for ectopic Cushing's syndrome.
Topics: ACTH Syndrome, Ectopic; Adult; Cabergoline; Carcinoid Tumor; Cushing Syndrome; Drug Therapy, Combination; Ergolines; Humans; Lung Neoplasms; Male; Peptides, Cyclic; Somatostatin | 2005 |
A case of postprandial cluster-like headache with prolactinoma: dramatic response to cabergoline.
Topics: Adolescent; Antineoplastic Agents; Cabergoline; Cluster Headache; Eating; Ergolines; Humans; Male; Pituitary Neoplasms; Prolactinoma; Recurrence; Treatment Outcome | 2005 |
The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.
Topics: Bromocriptine; Cabergoline; Child; Dopamine Agonists; Ergolines; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma; Treatment Outcome | 2005 |
Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas.
Topics: Adolescent; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2005 |
Pituitary apoplexy: a review of clinical presentation, management and outcome in 45 cases.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Cabergoline; Combined Modality Therapy; Decompression, Surgical; Ergolines; Female; Humans; Hypopituitarism; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Apoplexy; Pituitary Gland; Pituitary Neoplasms; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Vision Disorders | 2004 |
Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation.
Topics: Acromegaly; Cabergoline; Cell Division; Cell Line, Tumor; Dopamine; Ergolines; Gene Expression; Humans; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor II; Lung Neoplasms; Peptides, Cyclic; Pituitary Neoplasms; Receptors, Dopamine; Receptors, Somatostatin; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Somatostatin | 2005 |
Severe digital vasospasm caused by cabergoline.
Topics: Adult; Antineoplastic Agents; Cabergoline; Constriction, Pathologic; Ergolines; Female; Fingers; Humans; Peripheral Vascular Diseases; Pituitary Neoplasms; Prolactinoma | 2005 |
Psychiatric sequelae of Parkinson disease: a case report.
Topics: Antiparkinson Agents; Cabergoline; Carbidopa; Compulsive Behavior; Drug Combinations; Ergolines; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sex Offenses | 2006 |
Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients.
Topics: Acromegaly; Adult; Aged; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Octreotide | 2005 |
Obstructive hydrocephalus and intracranial hypertension caused by a giant macroprolactinoma. Prompt response to medical treatment.
Topics: Adult; Cabergoline; Dopamine Agonists; Drainage; Ergolines; Humans; Hydrocephalus; Intracranial Hypertension; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma; Treatment Outcome | 2006 |
Cystic macroprolactinoma: primary medical treatment?
Topics: Adolescent; Cabergoline; Central Nervous System Cysts; Dopamine Agonists; Ergolines; Female; Headache; Humans; Hyperprolactinemia; Treatment Outcome | 2005 |
Cabergoline-related severe restrictive mitral regurgitation.
Topics: Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Humans; Male; Mitral Valve; Mitral Valve Insufficiency; Parkinson Disease; Ultrasonography | 2005 |
Effects of the dopamine agonist cabergoline on the pulsatile and TRH-induced secretion of prolactin, LH, and testosterone in male beagle dogs.
Topics: Administration, Oral; Animals; Area Under Curve; Cabergoline; Dogs; Dopamine Agonists; Ergolines; Luteinizing Hormone; Male; Prolactin; Testosterone; Thyrotropin-Releasing Hormone | 2006 |
Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Topics: Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Pergolide; Pituitary Neoplasms; Prolactin; Prolactinoma; Remission Induction; Retrospective Studies; Treatment Outcome | 2005 |
A case of macroprolactinoma and elevated insulin-like growth factor-I in a young boy.
Topics: Antineoplastic Agents; Cabergoline; Child; Ergolines; Glucose Tolerance Test; Humans; Hypothyroidism; Insulin-Like Growth Factor I; Male; Pituitary Neoplasms; Prolactinoma | 2005 |
Cabergoline and mitral regurgitation.
Topics: Aged; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Male; Mitral Valve Insufficiency; Parkinson Disease | 2006 |
Combination dopamine agonist and prostaglandin agonist treatment of cystic endometrial hyperplasia-pyometra complex in the bitch.
Topics: Animals; Cabergoline; Cloprostenol; Dog Diseases; Dogs; Dopamine Agonists; Drug Therapy, Combination; Endometrial Hyperplasia; Endometritis; Ergolines; Female; Prostaglandins, Synthetic; Ultrasonography; Uterine Diseases | 2006 |
Suppression of prolactin does not reduce infant care by parentally experienced male common marmosets (Callithrix jacchus).
Topics: Animals; Behavior, Animal; Cabergoline; Callithrix; Dopamine Agonists; Ergolines; Male; Nesting Behavior; Paternal Behavior; Prolactin; Sexual Behavior, Animal | 2006 |
Morphology of canine placental sites after induced embryonic or fetal death.
Topics: Animals; Cabergoline; Cloprostenol; Dogs; Embryo Loss; Ergolines; Estrenes; Female; Fetal Death; Immunohistochemistry; Microscopy, Electron, Transmission; Placenta; Pregnancy | 2006 |
The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males.
Topics: Adult; Antineoplastic Agents; Cabergoline; Case-Control Studies; Drug Administration Schedule; Ergolines; Gonadotropins; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies; Semen; Sperm Count; Spermatozoa; Testosterone; Time Factors; Treatment Outcome | 2006 |
Headache induced by dopamine agonists prescribed for prolactinoma: think SUNCT!
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Headache; Humans; Male; Prolactinoma; Syndrome | 2006 |
Postischemic delayed Holmes' tremor responding to low-dose cabergoline.
Topics: Antiparkinson Agents; Brain Stem Infarctions; Cabergoline; Dose-Response Relationship, Drug; Ergolines; Humans; Ischemia; Male; Middle Aged; Tremor | 2006 |
Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy.
Topics: Adult; Cabergoline; Carotid Artery, Internal; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Sphenoid Sinus; Treatment Outcome | 2006 |
Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of 'hook effect'.
Topics: Abducens Nerve Diseases; Cabergoline; Diagnosis, Differential; Diagnostic Errors; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Oculomotor Nerve Diseases; Pituitary Neoplasms; Prolactin; Prolactinoma; Skull Base Neoplasms; Trochlear Nerve Diseases | 2006 |
Cabergoline in Huntington's disease: the first case report.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Huntington Disease; Treatment Outcome | 2006 |
Persistent sexual side effects after SSRI discontinuation.
Topics: Adult; Androgens; Anxiety; Bupropion; Cabergoline; Citalopram; Depressive Disorder; Dopamine Agonists; Dopamine Uptake Inhibitors; Ergolines; Female; Fluoxetine; Humans; Male; Monoamine Oxidase Inhibitors; Piperazines; Plants, Medicinal; Purines; Selective Serotonin Reuptake Inhibitors; Selegiline; Sertraline; Sexual Dysfunctions, Psychological; Sildenafil Citrate; Sleep Initiation and Maintenance Disorders; Sulfones; Testosterone; Time Factors; Treatment Outcome; Vasodilator Agents | 2006 |
Cabergoline scavenges peroxynitrite enhanced by L-DOPA therapy in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cabergoline; Chromatography, High Pressure Liquid; Ergolines; Female; Free Radical Scavengers; Humans; Levodopa; Male; Oxidative Stress; Parkinson Disease; Peroxynitrous Acid; Tyrosine | 2006 |
Chronic paroxysmal hemicrania in a patient with a macroprolactinoma.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cabergoline; Causality; Diagnosis, Differential; Dopamine Agonists; Ergolines; Female; Humans; Indomethacin; Paroxysmal Hemicrania; Prolactinoma; Treatment Outcome | 2006 |
Dramatic remission of treatment-resistant depression after the cessation of tricyclic antidepressants.
Topics: Adult; Antidepressive Agents, Tricyclic; Cabergoline; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Female; Fluvoxamine; Humans; Imipramine; Substance Withdrawal Syndrome; Treatment Outcome | 2006 |
Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study.
Topics: Aged; Antiparkinson Agents; Cabergoline; Circadian Rhythm; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Sleep; Wakefulness | 2006 |
[Constrictive pericarditis caused by carbergoline].
Topics: Aged; Antiparkinson Agents; Cabergoline; Dopamine Agents; Ergolines; Humans; Male; Pericarditis, Constrictive | 2006 |
Clinical and biochemical stabilization of Nelson's syndrome with long-term low-dose cabergoline treatment.
Topics: Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Middle Aged; Nelson Syndrome; Treatment Outcome | 2006 |
TMS-assisted neurophysiological profiling of the dopamine receptor agonist cabergoline in human motor cortex.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Evoked Potentials, Motor; Humans; Motor Cortex; Neuronal Plasticity; Transcranial Magnetic Stimulation | 2007 |
Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model.
Topics: Animals; Cabergoline; Capillary Permeability; Corpus Luteum; Disease Models, Animal; Dopamine Agonists; Ergolines; Female; Neovascularization, Physiologic; Ovarian Hyperstimulation Syndrome; Phosphorylation; Rats; Rats, Wistar; Receptors, Dopamine D2; RNA, Messenger; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Potential for long-term remission of microprolactinoma after withdrawal of dopamine-agonist therapy.
Topics: Adolescent; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma | 2006 |
Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas.
Topics: Adenoma; Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Gonadotropins; Humans; Ovarian Hyperstimulation Syndrome; Pituitary Neoplasms | 2006 |
[Case of juvenile parkinsonism in pregnancy].
Topics: Adult; Antiparkinson Agents; Benzothiazoles; Cabergoline; Carbidopa; Contraindications; Dopamine Agents; Dopamine Agonists; Ergolines; Family Planning Services; Female; Humans; Infant, Newborn; Levodopa; Parkinsonian Disorders; Pramipexole; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Thiazoles | 2006 |
The effects of a low dose of cabergoline on induction of estrus and pregnancy rates in anestrous bitches.
Topics: Anestrus; Animals; Breeding; Cabergoline; Dogs; Dose-Response Relationship, Drug; Ergolines; Estrus; Female; Ovulation Induction; Pregnancy; Pregnancy Rate; Pregnancy, Animal | 2007 |
Dopamine receptor expression and function in corticotroph ectopic tumors.
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Adult; Cabergoline; Ergolines; Female; Humans; Hydrocortisone; Lung Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Receptors, Dopamine; Reverse Transcriptase Polymerase Chain Reaction; Thymus Neoplasms | 2007 |
Mitral heart disease due to cabergoline.
Topics: Antiparkinson Agents; Cabergoline; Ergolines; Female; Heart Valve Diseases; Humans; Middle Aged; Mitral Valve Insufficiency | 2007 |
Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Aminoquinolines; Benzamides; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Iodine Radioisotopes; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Pyrrolidines; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon | 2006 |
[Use of cabergoline in persisting Cushing's disease].
Topics: Adrenocortical Hyperfunction; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hydrocortisone; Magnetic Resonance Imaging; Middle Aged; Pituitary ACTH Hypersecretion | 2006 |
The influences of hyperprolactinaemia and obesity on cardiovascular risk markers: effects of cabergoline therapy.
Topics: Cabergoline; Cardiovascular Diseases; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Insulin Resistance; Obesity; Risk Factors | 2006 |
Presentation of a functional pituitary adenoma as a significant decrease in prostate-specific antigen level in a patient followed for prostate cancer.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Male; Neoplasms, Second Primary; Pituitary Neoplasms; Prolactinoma; Prostate-Specific Antigen; Prostatic Neoplasms | 2006 |
Macroprolactinemia in a patient with infertility and hyperprolactinemia.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Infertility, Female; Prolactin | 2006 |
Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma.
Topics: Adult; Cabergoline; Disease Progression; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged; Pituitary Neoplasms; Prolactinoma | 2007 |
Drugs and valvular heart disease.
Topics: Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Pergolide; Receptor, Serotonin, 5-HT2B; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists | 2007 |
Dopamine agonists and the risk of cardiac-valve regurgitation.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cabergoline; Case-Control Studies; Cohort Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Logistic Models; Male; Middle Aged; Parkinson Disease; Pergolide; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists | 2007 |
Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
Topics: Aged; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Mitral Valve; Parkinson Disease; Pergolide; Regression Analysis; Risk; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists; Ultrasonography | 2007 |
Reduced growth of beard as the only diagnostic sign in a patient with macroprolactinoma.
Topics: Adenoma; Adult; Cabergoline; Dopamine Agonists; Ergolines; Face; Hair; Humans; Hydrocortisone; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactin; Testosterone; Thyroxine | 2007 |
[Simultaneous defect of visual fields and loss of libido--a coincidence?].
Topics: Cabergoline; Diagnosis, Differential; Dopamine Agonists; Erectile Dysfunction; Ergolines; Humans; Hyperprolactinemia; Hypogonadism; Libido; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Compression Syndromes; Optic Nerve Diseases; Pituitary Neoplasms; Prolactinoma; Visual Fields | 2006 |
SUNCT syndrome in a patient with prolactinoma and cabergoline-induced attacks.
Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Pituitary Neoplasms; Prolactinoma; SUNCT Syndrome | 2007 |
[Predictive value of the Knosp classification in grading the surgical resection of invasive pituitary macroadenomas. A prospective study of 23 cases].
Topics: Adenoma; Adult; Aged; Antineoplastic Agents; Cabergoline; Cavernous Sinus; Combined Modality Therapy; Cranial Irradiation; Diabetes Insipidus, Neurogenic; Dose Fractionation, Radiation; Endoscopy; Ergolines; Female; Follow-Up Studies; Humans; Hypophysectomy; Magnetic Resonance Imaging; Male; Meningitis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pituitary Neoplasms; Postoperative Complications; Predictive Value of Tests; Prognosis; Prospective Studies; Radiography; Radiotherapy, Adjuvant; Somatostatin; Sphenoid Bone; Treatment Outcome | 2006 |
Cerebrospinal fluid leakage as complication of treatment with cabergoline for macroprolactinomas.
Topics: Adult; Aged; Antineoplastic Agents; Cabergoline; Cerebrospinal Fluid Rhinorrhea; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma | 2006 |
First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group.
Topics: Acromegaly; Adenoma; Cabergoline; Dopamine Agonists; Ergolines; Humans; Somatostatin | 2006 |
Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men.
Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Time Factors; Treatment Outcome; Vision Disorders; Visual Fields | 2007 |
Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
Topics: Aged; Antiparkinson Agents; Aortic Valve Insufficiency; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Parkinson Disease; Pergolide; Retrospective Studies; Tricuspid Valve Insufficiency | 2007 |
Clinical presentation and response to therapy in patients with massive prolactin hypersecretion.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Testosterone | 2007 |
Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient.
Topics: Acromegaly; Adenoma, Acidophil; Adult; Cabergoline; Cell Proliferation; Cells, Cultured; Delayed-Action Preparations; Ergolines; Human Growth Hormone; Humans; Immunohistochemistry; Insulin-Like Growth Factor I; Magnetic Resonance Imaging; Male; Microscopy, Electron; Octreotide; Pituitary Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Somatostatin; Thymidine | 2007 |
Resolution of a hyperprolactinemia in a western lowland gorilla (Gorilla gorilla gorilla).
Topics: Animals; Antineoplastic Agents; Ape Diseases; Cabergoline; Ergolines; Female; Gorilla gorilla; Hyperprolactinemia; Pituitary Neoplasms; Prolactinoma; Reproduction; Treatment Outcome | 2006 |
Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome.
Topics: Adolescent; Adult; Antineoplastic Agents, Hormonal; Body Height; Body Mass Index; Bromocriptine; Cabergoline; Combined Modality Therapy; Ergolines; Female; Growth Hormone; Growth Hormone-Secreting Pituitary Adenoma; Headache; Hormone Antagonists; Humans; Insulin Resistance; Insulin-Like Growth Factor I; Male; Menstruation Disturbances; Octreotide; Peptides, Cyclic; Pituitary Neoplasms; Retrospective Studies; Somatostatin; Treatment Outcome | 2007 |
Parkinson's drugs linked to heart valve trouble.
Topics: Antiparkinson Agents; Cabergoline; Ergolines; Heart Valve Diseases; Humans; Pergolide | 2007 |
Spectrophotometric determination of dopaminergic drugs used for Parkinson's disease, cabergoline and ropinirole, in pharmaceutical preparations.
Topics: Cabergoline; Dopamine Agents; Ergolines; Humans; Hydrogen-Ion Concentration; Indoles; Parkinson Disease; Pharmaceutical Preparations; Reproducibility of Results; Sensitivity and Specificity | 2007 |
Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Cabergoline; Clonazepam; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Follow-Up Studies; Humans; Patient Care Team; Piperazines; Pituitary Neoplasms; Prolactin; Prolactinoma; Quinolones; Schizophrenia | 2007 |
Dopamine agonists and valvular heart disease.
Topics: Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Ventricular Remodeling | 2007 |
Dopamine agonists and valvular heart disease.
Topics: Antipsychotic Agents; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Methysergide; Pergolide; Receptor, Serotonin, 5-HT2B; Retroperitoneal Fibrosis; Serotonin 5-HT2 Receptor Agonists; Serotonin Antagonists | 2007 |
Prolactin and autoimmune diseases in humans.
Topics: Aminoquinolines; Animals; Arthritis, Rheumatoid; Autoimmune Diseases; Bromocriptine; Cabergoline; Cyclosporine; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Ergolines; Female; Humans; Hyperprolactinemia; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Male; Mice; Mice, Knockout; Penicillamine; Prednisone; Prolactin; Rats; Receptors, Prolactin | 2007 |
Remission of acromegaly following long-term therapy with cabergoline: report of two cases.
Topics: Abdominal Pain; Acromegaly; Adult; Biomarkers; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Libido; Male; Middle Aged; Secondary Prevention; Time Factors; Treatment Outcome | 2008 |
Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
Topics: Adolescent; Adult; Aged; Aminoquinolines; Cabergoline; Contraceptives, Oral, Hormonal; Dopamine Agonists; Ergolines; Female; Humans; Immunoglobulin G; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma | 2007 |
Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline.
Topics: Adolescent; Adult; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Fatal Outcome; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Apoplexy; Pituitary Neoplasms; Prolactinoma; Tomography, X-Ray Computed | 2008 |
Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Kaplan-Meier Estimate; Male; Middle Aged; Pituitary Neoplasms; Predictive Value of Tests; Prolactinoma; Prospective Studies; Regression Analysis; Remission Induction; ROC Curve; Secondary Prevention; Sex Distribution; Time Factors; Young Adult | 2007 |
Dopaminergic treatment of nonfunctioning pituitary adenomas.
Topics: Adenoma; Bromocriptine; Cabergoline; Dopamine Agents; Dopamine Agonists; Ergolines; Humans; Pituitary Neoplasms; Prolactin | 2007 |
Cabergoline treatment of pregnant women with macroprolactinomas.
Topics: Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactinoma; Treatment Outcome | 2007 |
Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
Topics: Antiparkinson Agents; Benzothiazoles; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Male; Parkinson Disease; Patient Selection; Pergolide; Pramipexole; Research Design; Sex Factors | 2007 |
Management of type 2 diabetes mellitus associated with pituitary gigantism.
Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Diabetes Mellitus, Type 2; Ergolines; Gigantism; Human Growth Hormone; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Pituitary Neoplasms; Radiotherapy | 2007 |
Growth hormone producing prolactinoma in juvenile cystinosis: a simple coincidence?
Topics: Administration, Oral; Administration, Topical; Body Height; Cabergoline; Child; Cysteamine; Cystinosis; Dopamine Agonists; Ergolines; Headache; Human Growth Hormone; Humans; Male; Ophthalmic Solutions; Pituitary Neoplasms; Prolactinoma; Radiation-Protective Agents; Treatment Outcome | 2008 |
An important new adaption of a specific drug?
Topics: Adenoma; Antineoplastic Agents; Cabergoline; Ergolines; Female; Gonadotropins; Humans; Neovascularization, Pathologic; Ovarian Hyperstimulation Syndrome; Pituitary Neoplasms; Polycystic Ovary Syndrome; Vascular Endothelial Growth Factor A | 2007 |
Editorial: Preventing ovarian hyperstimulation syndrome.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Fertilization in Vitro; Humans; Ovarian Hyperstimulation Syndrome; Pregnancy; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2007 |
A case of macroprolactinoma encasing an internal carotid artery aneurysm, presenting as pituitary apoplexy.
Topics: Angiography, Digital Subtraction; Antineoplastic Agents; Balloon Occlusion; Cabergoline; Carotid Artery, Internal; Dopamine Agonists; Ergolines; Headache; Humans; Intracranial Aneurysm; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Ophthalmoplegia; Pituitary Apoplexy; Pituitary Neoplasms; Prolactinoma; Treatment Outcome; Vision Disorders | 2008 |
[Aortic insufficiency under weak doses of cabergoline for non-tumoral hyperprolactinemia].
Topics: Aortic Valve Insufficiency; Cabergoline; Diagnosis, Differential; Dopamine Agents; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Middle Aged; Receptor, Serotonin, 5-HT2B | 2007 |
Evolution of a prolactin-secreting pituitary microadenoma into a fatal carcinoma: a case report.
Topics: Adult; Cabergoline; Carcinoma; Combined Modality Therapy; Disease Progression; Dopamine Agonists; Drug Resistance; Ergolines; Fatal Outcome; Female; Humans; Octreotide; Pituitary Apoplexy; Pituitary Neoplasms; Prolactinoma; Radiosurgery; Subarachnoid Hemorrhage | 2007 |
[Early pleuropulmonary toxicity associated with cabergoline, an antiparkinsonian drug].
Topics: Aged; Antiparkinson Agents; Cabergoline; Ergolines; Humans; Lung Diseases; Male; Pleural Effusion; Time Factors | 2007 |
Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study.
Topics: Adult; Cabergoline; Dopamine Agonists; Embryo Implantation; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Pilot Projects; Pregnancy; Pregnancy Rate; Reproductive Techniques, Assisted; Retrospective Studies | 2007 |
[Mitral valve replacement for cabergoline-related severe mitral regurgitation].
Topics: Aged, 80 and over; Antiparkinson Agents; Bioprosthesis; Cabergoline; Chordae Tendineae; Echocardiography; Ergolines; Heart Valve Prosthesis Implantation; Humans; Male; Mitral Valve; Mitral Valve Insufficiency; Parkinson Disease | 2007 |
[Association between amytrophic lateral sclerosis and Parkinson's disease].
Topics: Aged; Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Cabergoline; Carbidopa; Dopamine Agents; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Riluzole; Time Factors; Tomography, X-Ray Computed | 2007 |
Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report.
Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Humans; Male; Pituitary Neoplasms; Prolactinoma; Treatment Outcome | 2008 |
Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation?
Topics: Acromegaly; Adult; Astrocytoma; Brain Neoplasms; Cabergoline; Cranial Irradiation; Craniotomy; Disease Progression; Ergolines; Humans; Insulin-Like Growth Factor I; Magnetic Resonance Imaging; Male; Neoplasm Staging; Peptides, Cyclic; Somatostatin; Treatment Outcome; Up-Regulation | 2008 |
Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias.
Topics: Amino Acids; Animals; Antiparkinson Agents; Autoradiography; Basal Ganglia; Behavior, Animal; Cabergoline; Caudate Nucleus; Data Interpretation, Statistical; Dyskinesia, Drug-Induced; Ergolines; Excitatory Amino Acid Antagonists; Female; Levodopa; Macaca fascicularis; Ovariectomy; Putamen; Receptors, Metabotropic Glutamate; Xanthenes | 2008 |
Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma.
Topics: Antidepressive Agents; Antineoplastic Agents; Cabergoline; Citalopram; Delusions; Depressive Disorder, Major; Ergolines; Female; Gambling; Humans; Middle Aged; Pituitary Neoplasms; Prolactinoma | 2007 |
Dopamine gene predicts the brain's response to dopaminergic drug.
Topics: Adult; Brain; Cabergoline; Corpus Striatum; Dopamine Agonists; Ergolines; Feedback, Physiological; Female; Frontal Lobe; Genetic Variation; Gyrus Cinguli; Humans; Magnetic Resonance Imaging; Male; Neural Pathways; Predictive Value of Tests; Receptors, Dopamine D2; Reversal Learning; Reward | 2007 |
Tramadol and severe hypertension during anesthesia.
Topics: Aged; Analgesics, Opioid; Anesthesia, General; Cabergoline; Dopamine Agonists; Dopamine Uptake Inhibitors; Drug Interactions; Ergolines; Female; Humans; Hypertension; Restless Legs Syndrome; Selective Serotonin Reuptake Inhibitors; Spinal Fusion; Tramadol | 2008 |
Cabergoline-associated erythema nodosum.
Topics: Adult; Arthritis; Cabergoline; Ergolines; Erythema Nodosum; Female; Humans | 2008 |
Severe mitral valve regurgitation with fatal cardiogenic shock in a patient on long-term cabergoline treatment.
Topics: Aged; Cabergoline; Ergolines; Fatal Outcome; Female; Humans; Long-Term Care; Mitral Valve Insufficiency; Shock, Cardiogenic | 2009 |
Effect of long-term cabergoline therapy on the immunological pattern and pituitary function of patients with idiopathic hyperprolactinaemia positive for antipituitary antibodies.
Topics: Adult; Autoantibodies; Autoimmune Diseases; Cabergoline; Cohort Studies; Dopamine Agonists; Ergolines; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Longitudinal Studies; Male; Pituitary Diseases; Pituitary Function Tests; Pituitary Gland; Seroepidemiologic Studies; Thyroid Hormones; Thyrotropin; Time Factors | 2008 |
Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent.
Topics: Aged; Antiparkinson Agents; Cabergoline; Cardiovascular Diseases; Dopamine Agonists; Ergolines; Female; Humans; Male; Parkinson Disease; Pergolide; Treatment Outcome | 2008 |
Aortic regurgitation associated with cabergoline therapy.
Topics: Aortic Valve Insufficiency; Cabergoline; Dopamine Agonists; Dyspnea; Ergolines; Humans; Lewy Body Disease; Male; Middle Aged; Ultrasonography | 2008 |
Emotional speech in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Articulation Disorders; Cabergoline; Emotions; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease; Phonation; Speech | 2008 |
Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas.
Topics: Adenoma; Adult; Alleles; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Female; Gene Frequency; Genotype; Humans; Male; Middle Aged; Pituitary Neoplasms; Polymorphism, Genetic; Prolactin; Receptors, Dopamine D2; Retrospective Studies | 2008 |
Effect of co-administration of a serotonin-noradrenaline reuptake inhibitor and a dopamine agonist on extracellular monoamine concentrations in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Biogenic Monoamines; Cabergoline; Cyclopropanes; Dopamine; Dopamine Agonists; Drug Interactions; Ergolines; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Microdialysis; Milnacipran; Norepinephrine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Time Factors | 2008 |
A case of constrictive pericarditis during cabergoline treatment for hyperprolactinaemia.
Topics: Adult; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Hyperprolactinemia; Pericardiectomy; Pericarditis, Constrictive | 2008 |
The frequency of cardiac valvular regurgitation in Parkinson's disease.
Topics: Aged; Aortic Valve Insufficiency; Azepines; Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Mitral Valve Insufficiency; Parkinson Disease; Pergolide; Pramipexole; Prevalence | 2008 |
Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
Topics: Adult; Antineoplastic Agents; Cabergoline; Dopamine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Humans; Ligands; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2; Receptors, Somatostatin; RNA, Messenger; Somatostatin; Tumor Cells, Cultured | 2008 |
Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy.
Topics: Adolescent; Antineoplastic Agents; Cabergoline; Delayed-Action Preparations; Ergolines; Fibrous Dysplasia, Polyostotic; Gigantism; Humans; Male; Octreotide; Radiography | 2008 |
Nephrotic-range proteinuria in a patient with a giant prolactinoma.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms; Prolactinoma; Proteinuria | 2008 |
Cabergoline and the risk of valvular lesions in endocrine disease.
Topics: Adult; Aged; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Echocardiography; Endocrine System Diseases; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Mitral Valve; Mitral Valve Insufficiency; Risk Factors | 2008 |
More than a prolactinoma.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Humans; Magnetic Resonance Imaging; Male; Meningioma; Prolactinoma | 2010 |
Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia.
Topics: Adult; Aortic Valve Insufficiency; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Mitral Valve Insufficiency; Risk Factors; Tricuspid Valve Insufficiency | 2008 |
TSH-secreting adenoma improved with cabergoline.
Topics: Adult; Antineoplastic Agents; Bone and Bones; Cabergoline; Ergolines; Humans; Male; Pituitary Neoplasms; Thyrotropin; Thyroxine; Triiodothyronine | 2008 |
Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Hormonal; Cabergoline; Cell Division; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Ergolines; Female; Fibroblasts; Humans; Male; Middle Aged; Octreotide; Pituitary Neoplasms; Receptors, Dopamine D2; Receptors, Somatostatin; RNA, Messenger; Somatostatin; Sulpiride; Thymidine; Tritium; Tumor Cells, Cultured | 2008 |
Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
Topics: Adult; Aortic Valve; Cabergoline; Calcinosis; Case-Control Studies; Cross-Sectional Studies; Disease Progression; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Time Factors; Tricuspid Valve Insufficiency | 2008 |
Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease.
Topics: Adult; Cabergoline; Cross-Sectional Studies; Databases, Factual; Dopamine Agonists; Echocardiography; Echocardiography, Doppler, Color; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Middle Aged; Risk Factors | 2008 |
Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.
Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Benzothiazoles; Cabergoline; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Female; Levodopa; Mesencephalon; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Wistar; Stereotyped Behavior; Tyrosine 3-Monooxygenase | 2008 |
[An aortic insufficiency diagnosed under cabergoline].
Topics: Aortic Valve Insufficiency; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged | 2009 |
Insulin-like growth factor-1 is essential to the increased mortality caused by excess growth hormone: a case of thyroid cancer and non-Hodgkin's lymphoma in a patient with pituitary acromegaly.
Topics: Acromegaly; Adenoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Cyclophosphamide; Ergolines; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Lymphoma, Non-Hodgkin; Male; Neoplasms, Multiple Primary; Octreotide; Prednisone; Thyroid Neoplasms; Thyroidectomy; Thyroxine; Vincristine | 2009 |
Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Male; Middle Aged; Optic Chiasm; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Vision Disorders; Visual Fields; Young Adult | 2009 |
Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline.
Topics: Adult; Antineoplastic Agents; Cabergoline; Case-Control Studies; Chronic Disease; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Time Factors; Tricuspid Valve Insufficiency; Ultrasonography | 2008 |
Misdiagnosis due to the hook effect in prolactin assay.
Topics: Antineoplastic Agents; Cabergoline; Diabetes Insipidus, Neurogenic; Diagnostic Errors; Ergolines; Female; Glucocorticoids; Humans; Hypopituitarism; Middle Aged; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prednisolone; Prolactin; Prolactinoma; Thyroxine | 2008 |
Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias.
Topics: Animals; Autoradiography; Behavior, Animal; Benserazide; Benzoxazoles; Cabergoline; Corpus Striatum; Dopamine Agents; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Ergolines; Female; Humans; Levodopa; Macaca fascicularis; MPTP Poisoning; Ovariectomy; Piperidines; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate | 2009 |
Clinical use of cabergoline as primary and adjunctive treatment for acromegaly.
Topics: Acromegaly; Adenoma; Adult; Aged; Aged, 80 and over; Cabergoline; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Magnetic Resonance Imaging; Male; Medical Audit; Middle Aged; Pituitary Gland; Prospective Studies; Treatment Outcome | 2008 |
[Two cases of patients with Parkinson's disease developing valvular heart disease while taking cabergoline].
Topics: Aged; Antiparkinson Agents; Cabergoline; Ergolines; Fatal Outcome; Female; Heart Failure; Heart Valve Diseases; Humans; Parkinson Disease | 2008 |
Pituitary apoplexy within a macroprolactinoma.
Topics: Antineoplastic Agents; Cabergoline; Diagnosis, Differential; Ergolines; Female; Humans; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Middle Aged; Pituitary Apoplexy; Pituitary Neoplasms; Prolactin; Prolactinoma; Tomography, X-Ray Computed | 2008 |
High dose cabergoline therapy for a resistant macroprolactinoma during pregnancy.
Topics: Adult; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Infant, Newborn; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactin; Prolactinoma | 2009 |
[Some issues in the diagnosis and treatment of hyperprolactinemia].
Topics: Aminoquinolines; Cabergoline; Diagnosis, Differential; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Pituitary Gland; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma | 2008 |
Clinical profile and long term follow up of children and adolescents with prolactinomas.
Topics: Adolescent; Amenorrhea; Bromocriptine; Cabergoline; Child; Dopamine Agonists; Ergolines; Female; Galactorrhea; Humans; Male; Pregnancy; Prolactin; Prolactinoma; Retrospective Studies; Treatment Outcome; Young Adult | 2009 |
The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.
Topics: Adrenocorticotropic Hormone; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hydrocortisone; Insulin Resistance; Male; Middle Aged; Pituitary ACTH Hypersecretion | 2009 |
Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes.
Topics: Animals; Antihypertensive Agents; Aqueous Humor; Biological Availability; Cabergoline; Calcium; Cats; Cells, Cultured; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Drug Evaluation, Preclinical; Ergolines; Humans; Intraocular Pressure; Macaca fascicularis; Ocular Hypertension; Rabbits; Rats; Species Specificity | 2009 |
Effects of gonadectomy on prolactin and LH secretion and the pituitary-thyroid axis in male dogs.
Topics: Animals; Cabergoline; Dogs; Dopamine Agonists; Ergolines; Kinetics; Luteinizing Hormone; Male; Orchiectomy; Pituitary Gland; Prolactin; Testis; Thyroid Gland; Thyrotropin; Thyrotropin-Releasing Hormone; Thyroxine | 2009 |
Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia.
Topics: Adult; Cabergoline; Cohort Studies; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Middle Aged | 2008 |
[Hyperprolactinemia in a man's world].
Topics: Algorithms; Cabergoline; Diagnosis, Differential; Dopamine Agonists; Ergolines; Follow-Up Studies; Gynecomastia; Humans; Hyperprolactinemia; Hypogonadism; Male; Middle Aged; Prolactin; Testosterone; Time Factors; Ultrasonography, Mammary | 2008 |
The cabergoline-resistant prolactinoma patient: new challenges.
Topics: Adult; Cabergoline; Dopamine Agonists; Drug Resistance; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Receptors, Dopamine; Young Adult | 2008 |
Conduct disorder in an adolescent girl treated with an insulin-sensitizing agent.
Topics: Adolescent; Cabergoline; Conduct Disorder; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Menarche; Pioglitazone; Polycystic Ovary Syndrome; Psychiatric Status Rating Scales; Thiazolidinediones; Violence | 2008 |
High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease.
Topics: Age Factors; Aged; Benzothiazoles; Bromocriptine; Cabergoline; Case-Control Studies; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Hypertension; Male; Parkinson Disease; Pergolide; Pramipexole; Risk Factors | 2009 |
Protection against paraquat and A53T alpha-synuclein toxicity by cabergoline is partially mediated by dopamine receptors.
Topics: alpha-Synuclein; Analysis of Variance; Apoptosis; Blotting, Western; Cabergoline; Caspase 3; Cell Line; Enzyme Activation; Ergolines; Glutathione; Humans; Immunohistochemistry; JNK Mitogen-Activated Protein Kinases; Lactate Dehydrogenases; Membrane Potential, Mitochondrial; Paraquat; Parkinsonian Disorders; Reactive Oxygen Species; Receptors, Dopamine D2 | 2009 |
Valvular heart disease and the use of cabergoline for the treatment of prolactinoma.
Topics: Aortic Valve Insufficiency; Cabergoline; Calcinosis; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Prolactinoma; Ventricular Dysfunction, Left | 2009 |
Role of D1 and D2 receptors in the regulation of voluntary movements.
Topics: Adult; Brain; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Movement; Muscle Contraction; Muscle Tonus; Receptors, Dopamine D1; Receptors, Dopamine D2; Young Adult | 2008 |
Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report.
Topics: Aged; Antiparkinson Agents; Azepines; Benzothiazoles; Cabergoline; Carbidopa; Catatonia; Catechols; Drug Therapy, Combination; Electroconvulsive Therapy; Ergolines; Female; Humans; Levodopa; Nitriles; Parkinson Disease; Pramipexole | 2009 |
Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Humans; Male; Octreotide; Pituitary Neoplasms; Prolactinoma; Treatment Outcome | 2011 |
Rapid left ventricular recovery after cabergoline treatment in a patient with peripartum cardiomyopathy.
Topics: Adult; Cabergoline; Cardiomyopathies; Echocardiography; Ergolines; Female; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Pregnancy; Prolactin; Puerperal Disorders; Ventricular Dysfunction, Left | 2009 |
Body fat in men with prolactinoma.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Humans; Male; Prolactinoma | 2008 |
Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.
Topics: Aged; Aged, 80 and over; Apomorphine; Benzothiazoles; Bromocriptine; Cabergoline; Databases, Factual; Dopamine Agonists; Endomyocardial Fibrosis; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Indoles; Male; Middle Aged; Pergolide; Pericarditis; Pleural Diseases; Pramipexole; Pulmonary Fibrosis; Retroperitoneal Fibrosis; Tetrahydronaphthalenes; Thiophenes; United States | 2009 |
Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Cabergoline; Drug Resistance, Neoplasm; Ergolines; Humans; Hypothyroidism; Immunohistochemistry; Magnetic Resonance Imaging; Male; Neovascularization, Pathologic; Pituitary Neoplasms; Prolactin; Prolactinoma | 2009 |
Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do.
Topics: Cabergoline; Dopamine Agonists; Echocardiography; Ergolines; Heart Valve Diseases; Heart Valves; Humans; Hyperprolactinemia; Parkinson Disease; Pergolide; Tricuspid Valve Insufficiency | 2009 |
Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis.
Topics: Animals; Cabergoline; Cell Proliferation; Disease Models, Animal; Dopamine Agonists; Endometriosis; Ergolines; Female; Gene Expression Regulation; Humans; Mice; Neovascularization, Pathologic; Phosphorylation; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
The effects of treating male hypogonadism on couples' sexual desire and function.
Topics: Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Hormone Replacement Therapy; Humans; Hypogonadism; Male; Middle Aged; Personal Satisfaction; Sexual Dysfunctions, Psychological; Surveys and Questionnaires; Testosterone | 2009 |
Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cabergoline; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Treatment Failure; Young Adult | 2009 |
[Pleural effusion and pulmonary hypertension in a patient with Parkinson disease treated with cabergoline].
Topics: Aged; Antiparkinson Agents; Cabergoline; Ergolines; Humans; Hypertension, Pulmonary; Male; Parkinson Disease; Pleural Effusion | 2009 |
Cabergoline decreases alcohol drinking and seeking behaviors via glial cell line-derived neurotrophic factor.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Cabergoline; Conditioning, Operant; Dopamine Agonists; Enzyme-Linked Immunosorbent Assay; Ergolines; Extinction, Psychological; Glial Cell Line-Derived Neurotrophic Factor; Injections, Intraperitoneal; Mesencephalon; Mice; Mice, Knockout; Microinjections; Rats; Self Administration; Substantia Nigra | 2009 |
Pathological gambling and hypersexuality in cabergoline-treated prolactinoma.
Topics: Antineoplastic Agents; Cabergoline; Ergolines; Gambling; Humans; Libido; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma | 2009 |
Changes in artistic style and behaviour in Parkinson's disease: dopamine and creativity.
Topics: Antiparkinson Agents; Arm; Art; Benzothiazoles; Brain; Cabergoline; Creativity; Depressive Disorder; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Motor Skills; Obsessive Behavior; Paintings; Parkinson Disease; Pramipexole | 2009 |
Dopamine agonists and hyperprolactinaemia.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia | 2009 |
Macroprolactinomas presenting as nasal polyps: a series of three cases.
Topics: Adult; Antineoplastic Agents; Cabergoline; Diagnosis, Differential; Diagnostic Errors; Ergolines; Humans; Male; Middle Aged; Nasal Polyps; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin | 2012 |
Giant prolactinoma.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Humans; Magnetic Resonance Imaging; Male; Prolactinoma | 2009 |
Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prognosis; Prolactinoma; Recurrence; Retrospective Studies; Time Factors; Withholding Treatment; Young Adult | 2009 |
McCune-Albright syndrome and acromegaly: hormonal control with use of cabergoline and long-acting somatostatin--case report.
Topics: Acromegaly; Adenoma; Adult; Antineoplastic Agents, Hormonal; Cabergoline; Ergolines; Facial Bones; Female; Fibrous Dysplasia, Polyostotic; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Octreotide; Pituitary Neoplasms; Skull | 2009 |
Brain and optic chiasmal herniations into sella after cabergoline therapy of giant prolactinoma.
Topics: Adult; Cabergoline; Dopamine Agonists; Encephalocele; Ergolines; Humans; Male; Optic Chiasm; Pituitary Neoplasms; Prolactinoma; Sella Turcica; Tumor Burden | 2011 |
Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Case-Control Studies; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Parkinson Disease; Pergolide; Prolactin; Serotonin 5-HT2 Receptor Agonists; Ultrasonography | 2009 |
Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma.
Topics: Brain Ischemia; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Fatal Outcome; Fibrosis; Heart Valve Prosthesis Implantation; Humans; Intestinal Obstruction; Male; Middle Aged; Mitral Valve Insufficiency; Pituitary Neoplasms; Prolactinoma; Tricuspid Valve Insufficiency; Ventricular Dysfunction, Left | 2009 |
Cabergoline resistance in pediatric prolactinomas.
Topics: Adolescent; Antineoplastic Agents; Cabergoline; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Male; Pituitary Neoplasms; Prolactinoma | 2009 |
Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cabergoline; Case-Control Studies; Echocardiography; Ergolines; Female; Heart Valves; Hormone Antagonists; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Sex Characteristics; Young Adult | 2010 |
[Pulmonary toxicity associated with cabergoline].
Topics: Aged; Antiparkinson Agents; Cabergoline; Ergolines; Female; Humans; Lung Diseases | 2009 |
High dose cabergoline in management of ovarian hyperstimulation syndrome.
Topics: Adult; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Severity of Illness Index; Treatment Outcome | 2009 |
Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series.
Topics: Adult; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Female; Gonadotropin-Releasing Hormone; Humans; Ovarian Hyperstimulation Syndrome; Treatment Outcome | 2009 |
Non-surgical management of cystic prolactinomas.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Follow-Up Studies; Gadolinium; Hormones; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Young Adult | 2009 |
An experimental model to study resistance index and systolic/diastolic ratio of uterine arteries in adverse canine pregnancy outcome.
Topics: Abortifacient Agents; Abortion, Induced; Abortion, Veterinary; Animals; Blood Pressure; Cabergoline; Cloprostenol; Dogs; Ergolines; Female; Pregnancy; Pregnancy Outcome; Pregnancy, Animal; Uterine Artery; Uterus | 2009 |
Influence of progesterone withdrawal on pregnancy-related parameters during post-implantation early pregnancy loss.
Topics: Abortion, Induced; Abortion, Veterinary; Animals; Cabergoline; Cloprostenol; Dogs; Embryonic Development; Ergolines; Estrenes; Female; Pregnancy; Pregnancy, Animal; Progesterone; Prolactin; Relaxin | 2009 |
Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma.
Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies | 2009 |
Intranasal cabergoline: pharmacokinetic and pharmacodynamic studies.
Topics: Administration, Intranasal; Animals; Anti-Obesity Agents; Cabergoline; Diffusion; Drug Stability; Emulsions; Ergolines; Female; Male; Prolactin; Rats; Solubility; Tissue Distribution | 2009 |
Failure of cabergoline to prevent severe ovarian hyperstimulation syndrome in patients with extremely high estradiol levels.
Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Estradiol; Female; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Treatment Failure | 2010 |
Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease.
Topics: Adult; Cabergoline; Drug Therapy, Combination; Ergolines; Female; Humans; Hydrocortisone; Ketoconazole; Male; Middle Aged; Pituitary ACTH Hypersecretion; Prospective Studies; Treatment Outcome | 2010 |
Effect of everolimus on cell viability in nonfunctioning pituitary adenomas.
Topics: Adenoma; Aged; Apoptosis; Cabergoline; Cell Line, Tumor; Cell Survival; Ergolines; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Pituitary Neoplasms; Receptors, Somatostatin; Ribosomal Protein S6 Kinases, 70-kDa; Sirolimus; Somatostatin; Vascular Endothelial Growth Factor A | 2010 |
Comparative efficacy of bromocriptine, cabergoline and thyroxine in inducing oestrus in bitches.
Topics: Animals; Bromocriptine; Cabergoline; Dogs; Ergolines; Estrous Cycle; Female; Fertilization; Hormone Antagonists; Litter Size; Progesterone; Prolactin; Thyroxine | 2010 |
Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
Topics: Adult; Cabergoline; Case-Control Studies; Clinical Trials as Topic; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2 | 2010 |
Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cabergoline; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Ergolines; Female; Glycogen Synthase Kinase 3; Levodopa; Macaca fascicularis; Oncogene Protein v-akt; Parkinsonian Disorders; Phosphorylation; Piperidines; Serine; Signal Transduction; Statistics as Topic | 2010 |
A double pituitary adenoma presenting as a prolactin-secreting tumor with partial response to medical therapy. Case report.
Topics: Adenoma; Adult; Antineoplastic Agents; Breast Neoplasms, Male; Cabergoline; Combined Modality Therapy; Ergolines; Gonadotrophs; Humans; Male; Microscopy, Electron, Transmission; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Neurofibromatosis 1; Neurosurgical Procedures; Prolactinoma | 2010 |
Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
Topics: Acromegaly; Blood Sedimentation; C-Reactive Protein; Cabergoline; Creatinine; Cross-Sectional Studies; Dopamine Agonists; Echocardiography; Electrocardiography; Ergolines; Female; Fibrosis; Glomerular Filtration Rate; Heart Valve Diseases; Heart Valves; Humans; Hyperprolactinemia; Lung; Lung Diseases; Male; Middle Aged; Respiratory Function Tests; Retroperitoneal Fibrosis; Statistics, Nonparametric | 2010 |
Management of prolactinomas in Brazil: an electronic survey.
Topics: Brazil; Bromocriptine; Cabergoline; Data Collection; Dopamine Agonists; Ergolines; Female; Humans; Pregnancy; Prolactinoma | 2010 |
[Galastop].
Topics: Abortifacient Agents; Abortion, Veterinary; Animals; Cabergoline; Dogs; Ergolines; Female; Legislation, Veterinary; Netherlands; Pregnancy; Pregnancy, Animal; Ultrasonography, Prenatal | 2009 |
Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance.
Topics: Analysis of Variance; Animals; Blood Glucose; Cabergoline; Cell Proliferation; Dopamine Agonists; Dopamine Antagonists; Ergolines; Female; Glucose; Glucose Intolerance; Haloperidol; Immunohistochemistry; Insulin; Insulin Secretion; Insulin-Like Growth Factor I; Male; Mice; Mice, Knockout; Pancreas; Prolactin; Radioimmunoassay; Receptors, Dopamine D2; Time Factors | 2010 |
Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Autoradiography; Benzoxazoles; Brain; Cabergoline; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Female; Imidazoles; Levodopa; Ligands; Macaca fascicularis; MPTP Poisoning; Piperidines; Quinazolines; Receptors, AMPA; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate | 2010 |
Pituitary gland: can prolactinomas be cured medically?
Topics: Antineoplastic Agents, Hormonal; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Meta-Analysis as Topic; Pituitary Gland; Pituitary Neoplasms; Prolactinoma; Recurrence; Withholding Treatment | 2010 |
Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
Topics: Adult; Birth Weight; Bromocriptine; Cabergoline; Cohort Studies; Dopamine Agonists; Drug Resistance; Ergolines; Female; Humans; Hyperprolactinemia; Infertility, Female; Magnetic Resonance Imaging; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Progesterone; Prolactin; Prolactinoma | 2010 |
[Application of Pfizer drugs in the obstetrics and gynecology practice].
Topics: Anti-Bacterial Agents; Antifungal Agents; Cabergoline; Carboprost; Clindamycin; Dopamine Agonists; Drug Combinations; Ergolines; Female; Fertility Agents, Female; Fluconazole; Genital Diseases, Female; Humans; Nafarelin; Pregnancy; Pregnancy Complications; Tromethamine | 2009 |
Suppression of prolactin expression by cabergoline requires prolactin regulatory element-binding protein (PREB) in GH3 cells.
Topics: Cabergoline; Cell Line, Tumor; DNA-Binding Proteins; Down-Regulation; Ergolines; Guanine Nucleotide Exchange Factors; Humans; Prolactin; Prolactinoma; Promoter Regions, Genetic; Transcription Factors; Transcription, Genetic | 2010 |
Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam.
Topics: Analysis of Variance; Animals; Biopsy, Needle; Body Weight; Cabergoline; Chorionic Gonadotropin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Ergolines; Female; Immunohistochemistry; Injections, Intramuscular; Meloxicam; Organ Size; Ovarian Hyperstimulation Syndrome; Ovary; Ovulation Induction; Pregnancy; Pregnancy, Animal; Probability; Random Allocation; Rats; Rats, Wistar; Thiazines; Thiazoles; Vascular Endothelial Growth Factor A | 2010 |
Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas.
Topics: Adult; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Humans; Male; Middle Aged; Prolactinoma; Quality of Life | 2010 |
Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women.
Topics: Adult; Antineoplastic Agents; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Infant, Newborn; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prenatal Exposure Delayed Effects; Prolactinoma; Retrospective Studies | 2010 |
Comparison of cabergoline and bromocriptine in patients with asymptomatic incidental hyperprolactinemia undergoing ICSI-ET.
Topics: Adult; Bromocriptine; Cabergoline; Databases, Factual; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Infertility, Female; Pregnancy; Pregnancy Rate; Retrospective Studies; Sperm Injections, Intracytoplasmic; Treatment Outcome | 2010 |
[Priapism secondary to treatment due to cabergoline: the first description of this association].
Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Male; Priapism | 2010 |
Further data favouring hormonal dependency of cerebral meningiomas: evidence from a patient treated with cabergoline.
Topics: Adult; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Meningeal Neoplasms; Meningioma; Neoplasms, Hormone-Dependent | 2011 |
Cabergoline, a dopamine receptor agonist, has an antidepressant-like property and enhances brain-derived neurotrophic factor signaling.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cabergoline; Depression; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Fluvoxamine; Hippocampus; Male; Mitogen-Activated Protein Kinase 3; Rats; Rats, Inbred WKY; Rats, Wistar; Signal Transduction; Up-Regulation | 2010 |
Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia.
Topics: Adult; Antiparkinson Agents; Blood Pressure; Cabergoline; Cross-Sectional Studies; Dose-Response Relationship, Drug; Echocardiography; Ergolines; Female; Heart Valve Diseases; Heart Valves; Humans; Hyperprolactinemia; Male; Middle Aged; Prospective Studies; Risk Assessment; Ventricular Function, Left; Ventricular Function, Right | 2010 |
Prolactinomas and pregnancy.
Topics: Aminoquinolines; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Embryonic Development; Ergolines; Female; Humans; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactinoma | 2010 |
Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.
Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Heart Valve Diseases; Humans; Italy; Male; Middle Aged; Parkinson Disease; Patient Selection; Pergolide; Prevalence; Prognosis; Prospective Studies; Risk Assessment; Risk Factors; Time Factors; Ultrasonography | 2011 |
BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists.
Topics: Adult; Aftercare; Aged; Blood Glucose; Body Composition; Body Mass Index; Body Weight; Bromocriptine; Cabergoline; Cholesterol, HDL; Cholesterol, LDL; Dopamine Agonists; Ergolines; Female; Humans; Insulin; Insulin Resistance; Leptin; Male; Metabolic Syndrome; Metabolome; Middle Aged; Obesity; Prevalence; Prolactinoma; Waist Circumference; Weight Gain; Young Adult | 2011 |
Identification and quantification of dopamine receptor 2 in human eutopic and ectopic endometrium: a novel molecular target for endometriosis therapy.
Topics: Adolescent; Adult; Animals; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Endometriosis; Endometrium; Ergolines; Female; Gene Expression Regulation; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Oocyte Donation; Receptors, Dopamine D2; Severity of Illness Index; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors; Young Adult | 2010 |
The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment.
Topics: Acromegaly; Adult; Aged; Blood Glucose; Cabergoline; Cross-Sectional Studies; Ergolines; Female; Human Growth Hormone; Humans; Insulin; Insulin-Like Growth Factor I; Male; Middle Aged; Receptors, Somatotropin | 2010 |
Gender differences in macroprolactinomas: study of clinical features, outcome of patients and ki-67 expression in tumor tissue.
Topics: Adult; Age Factors; Cabergoline; Ergolines; Estradiol; Female; Humans; Ki-67 Antigen; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Sex Characteristics | 2010 |
Resolution of third nerve palsy following treatment of prolactinoma with cabergoline.
Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Male; Oculomotor Nerve; Oculomotor Nerve Diseases; Pituitary Neoplasms; Prolactinoma | 2010 |
Acquired resistance to cabergoline: progression from initially responsive micro to macroprolactinoma.
Topics: Adult; Antineoplastic Agents; Cabergoline; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Prolactinoma | 2010 |
Cabergoline therapy of paraneoplastic Cushing syndrome in children.
Topics: Adolescent; Cabergoline; Cushing Syndrome; Dopamine Agonists; Ergolines; Female; Humans; Kidney Neoplasms; Paraneoplastic Syndromes; Wilms Tumor | 2010 |
Clozapine for medication-related pathological gambling in Parkinson disease.
Topics: Adult; Antiparkinson Agents; Benzothiazoles; Cabergoline; Clozapine; Ergolines; Female; Gambling; Humans; Male; Middle Aged; Parkinson Disease; Pramipexole; Selegiline; Serotonin Antagonists | 2010 |
Cystic degeneration of macroprolactinoma on long-term cabergoline.
Topics: Adult; Antineoplastic Agents; Cabergoline; Cerebrospinal Fluid Rhinorrhea; Ergolines; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma; Radiography; Treatment Outcome | 2010 |
Cabergoline monotherapy in the long-term treatment of Cushing's disease.
Topics: Adult; Aged; Cabergoline; Cohort Studies; Ergolines; Female; Follow-Up Studies; Humans; Hydrocortisone; Male; Middle Aged; Pituitary ACTH Hypersecretion; Recurrence; Retrospective Studies; Time Factors; Young Adult | 2010 |
Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents; Cabergoline; Ergolines; Hemoglobins; Humans; Hypogonadism; Male; Middle Aged; Prolactin; Prolactinoma; Retrospective Studies; Testosterone | 2011 |
Effect of dopaminergic drug treatment on surgical findings in prolactinomas.
Topics: Adenoma; Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Child; Dopamine Agents; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Young Adult | 2011 |
Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR.
Topics: Acromegaly; Adenoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Delayed-Action Preparations; Drug Resistance, Neoplasm; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Octreotide; Time Factors; Young Adult | 2011 |
Two diagnostic pitfalls mimicking a prolactin-secreting microadenoma.
Topics: Adenoma; Adult; Antineoplastic Agents; Cabergoline; Diagnosis, Differential; Diagnostic Errors; Ergolines; Female; Galactorrhea; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Menstruation Disturbances; Pituitary Neoplasms; Prolactin | 2010 |
Transsphenoidal treatment of secondary empty sella syndrome using low field strength intraoperative MRI: case report.
Topics: Aged; Cabergoline; Empty Sella Syndrome; Ergolines; Female; Humans; Magnetic Resonance Imaging; Pituitary Neoplasms; Prolactinoma; Treatment Outcome; Visual Fields | 2010 |
Disorganized schizophrenia does not deteriorate with dopamine agonists cabergoline and bromocriptine used for ablactation.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Lactation; Mastitis; Schizophrenia, Disorganized | 2011 |
The older Parkinson's disease drugs pergolide and cabergoline have been linked to heart problems. Are there any new Parkinson's drugs which are safer for patients with heart risks?
Topics: Antiparkinson Agents; Aortic Valve Insufficiency; Cabergoline; Dopamine Agonists; Ergolines; Health Knowledge, Attitudes, Practice; Humans; Parkinson Disease; Pergolide | 2009 |
Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly.
Topics: Acromegaly; Cabergoline; Diuretics; Echocardiography, Doppler, Color; Ergolines; Female; Furosemide; Heart Failure; Hormone Antagonists; Humans; Middle Aged; Severity of Illness Index; Treatment Outcome; Tricuspid Valve Insufficiency | 2010 |
Pituitary tumors: cabergoline versus bromocriptine: a meta-analysis?
Topics: Antineoplastic Agents; Bromocriptine; Cabergoline; Ergolines; Humans; Meta-Analysis as Topic; Pituitary Neoplasms; Treatment Outcome | 2011 |
Giant prolactinoma causing cranio-cervical junction instability: a case report.
Topics: Adult; Antineoplastic Agents; Arthrodesis; Cabergoline; Cervical Vertebrae; Cranial Fossa, Posterior; Cranial Nerve Diseases; Craniotomy; Ergolines; Humans; Hyperprolactinemia; Joint Instability; Magnetic Resonance Imaging; Male; Neoplasm Invasiveness; Occipital Bone; Orthotic Devices; Pituitary Neoplasms; Prolactinoma; Recovery of Function; Treatment Outcome | 2011 |
[Spontaneous ovarian hyperstimulation syndrome in a pregnancy with hypothyroidism].
Topics: Abdominal Pain; Adrenal Cortex Hormones; Adult; Cabergoline; Chorionic Gonadotropin; Ergolines; Female; Fibrinolytic Agents; Follicle Stimulating Hormone; Gestational Age; Graves Disease; Humans; Hypothyroidism; Luteinizing Hormone; Ovarian Hyperstimulation Syndrome; Pregnancy; Pregnancy Complications; Thyroidectomy; Thyrotropin | 2011 |
Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prolactinoma; Treatment Outcome; Young Adult | 2012 |
The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008.
Topics: Cabergoline; Databases, Factual; Dopamine Agonists; Drug Prescriptions; Drug Utilization Review; Ergolines; Government Regulation; Heart Valve Diseases; Humans; Insurance Claim Review; Japan; Legislation, Drug; Parkinson Disease; Pergolide; Regression Analysis; Ultrasonography | 2011 |
[Clinical utility of cabergoline in ovarian hyperstimulation syndrome].
Topics: Adult; Cabergoline; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome | 2011 |
Dopamine-induced apoptosis of lactotropes is mediated by the short isoform of D2 receptor.
Topics: Animals; Apoptosis; Cabergoline; Dopamine; Ergolines; Estradiol; Female; Lactotrophs; p38 Mitogen-Activated Protein Kinases; Protein Isoforms; Protein Kinase Inhibitors; Rats; Rats, Wistar; Receptors, Dopamine D2 | 2011 |
Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease.
Topics: Adult; Aged; Cabergoline; Dopamine Agonists; Drug Labeling; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Incidence; Japan; Male; Middle Aged; Parkinson Disease; Pergolide; Retrospective Studies; Risk Factors | 2011 |
Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Biogenic Amines; Brain; Cabergoline; Dopamine Agents; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Ketanserin; Levodopa; Macaca; Parkinsonian Disorders; Receptor, Serotonin, 5-HT2A | 2011 |
The bulky N6 substituent of cabergoline is responsible for agonism of this drug at 5-hydroxytryptamine 5-HT2A and 5-HT2B receptors and thus is a determinant of valvular heart disease.
Topics: Animals; Cabergoline; Cells, Cultured; CHO Cells; Cricetinae; Cricetulus; Ergolines; Heart Valve Diseases; Humans; Pulmonary Artery; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2B; Serotonin Receptor Agonists; Swine | 2011 |
Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinson's disease.
Topics: Antiparkinson Agents; Cabergoline; Echocardiography, Doppler, Color; Ergolines; Fibrosis; Heart Valve Diseases; Heart Valves; Humans; Male; Middle Aged; Parkinson Disease | 2011 |
Chronic anemia as first clinical manifestation of a prolactin-secreting pituitary macroadenoma in a male patient.
Topics: Anemia; Antineoplastic Agents; Biomarkers, Tumor; Cabergoline; Chronic Disease; Dopamine Agonists; Drug Therapy, Combination; Early Detection of Cancer; Ergolines; Hematocrit; Hemoglobins; Hormone Replacement Therapy; Humans; Hydrocortisone; Hypogonadism; Hypopituitarism; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Testosterone; Thyroxine; Treatment Outcome | 2011 |
Evidences for the existence of a low dopaminergic tone in polycystic ovarian syndrome: implications for OHSS development and treatment.
Topics: Adult; Cabergoline; Cells, Cultured; Dopamine; Dopamine Agonists; Ergolines; Female; Granulosa Cells; Humans; Luteal Cells; Neovascularization, Physiologic; Oocytes; Ovarian Hyperstimulation Syndrome; Polycystic Ovary Syndrome; Receptors, Dopamine D2; Risk Factors; Signal Transduction; Tissue Banks; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2011 |
[Complications of treatment of prolactinoma by dopamine agonists].
Topics: Adolescent; Adult; Cabergoline; Cerebrospinal Fluid Rhinorrhea; Dopamine Agonists; Ergolines; Humans; Intracranial Hemorrhages; Male; Middle Aged; Neurosurgical Procedures; Pituitary Neoplasms; Prolactinoma; Radiography; Treatment Outcome; Vision Disorders; Young Adult | 2011 |
[Pathological gambling induced by dopamine agonists].
Topics: Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Gambling; Humans; Indoles; International Classification of Diseases; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Restless Legs Syndrome | 2011 |
Adverse drug reaction suggested by a clinical vignette.
Topics: Antineoplastic Agents; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans | 2011 |
A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Prolactinoma | 2012 |
Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.
Topics: Adenoma; Adult; Cabergoline; Cell Proliferation; Dopamine; Dopamine Agonists; Drug Synergism; Ergolines; Gene Expression; Humans; Immunohistochemistry; Male; Octreotide; Pituitary Neoplasms; Protein Isoforms; Receptors, Dopamine D2; Receptors, Somatostatin; Reverse Transcriptase Polymerase Chain Reaction; Somatostatin; Thyrotropin; Thyroxine; Treatment Outcome; Triiodothyronine; Tumor Cells, Cultured | 2012 |
The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis.
Topics: Animals; Blood Vessels; Cabergoline; Cell Count; Cell Proliferation; Claviceps; Disease Models, Animal; Dopamine Agonists; Endometriosis; Endometrium; Ergolines; Female; Humans; Mice; Neovascularization, Pathologic; Receptors, Dopamine D2; Uterine Diseases; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Extralabel use of cabergoline in the treatment of a pituitary adenoma in a rat.
Topics: Adenoma; Animals; Antineoplastic Agents; Cabergoline; Ergolines; Male; Pets; Pituitary Neoplasms; Rats; Rodent Diseases | 2011 |
Risk assessment and follow-up of valvular regurgitation in Parkinson patients treated with cabergoline.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cabergoline; Cohort Studies; Cross-Sectional Studies; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Odds Ratio; Parkinson Disease; Retrospective Studies; Risk Assessment | 2012 |
Recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline.
Topics: Analysis of Variance; Cabergoline; Enzyme-Linked Immunosorbent Assay; Ergolines; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Hypothalamo-Hypophyseal System; Luteinizing Hormone; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Radioimmunoassay; Sperm Count; Sperm Motility; Testis; Testosterone; Time Factors | 2011 |
[Prescription of ergot derivatives for lactation inhibition in France: Current practices].
Topics: Bromocriptine; Cabergoline; Dihydroergocryptine; Dopamine Agonists; Ergolines; Ergot Alkaloids; Female; France; Humans; Lactation; Lisuride; Practice Patterns, Physicians'; Prolactin; Surveys and Questionnaires | 2012 |
[Prolactinoma treatment status in the cabergoline era].
Topics: Adolescent; Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma; Treatment Outcome | 2011 |
Macrocorticotropinoma shrinkage and control of hypercortisolism under long-term cabergoline therapy: case report.
Topics: Adult; Cabergoline; Cushing Syndrome; Ergolines; Female; Humans; Magnetic Resonance Imaging; Pituitary ACTH Hypersecretion | 2012 |
Acute shrinkage of a giant prolactinoma, masquerading as an erosive skull base tumour, with cabergoline.
Topics: Adult; Antineoplastic Agents; Cabergoline; Diagnosis, Differential; Ergolines; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma; Skull Base Neoplasms | 2013 |
Dopamine agonist use and the risk of heart failure.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzothiazoles; Cabergoline; Case-Control Studies; Databases, Factual; Dopamine Agonists; Ergolines; Female; Heart Failure; Humans; Incidence; Logistic Models; Male; Middle Aged; Pramipexole; Risk; United Kingdom | 2012 |
[Inappropriate lactation syndrome in goats--case collection and experiences with mastectomy].
Topics: Animals; Cabergoline; Dopamine Agonists; Ergolines; Female; Galactorrhea; Goat Diseases; Goats; Mastectomy; Recurrence; Surgical Flaps; Treatment Outcome | 2011 |
Fibroepithelial hyperplasia in an entire male cat: cytologic and histopathological features.
Topics: Adenofibroma; Alkaline Phosphatase; Animals; Antineoplastic Agents; Biopsy, Fine-Needle; Cabergoline; Cats; Diagnosis, Differential; Ergolines; Hyperplasia; Male; Mammary Glands, Animal; Mammary Neoplasms, Animal; Orchiectomy; Phosphorus; Progesterone; Treatment Outcome | 2011 |
[Cabergoline-induced tension pneumocephalus in a patient with giant invasive prolactinoma. Case report].
Topics: Antineoplastic Agents; Cabergoline; Ergolines; Humans; Male; Middle Aged; Pituitary Neoplasms; Pneumocephalus; Prolactinoma; Tomography, X-Ray Computed | 2011 |
Selective IGT decision-making impairment in a patient with juvenile Parkinson's disease and pathological gambling: a role for dopaminergic therapy?
Topics: Adult; Antiparkinson Agents; Benzothiazoles; Cabergoline; Case-Control Studies; Compulsive Behavior; Decision Making; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Gambling; Humans; Levodopa; Matched-Pair Analysis; Neuropsychological Tests; Parkinsonian Disorders; Pramipexole; Reference Values | 2012 |
Von Hippel-Lindau disease and aggressive GH-PRL pituitary adenoma in a young boy.
Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Ergolines; Human Growth Hormone; Humans; Magnetic Resonance Imaging; Male; Mutation; Pituitary Neoplasms; Prolactin; Somatostatin; Treatment Outcome; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein | 2012 |
Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism.
Topics: Animals; Cabergoline; Calcium; Dopamine Agonists; Dose-Response Relationship, Drug; Eating; Ergolines; Ghrelin; Hypothalamus; Mice; Neurons; Quinpirole; Receptors, Dopamine D2; Receptors, Ghrelin; Signal Transduction | 2012 |
No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Cross-Sectional Studies; Echocardiography; Ergolines; Female; Humans; Male; Middle Aged; Prolactinoma; Retrospective Studies; Tricuspid Valve Insufficiency; Young Adult | 2012 |
Hypogonadism due to hyperprolactinemia and subsequent first episode of psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cabergoline; Ergolines; Humans; Hyperprolactinemia; Hypogonadism; Male; Obesity, Morbid; Piperazines; Pituitary Neoplasms; Prolactin; Prolactinoma; Psychotic Disorders; Quinolones; Schizophrenia | 2012 |
Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion.
Topics: Adenoviridae; Adolescent; Adult; Cabergoline; Dopamine; Dopamine Agonists; Ergolines; Female; Genetic Vectors; Humans; Male; Octreotide; Pituitary Neoplasms; Primary Cell Culture; Prolactin; Prolactinoma; Receptors, Dopamine D2; Receptors, Somatostatin; Somatostatin; Transfection | 2012 |
Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.
Topics: Aged; Cabergoline; Cell Survival; Ergolines; Female; Humans; Male; Microscopy, Fluorescence; Middle Aged; Pituitary Neoplasms; Receptors, Dopamine; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2013 |
Effect of cabergoline on increase of several ER stress-related molecules in 6-OHDA-lesioned mice.
Topics: Animals; Antiparkinson Agents; Cabergoline; Caspase 12; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Ergolines; Male; Mice; Mice, Inbred ICR; Oligopeptides; Oxidopamine; Parkinson Disease, Secondary; Substantia Nigra; Transcription Factor CHOP | 2013 |
Pegvisomant and cabergoline combination therapy in acromegaly.
Topics: Acromegaly; Adult; Cabergoline; Drug Therapy, Combination; Ergolines; Female; Human Growth Hormone; Humans; Male; Middle Aged; Retrospective Studies | 2013 |
Spontaneous coronary artery dissection during cabergoline therapy.
Topics: Adult; Angina Pectoris; Antineoplastic Agents, Hormonal; Aortic Dissection; Cabergoline; Cardiovascular Agents; Coronary Aneurysm; Coronary Angiography; Coronary Vasospasm; Ergolines; Female; Humans; Pituitary Neoplasms; Predictive Value of Tests; Prolactinoma; Recurrence; Risk Factors; Time Factors; Treatment Outcome | 2012 |
The first case of Brucella canis in Sweden: background, case report and recommendations from a northern European perspective.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Brucella canis; Brucellosis; Cabergoline; Contact Tracing; Dog Diseases; Dogs; Ergolines; Female; Humans; Practice Guidelines as Topic; Sweden | 2012 |
Comparison of the use of cabergoline and gonadotrophin to treat primary and secondary anoestrus in bitches.
Topics: Administration, Oral; Anestrus; Animals; Breeding; Cabergoline; Dogs; Dose-Response Relationship, Drug; Ergolines; Estrus; Female; Gonadotropins; Injections, Intramuscular; Ovulation Induction; Pregnancy; Pregnancy Rate | 2012 |
Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.
Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Case-Control Studies; Dopamine Agonists; Echocardiography; Ergolines; Female; Fibrosis; Heart Valve Diseases; Heart Valves; Humans; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Prospective Studies | 2012 |
Finasteride attenuates pathological gambling in patients with Parkinson disease.
Topics: 5-alpha Reductase Inhibitors; Aged; Antiparkinson Agents; Benzothiazoles; Cabergoline; Carbidopa; Catechols; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Ergolines; Finasteride; Gambling; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Pramipexole; Treatment Outcome; Video Games | 2012 |
[Gender effect on cardiomyopathy].
Topics: Bromocriptine; Cabergoline; Cardiomyopathies; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; Cardiomyopathy, Restrictive; Dopamine Agonists; Ergolines; Evidence-Based Medicine; Female; Genetic Counseling; Humans; Phenotype; Pregnancy; Pregnancy Complications, Cardiovascular; Prognosis; Prolactin; Risk Assessment; Risk Factors; Sex Factors; Treatment Outcome | 2012 |
Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
Topics: Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Retrospective Studies; Risk Factors; Ultrasonography; Young Adult | 2012 |
Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas.
Topics: Adult; Aged; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily D, Member 1; ATP-Binding Cassette Transporters; Cabergoline; Case-Control Studies; Ergolines; Fatigue; Female; Headache; Humans; Male; Mice; Mice, Knockout; Middle Aged; Pituitary Neoplasms; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prolactinoma; Treatment Outcome | 2012 |
'You never told me I would turn into a gambler': a first person account of dopamine agonist--induced gambling addiction in a patient with restless legs syndrome.
Topics: Cabergoline; Carbidopa; Cognitive Behavioral Therapy; Dopamine Agonists; Drug Combinations; Ergolines; Gambling; Humans; Indoles; Levodopa; Male; Middle Aged; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes | 2011 |
[Hyperprolactin as cause of hypoactive sexual desire in men].
Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Hyperprolactinemia; Libido; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Sexual Dysfunction, Physiological | 2012 |
No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly.
Topics: Acromegaly; Adolescent; Adult; Aged; Aortic Valve Insufficiency; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Echocardiography; Echocardiography, Doppler; Ergolines; Female; Heart Valve Diseases; Heart Valves; Humans; Hypertrophy, Left Ventricular; Longitudinal Studies; Male; Middle Aged; Mitral Valve Insufficiency; Retrospective Studies; Tricuspid Valve Insufficiency; Young Adult | 2012 |
Ectopic posterior pituitary causing hyperprolactinemia.
Topics: Adult; Cabergoline; Choristoma; Diagnosis, Differential; Ergolines; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Oligomenorrhea; Pituitary Diseases; Pituitary Gland, Posterior; Prolactin; Recurrence; Treatment Outcome | 2012 |
Short-term treatment with cabergoline can lead to tumor shrinkage in patients with nonfunctioning pituitary adenomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cabergoline; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Treatment Outcome; Young Adult | 2013 |
Disappearance of pituitary macro adenoma with combination of ketoconazole and cabergoline treatment: an unusual case of Cushing's syndrome with interesting findings.
Topics: 14-alpha Demethylase Inhibitors; Adenoma; Adult; Antineoplastic Agents; Cabergoline; Cushing Syndrome; Diagnosis, Differential; Drug Therapy, Combination; Ergolines; Humans; Ketoconazole; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Severity of Illness Index; Tomography, X-Ray Computed | 2012 |
[Postpartum psychosis associated with cabergoline].
Topics: Adult; Antipsychotic Agents; Cabergoline; Cesarean Section; Dopamine Agonists; Ergolines; Female; Hallucinations; Humans; Lactation; Postoperative Complications; Pregnancy; Pregnancy Complications; Pregnancy, Twin; Psychomotor Agitation; Psychotic Disorders; Puerperal Disorders; Risperidone; Sleep Initiation and Maintenance Disorders | 2013 |
Cabergoline-induced pneumocephalus in a medically treated macroprolactinoma.
Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Pituitary Neoplasms; Pneumocephalus; Prolactinoma | 2012 |
Safety of cabergoline in the management of pituitary prolactin-induced symptoms with patients treated with atypical neuroleptics.
Topics: Adult; Antipsychotic Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Male; Treatment Outcome | 2012 |
Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cabergoline; Chemotherapy, Adjuvant; Child; Drug Administration Schedule; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Hyperprolactinemia; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Mutation; Pituitary Neoplasms; Prolactinoma; Proto-Oncogene Proteins; Retrospective Studies; Treatment Failure | 2012 |
Effect of antiangiogenic treatment on peritoneal endometriosis-associated nerve fibers.
Topics: Actins; Angiogenesis Inhibitors; Animals; Biomarkers; Cabergoline; Disease Models, Animal; Endometriosis; Endometrium; Ergolines; Female; Fluorescent Antibody Technique; Humans; Immunohistochemistry; Macrophages; Mast Cells; Mice; Mice, Nude; Microvessels; Neovascularization, Pathologic; Nerve Fibers; Ovariectomy; Peritoneal Diseases; Time Factors; von Willebrand Factor | 2012 |
Medically treated prolactin-secreting pituitary adenomas: when should we operate?
Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Ergolines; Female; Hormone Antagonists; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Postmenopause; Premenopause; Prolactinoma; Prospective Studies; Retrospective Studies; Sphenoid Bone; Time Factors; Treatment Failure | 2013 |
Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases.
Topics: Acromegaly; Adult; Bromocriptine; Cabergoline; Databases, Factual; Ergolines; Female; Human Growth Hormone; Humans; Male; Middle Aged; Octreotide; Peptides, Cyclic; Retrospective Studies; Somatostatin; United States | 2013 |
Cabergoline therapy for macroprolactinoma during pregnancy: a case report.
Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactin; Prolactinoma | 2012 |
Short-term pharmacological suppression of the hyperprolactinemia of infertile hCG-overproducing female mice persistently restores their fertility.
Topics: Animals; Bromocriptine; Cabergoline; Chorionic Gonadotropin; Disease Models, Animal; Ergolines; Female; Fertility; Gene Expression Regulation; Humans; Hyperprolactinemia; Infertility; Mice; Mice, Transgenic; Ovulation; Phenotype; Time Factors | 2012 |
Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation.
Topics: Adult; Antineoplastic Agents; Breast Feeding; Cabergoline; Data Collection; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Infertility, Female; Lactation; Observation; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactinoma; Puerperal Disorders; Recurrence; Time Factors | 2013 |
Risk of thromboembolic events in patients with prolactinomas compared with patients with nonfunctional pituitary adenomas.
Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Ergolines; Female; Humans; Male; Middle Aged; Pergolide; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Thromboembolism; Young Adult | 2013 |
Cabergoline-induced psychosis in a patient with undiagnosed depression.
Topics: Adult; Cabergoline; Depressive Disorder; Ergolines; Female; Humans; Pituitary Neoplasms; Prolactinoma; Psychoses, Substance-Induced | 2012 |
Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease.
Topics: Adult; Aged; Cabergoline; Circadian Rhythm; Dopamine Agonists; Ergolines; Female; Humans; Hydrocortisone; Ketoconazole; Male; Middle Aged; Pituitary ACTH Hypersecretion; Quality of Life; Somatostatin; Surveys and Questionnaires; Young Adult | 2013 |
Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy.
Topics: Adolescent; Aminoquinolines; Cabergoline; Dopamine Agonists; Ergolines; Exophthalmos; Humans; Hydrocephalus; Male; Pituitary Neoplasms; Prolactin; Prolactinoma | 2012 |
Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.
Topics: Acromegaly; Adenoma; Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Delayed-Action Preparations; Drug Resistance; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Humans; Insulin-Like Growth Factor I; Japan; Male; Middle Aged; Octreotide; Pituitary Gland; Retrospective Studies; Somatostatin; Tumor Burden; Young Adult | 2013 |
Hyperprolactinemia: an unusual cause of erectile dysfunction.
Topics: Adenoma; Adult; Cabergoline; Dopamine Agonists; Erectile Dysfunction; Ergolines; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms; Treatment Outcome | 2013 |
Hyperprolactinemia in children: clinical features and long-term results.
Topics: Adolescent; Bromocriptine; Cabergoline; Child; Combined Modality Therapy; Ergolines; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Treatment Outcome | 2012 |
Transsphenoidal microsurgical results of female patients with prolactinomas.
Topics: Adult; Cabergoline; Cavernous Sinus; Dopamine Agonists; Endoscopy; Ergolines; Female; Humans; Magnetic Resonance Imaging; Microsurgery; Neoplasm Recurrence, Local; Neurosurgical Procedures; Pituitary Neoplasms; Postoperative Complications; Pregnancy; Prolactin; Prolactinoma; Retrospective Studies; Sphenoid Bone; Treatment Outcome | 2013 |
Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study.
Topics: Adult; Aged; Cabergoline; Case-Control Studies; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Impulsive Behavior; Male; Middle Aged; Pilot Projects; Prevalence; Psychometrics; Self Report; Surveys and Questionnaires; Treatment Outcome | 2014 |
Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.
Topics: Adiposity; Adult; Blood Glucose; Body Mass Index; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Insulin Resistance; Lipids; Male; Metabolome; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Waist Circumference; Young Adult | 2013 |
Combination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels--a retrospective study.
Topics: Adult; Cabergoline; Cryopreservation; Embryo Transfer; Ergolines; Estradiol; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Retrospective Studies; Sperm Injections, Intracytoplasmic | 2013 |
[Recurrent left sided sinusitis with hearing loss and occipital headache].
Topics: Adult; Cabergoline; Diagnosis, Differential; Dopamine Antagonists; Epistaxis; Ergolines; Headache Disorders; Hearing Loss, High-Frequency; Hearing Loss, Sensorineural; Hearing Loss, Unilateral; Humans; Magnetic Resonance Imaging; Male; Nasal Obstruction; Pituitary Neoplasms; Prolactinoma; Sinusitis; Tinnitus; Tomography, X-Ray Computed | 2013 |
Preventing ovarian hyperstimulation syndrome: cabergoline versus coasting.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Estradiol; Female; Fertility Agents, Female; Fertilization in Vitro; Follicle Stimulating Hormone; Hormones; Humans; Infertility, Female; Leuprolide; Longitudinal Studies; Ovarian Follicle; Ovarian Hyperstimulation Syndrome; Pregnancy; Pregnancy Rate; Retrospective Studies; Young Adult | 2013 |
Tension pneumocephalus after administration of two 0.25 mg cabergoline tablets in MEN1-related macroprolactinoma.
Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Magnetic Resonance Imaging; Male; Multiple Endocrine Neoplasia Type 1; Pneumocephalus; Prolactinoma; Tablets | 2013 |
Male prolactinomas presenting with normal testosterone levels.
Topics: Adult; Aged; Antineoplastic Agents; Cabergoline; Cohort Studies; Ergolines; Humans; Hypogonadism; Male; Middle Aged; Pituitary Neoplasms; Prognosis; Prolactinoma; Testosterone; Treatment Outcome | 2014 |
Glucocorticoid hypersensitivity syndrome--a case report.
Topics: 14-alpha Demethylase Inhibitors; Adult; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Glucocorticoids; Humans; Hypersensitivity; Ketoconazole | 2012 |
Impressive shrinkage of a giant prolactinoma treated with cabergoline in a prepubescent girl. What now?
Topics: Adolescent; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Induction Chemotherapy; Menarche; Pituitary Neoplasms; Prolactinoma; Tumor Burden | 2013 |
Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients.
Topics: Adult; Amisulpride; Antipsychotic Agents; Cabergoline; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Haloperidol; Humans; Hyperprolactinemia; Longitudinal Studies; Maintenance Chemotherapy; Male; Middle Aged; Prolactin; Prospective Studies; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Sexual Dysfunction, Physiological; Sulpiride | 2013 |
Comparison of bevacizumab and cabergoline in the treatment of ovarian hyperstimulation syndrome in a rat model.
Topics: Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Cabergoline; Cell Count; Disease Models, Animal; Drug Evaluation, Preclinical; Ergolines; Female; Organ Size; Ovarian Hyperstimulation Syndrome; Ovary; Ovum; Rats; Rats, Wistar | 2013 |
Cabergoline therapy for Cushing disease throughout pregnancy.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Infant, Newborn; Live Birth; Pituitary ACTH Hypersecretion; Pregnancy; Pregnancy Complications | 2013 |
The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma.
Topics: Adolescent; Anemia, Hemolytic; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Pituitary Neoplasms; Prolactinoma | 2014 |
Regulation of intraocular pressure in mice: structural analysis of dopaminergic and serotonergic systems in response to cabergoline.
Topics: Animals; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Humans; Intraocular Pressure; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Molecular Docking Simulation; Molecular Dynamics Simulation; Ocular Hypertension; Protein Conformation; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2B; Receptors, Dopamine D3; Sequence Alignment | 2013 |
[Abnormalities of carbohydrate metabolism in acromegaly].
Topics: Acromegaly; Adult; Aged; Blood Glucose; Body Mass Index; Cabergoline; Combined Modality Therapy; Cranial Irradiation; Cross-Sectional Studies; Ergolines; Female; Glucose; Glycated Hemoglobin; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hyperglycemia; Hypophysectomy; Insulin-Like Growth Factor I; Male; Middle Aged; Pituitary Neoplasms; Retrospective Studies; Somatostatin; Tumor Burden | 2013 |
[Management of prolactinoma].
Topics: Antineoplastic Agents; Cabergoline; Diagnosis, Differential; Ergolines; Humans; Pituitary Neoplasms; Prolactinoma; Radiotherapy, Adjuvant | 2013 |
Remission with cabergoline in adolescent boys with Cushing's disease.
Topics: Adolescent; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hypertension; Male; Petrosal Sinus Sampling; Pituitary ACTH Hypersecretion; Remission Induction | 2013 |
[Visual outcome in patients with macroprolactinoma treated with dopamine agonists].
Topics: Adolescent; Adult; Bromocriptine; Cabergoline; Child; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prolactinoma; Retrospective Studies; Vision Disorders; Visual Acuity; Visual Fields; Young Adult | 2013 |
Cushing's disease and hypertension: in vivo and in vitro study of the role of the renin-angiotensin-aldosterone system and effects of medical therapy.
Topics: Adult; Aged; Aldosterone; Angiotensinogen; Animals; Cabergoline; Ergolines; Female; Humans; Hypertension; Iliac Artery; In Vitro Techniques; Male; Middle Aged; Pituitary ACTH Hypersecretion; Rats; Renin; Renin-Angiotensin System; Somatostatin; Vasoconstriction | 2014 |
The role of primary pharmacological therapy in acromegaly.
Topics: Acromegaly; Adenoma; Cabergoline; Dopamine Agonists; Ergolines; Human Growth Hormone; Humans; Male; Octreotide; Pituitary Neoplasms; Somatostatin; Young Adult | 2014 |
Thyrotropin-secreting pituitary tumor presenting with congestive heart failure and good response to dopaminergic agonist cabergoline.
Topics: Aged; Cabergoline; Dopamine Agonists; Ergolines; Follow-Up Studies; Heart Failure; Humans; Male; Pituitary Neoplasms; Thyrotropin | 2013 |
A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists.
Topics: Adult; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Echocardiography; Ergolines; Ergot Alkaloids; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Middle Aged; Prevalence; United Kingdom | 2014 |
Acromegaly and pregnancy: a prospective study.
Topics: Acromegaly; Adult; Cabergoline; Ergolines; Female; Human Growth Hormone; Humans; Infant, Newborn; Insulin-Like Growth Factor I; Magnetic Resonance Imaging; Octreotide; Pregnancy; Pregnancy Complications, Neoplastic; Prospective Studies; Sella Turcica | 2014 |
Pituitary carcinoma with fourth ventricle metastasis: treatment by excision and Gamma-knife radiosurgery.
Topics: Cabergoline; Cerebral Ventricle Neoplasms; Dopamine Agonists; Ergolines; Fourth Ventricle; Humans; Male; Pituitary Hormones; Pituitary Neoplasms; Prolactinoma; Radiosurgery; Young Adult | 2014 |
Occlusal treatment with bite splint improves dyskinesia in Parkinson's disease patient: a case report.
Topics: Activities of Daily Living; Antiparkinson Agents; Bromocriptine; Cabergoline; Clonidine; Dyskinesias; Ergolines; Female; Hand Strength; Humans; Levodopa; Middle Aged; Motor Skills; Occlusal Splints; Parkinson Disease; Posture | 2013 |
Prolactinoma-associated headache and dopamine agonist treatment.
Topics: Adult; Aminoquinolines; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Headache; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Recurrence; Substance Withdrawal Syndrome | 2014 |
Effect of cabergoline on metabolism in prolactinomas.
Topics: Adiposity; Adult; Antineoplastic Agents; Cabergoline; Dose-Response Relationship, Drug; Ergolines; Fasting; Female; Humans; Hyperprolactinemia; Insulin; Insulin Resistance; Male; Metabolic Diseases; Metabolic Syndrome; Pituitary Neoplasms; Prevalence; Prognosis; Prolactin; Prolactinoma; Prospective Studies; Time Factors; Treatment Outcome | 2013 |
Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas.
Topics: Adult; Antineoplastic Agents; Cabergoline; Drug Therapy, Combination; Ergolines; Humans; Insulinoma; Male; Multiple Endocrine Neoplasia Type 1; Pancreatic Neoplasms; Peptides, Cyclic; Somatostatin; Treatment Outcome | 2014 |
Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study.
Topics: Cabergoline; Cohort Studies; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Parkinson Disease | 2014 |
[Inhibition of lactation: end to the bromocriptin, long life to the carbergolin?].
Topics: Bromocriptine; Cabergoline; Cardiovascular Diseases; Ergolines; Female; France; Hormone Antagonists; Humans; Lactation | 2014 |
Cabergoline treatment in acromegaly: cons.
Topics: Acromegaly; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Humans; Octreotide | 2014 |
Pons herniation into skull base after cabergoline therapy of giant prolactinoma.
Topics: Antineoplastic Agents; Cabergoline; Ergolines; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Pons; Prolactinoma | 2015 |
Cabergoline treatment in acromegaly: pros.
Topics: Acromegaly; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Humans; Octreotide; Treatment Outcome | 2014 |
Prolactin mediates psychological stress-induced dysfunction of regulatory T cells to facilitate intestinal inflammation.
Topics: Animals; Cabergoline; Colitis; Dextran Sulfate; Disease Models, Animal; Dopamine Agonists; Ergolines; Forkhead Transcription Factors; Immunity, Mucosal; Inflammation; Interleukins; Mice; Mice, Inbred BALB C; Prolactin; Stress, Psychological; T-Lymphocytes, Regulatory; Trinitrobenzenesulfonic Acid; Tumor Necrosis Factor-alpha | 2014 |
Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study.
Topics: Adenoma; Adult; Antineoplastic Agents; Cabergoline; Drug Therapy, Combination; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Injections, Subcutaneous; Insulin-Like Growth Factor I; Lipodystrophy; Male; Middle Aged; Octreotide; Receptors, Somatotropin; Retrospective Studies; Spain; Treatment Failure; Treatment Outcome | 2014 |
Relaxant effects of metoclopramide and magnesium sulfate on isolated pregnant myometrium: an in vitro study.
Topics: Adult; Cabergoline; Dopamine Agonists; Dopamine Antagonists; Ergolines; Female; Humans; In Vitro Techniques; Magnesium Sulfate; Metoclopramide; Muscle Relaxation; Myometrium; Oxytocin; Pregnancy; Tocolytic Agents; Uterine Contraction | 2014 |
Hypopituitarism patterns and prevalence among men with macroprolactinomas.
Topics: Adult; Aged; Aged, 80 and over; Cabergoline; Ergolines; Humans; Hypopituitarism; Male; Middle Aged; Prevalence; Prolactinoma; Retrospective Studies; Testosterone; Young Adult | 2015 |
Women with prolactinomas presented at the postmenopausal period.
Topics: Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Follicle Stimulating Hormone; Humans; Hyperprolactinemia; Luteinizing Hormone; Middle Aged; Pituitary Neoplasms; Postmenopause; Prolactin; Prolactinoma; Retrospective Studies; Treatment Outcome | 2014 |
Lesson of the month (1): cabergoline - 'i eat funny on that'.
Topics: Adult; Bulimia; Cabergoline; Compulsive Behavior; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Impulsive Behavior; Self-Injurious Behavior | 2014 |
Valvular heart disease in hyperprolactinemic patients treated with low doses of cabergoline.
Topics: Adult; Cabergoline; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Middle Aged | 2013 |
Young female with acromegaloid features and pituitary macroadenoma: what is your diagnosis?
Topics: Acanthosis Nigricans; Acromegaly; Adult; Bromocriptine; Cabergoline; Diagnosis, Differential; Ergolines; Female; Gastrointestinal Diseases; Hirsutism; Human Growth Hormone; Humans; Hyperprolactinemia; Insulin; Insulin Resistance; Insulin-Like Growth Factor I; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Complications, Neoplastic; Prognathism; Prolactinoma | 2014 |
A case of iatrogenic severe mitral regurgitation.
Topics: Antineoplastic Agents; Bromocriptine; Cabergoline; Drug Therapy, Combination; Ergolines; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hormone Antagonists; Humans; Male; Middle Aged; Mitral Valve Insufficiency; Pituitary Neoplasms; Prolactinoma; Treatment Outcome | 2013 |
Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010.
Topics: Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Drug Prescriptions; Ergolines; Female; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 2014 |
Cabergoline, dopamine D2 receptor agonist, prevents neuronal cell death under oxidative stress via reducing excitotoxicity.
Topics: Amino Acid Transport System X-AG; Animals; Cabergoline; Cell Death; Cells, Cultured; Cerebral Cortex; Ergolines; Extracellular Signal-Regulated MAP Kinases; Glutamic Acid; Hydrogen Peroxide; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Models, Biological; Neurons; Neuroprotective Agents; Neurotoxins; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Rats, Wistar; Receptors, Dopamine D2; Time Factors; Up-Regulation | 2014 |
[Contemporary options and perspectives in the treatment of acromegaly].
Topics: Acromegaly; Adenoma; Antineoplastic Agents; Cabergoline; Ergolines; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Octreotide; Peptides, Cyclic; Radiosurgery; Receptors, Somatotropin; Somatostatin | 2014 |
AACE/ACE Disease State Clinical Review: Dopamine Agonists for Hyperprolactinemia and the Risk of Cardiac Valve Disease.
Topics: Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Risk | 2014 |
Diagnosis of prolactinoma in two male-to-female transsexual subjects following high-dose cross-sex hormone therapy.
Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Estrogens; Female; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Transgender Persons | 2015 |
Giant prolactinomas: clinical manifestations and outcomes of 16 Arab cases.
Topics: Adult; Antineoplastic Agents; Arabs; Biomarkers, Tumor; Cabergoline; Comorbidity; Ergolines; Female; Humans; Male; Middle Aged; Neurosurgical Procedures; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Saudi Arabia; Tertiary Care Centers; Time Factors; Treatment Outcome; Tumor Burden; Young Adult | 2015 |
Primary anestrus due to dietary hyperthyroidism in a miniature pinscher bitch.
Topics: Administration, Oral; Anestrus; Animal Feed; Animals; Cabergoline; Diagnosis, Differential; Dog Diseases; Dogs; Ergolines; Female; Humans; Hyperthyroidism; Pedigree; Pregnancy; Pregnancy, Animal; Thyroxine | 2014 |
A dopamine receptor d2-type agonist attenuates the ability of stress to alter sleep in mice.
Topics: Animals; Cabergoline; Dopamine Agonists; Electroencephalography; Ergolines; Female; Male; Mice; Mice, Inbred C57BL; Prolactin; Receptors, Dopamine D2; Restraint, Physical; Sleep; Sleep Deprivation; Stress, Psychological | 2014 |
Lower prolactin levels during cabergoline treatment are associated to tumor shrinkage in prolactin secreting pituitary adenoma.
Topics: Adult; Cabergoline; Ergolines; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pituitary Neoplasms; Prolactin; Prolactinoma; Treatment Outcome | 2014 |
Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy.
Topics: Aged; Antiparkinson Agents; Cabergoline; Cohort Studies; Echocardiography; Ergolines; Female; Guideline Adherence; Heart Valve Diseases; Heart Valves; Humans; Incidence; Italy; Male; Middle Aged; Parkinson Disease; Pergolide; Practice Guidelines as Topic; Prevalence; Retrospective Studies; Risk Factors; Supranuclear Palsy, Progressive | 2015 |
Effects of cabergoline and rotigotine on tacrine-induced tremulous jaw movements in rats.
Topics: Animals; Cabergoline; Corpus Striatum; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Jaw; Male; Nucleus Accumbens; Proto-Oncogene Proteins c-fos; Rats; Tacrine; Tetrahydronaphthalenes; Thiophenes; Tremor | 2014 |
Recurrence of hyperprolactinemia and continuation of ovarian acyclicity in captive African elephants (Loxodonta africana) treated with cabergoline.
Topics: Animals; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Elephants; Ergolines; Estrous Cycle; Female; Hyperprolactinemia; Progestins; Prolactin | 2014 |
[Pituitary apoplexy in a young woman].
Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Magnetic Resonance Imaging; Pituitary Apoplexy; Pituitary Neoplasms | 2014 |
Treatment of maternal hypergalactia.
Topics: Adult; Breast Feeding; Breast Milk Expression; Cabergoline; Ergolines; Estrogens; Feeding Behavior; Female; Homeopathy; Humans; Infant, Newborn; Lactation Disorders; Nasal Decongestants; Pregnancy; Prolactin; Pseudoephedrine; Severity of Illness Index | 2014 |
Conflict acts as an implicit cost in reinforcement learning.
Topics: Adolescent; Adult; Cabergoline; Conflict, Psychological; Cues; Dopamine; Dopamine Agonists; Dopamine and cAMP-Regulated Phosphoprotein 32; Ergolines; Eye Movements; Female; Humans; Male; Reinforcement, Psychology; Theta Rhythm; Young Adult | 2014 |
Comparison of efficacy of bromocriptine and cabergoline to GnRH agonist in a rat endometriosis model.
Topics: Adult; Animals; Antineoplastic Agents; Bromocriptine; Cabergoline; Disease Models, Animal; Dopamine Agonists; Endometriosis; Endometrium; Ergolines; Female; Gonadotropin-Releasing Hormone; Humans; Laparotomy; Leuprolide; Prospective Studies; Random Allocation; Rats; Rats, Wistar; Triptorelin Pamoate | 2015 |
Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas.
Topics: Adult; Aged; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Young Adult | 2015 |
Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents; Cabergoline; Ergolines; Female; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Receptors, Dopamine D2; RNA, Messenger; Treatment Outcome | 2015 |
Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience.
Topics: Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
Treating prolactinoma can prevent autoimmune diseases.
Topics: Adolescent; Antineoplastic Agents; Cabergoline; Child; Ergolines; Female; Humans; Hyperprolactinemia; Multiple Sclerosis; Prolactin; Prolactinoma | 2015 |
Complete clinical and biochemical control with cabergoline and octreotide in a patient with ectopic ACTH syndrome before surgery.
Topics: ACTH Syndrome, Ectopic; Aged; Cabergoline; Drug Therapy, Combination; Ergolines; Female; Humans; Octreotide; Treatment Outcome | 2015 |
[Use of cabergoline for prevention of ovarian hyperstimulation syndrome in assisted reproductive technologies].
Topics: Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Ovary; Ovulation Induction; Pregnancy | 2014 |
Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Hormone Replacement Therapy; Humans; Hyperprolactinemia; Male; Metabolome; Middle Aged; Pituitary Neoplasms; Prolactinoma; Testosterone | 2015 |
Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model.
Topics: Acetates; Animals; Ascitic Fluid; Body Weight; Cabergoline; Capillary Permeability; Chorionic Gonadotropin; Cyclopropanes; Dopamine Agonists; Ergolines; Female; Gonadotropins, Equine; Horses; Humans; Immunohistochemistry; Leukotriene Antagonists; Organ Size; Ovarian Hyperstimulation Syndrome; Ovary; Ovulation Induction; Quinolines; Rats; Rats, Wistar; Reproductive Control Agents; Sulfides; Vascular Endothelial Growth Factor A | 2015 |
Treatment outcome results from the Bulgarian Acromegaly Database: adjuvant dopamine agonist therapy is efficient in less than one fifth of non-irradiated patients.
Topics: Acromegaly; Adolescent; Adult; Aged; Bromocriptine; Bulgaria; Cabergoline; Child; Databases, Factual; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Humans; Male; Middle Aged; Radiotherapy; Remission Induction; Retrospective Studies; Somatostatin | 2015 |
[Pituitary apoplexy in a pregnant woman with cystic microprolactinoma].
Topics: Adult; Bromocriptine; Cabergoline; Combined Modality Therapy; Contraindications; Dopamine Agonists; Drug Substitution; Ergolines; Female; Headache; Hormone Replacement Therapy; Humans; Hydrocortisone; Hypophysectomy; Infant, Newborn; Male; Pituitary Apoplexy; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Complications, Neoplastic; Prolactinoma; Thyroxine; Vision Disorders | 2015 |
Rapid improvement in visual loss with cabergoline treatment in a giant prolactinoma case: 5 years survey.
Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Follow-Up Studies; Humans; Male; Optic Chiasm; Pituitary Neoplasms; Prolactinoma; Treatment Outcome; Vision, Low | 2015 |
Giant GH-secreting pituitary adenomas: management of rare and aggressive pituitary tumors.
Topics: Acromegaly; Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Drug Therapy, Combination; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Male; Middle Aged; Remission Induction; Somatostatin; Treatment Outcome; Young Adult | 2015 |
Cabergoline protects dopaminergic neurons against rotenone-induced cell death in primary mesencephalic cell culture.
Topics: Animals; Cabergoline; Cell Death; Cells, Cultured; Dopamine Agonists; Dopaminergic Neurons; Ergolines; Female; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Reactive Oxygen Species; Rotenone | 2015 |
Role of Dopamine and D2 Dopamine Receptor in the Pathogenesis of Inflammatory Bowel Disease.
Topics: Animals; Biopsy, Needle; Blotting, Western; Cabergoline; Capillary Permeability; Colitis, Ulcerative; Disease Models, Animal; Dopamine; Ergolines; Female; Humans; Immunohistochemistry; Inflammation Mediators; Inflammatory Bowel Diseases; Interleukin-10; Iodoacetamide; Mice; Mice, Inbred C57BL; Mice, Knockout; Quinpirole; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Statistics, Nonparametric | 2015 |
Prolactin serum concentrations after electroconvulsive therapy in a depressed patient with cabergoline-treated prolactinoma: implications for treatment.
Topics: Antidepressive Agents; Antineoplastic Agents; Cabergoline; Depressive Disorder, Major; Electroconvulsive Therapy; Ergolines; Female; Humans; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma | 2015 |
SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Cabergoline; Cohort Studies; Down-Regulation; Ergolines; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Prognosis; Prolactin; Prolactinoma; Remission Induction; Time Factors; Tumor Burden; Young Adult | 2015 |
Short communication: The effects of cabergoline administration at dry-off of lactating cows on udder engorgement, milk leakages, and lying behavior.
Topics: Animals; Behavior, Animal; Cabergoline; Cattle; Dopamine Agonists; Ergolines; Female; France; Lactation; Mammary Glands, Animal; Milk; Posture; Prolactin | 2015 |
Cabergoline for Cushing's disease: A case report.
Topics: Adrenocorticotropic Hormone; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hydrocortisone; Magnetic Resonance Imaging; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Remission Induction; Tumor Burden | 2015 |
Prevention of ovarian hyperstimulation syndrome in a rat model: comparison of the efficacy of tocilizumab with that of ranibizumab, cabergoline, and a gonadotropin-releasing hormone antagonist.
Topics: Animals; Antibodies, Monoclonal, Humanized; Cabergoline; Ergolines; Estrogens; Female; Gonadotropin-Releasing Hormone; Interleukin-6; Ovarian Hyperstimulation Syndrome; Ovary; Progesterone; Ranibizumab; Rats; Rats, Wistar; Vascular Endothelial Growth Factor A | 2015 |
Different Effects of Metformin on the Hypothalamic-Pituitary-Thyroid Axis in Bromocriptine- and Cabergoline-treated Patients with Hashimoto's Thyroiditis and Glucose Metabolism Abnormalities.
Topics: Adult; Bromocriptine; Cabergoline; Ergolines; Female; Glucose Metabolism Disorders; Hashimoto Disease; Humans; Hypothalamo-Hypophyseal System; Metformin; Middle Aged; Thyroid Gland | 2015 |
Dopamine agonist inhibits vascular endothelial growth factor protein production and secretion in granulosa cells.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Granulosa Cells; Humans; Receptors, Dopamine D2; Vascular Endothelial Growth Factor A | 2015 |
Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study.
Topics: Acromegaly; Adolescent; Adult; Antineoplastic Agents; Apnea; Cabergoline; Comorbidity; Ergolines; Female; Follow-Up Studies; Heart Diseases; Human Growth Hormone; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Retrospective Studies; Somatostatin; Young Adult | 2015 |
Montelukast is effective in preventing of ovarian hyperstimulation syndrome; an experimental study.
Topics: Acetates; Animals; Cabergoline; Chorionic Gonadotropin; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Ergolines; Female; Ovarian Hyperstimulation Syndrome; Ovary; Quinolines; Random Allocation; Rats; Rats, Wistar; Sulfides | 2015 |
Suppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cabergoline; Cell Death; Ergolines; Female; Heterografts; Mice; Mice, Nude; Prolactinoma; Rats; TOR Serine-Threonine Kinases; Transfection | 2015 |
Does DRD2 polymorphism influence the clinical characteristics of prolactinoma?
Topics: Adult; Alleles; Antineoplastic Agents; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Genotype; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Prolactin; Prolactinoma; Receptors, Dopamine D2 | 2015 |
Subthalamic stimulation or subthalamic lesion for Parkinson's disease? A case report.
Topics: Adult; Antiparkinson Agents; Cabergoline; Chorea; Combined Modality Therapy; Deep Brain Stimulation; Equipment Failure; Ergolines; Female; Haloperidol; Humans; Magnetic Resonance Imaging; Parkinson Disease; Recurrence; Severity of Illness Index; Subthalamic Nucleus | 2015 |
Cost-Effectiveness Analysis of Microscopic and Endoscopic Transsphenoidal Surgery Versus Medical Therapy in the Management of Microprolactinoma in the United States.
Topics: Adult; Aged; Bromocriptine; Cabergoline; Cost-Benefit Analysis; Decision Support Techniques; Decision Trees; Ergolines; Female; Health Care Costs; Hormone Antagonists; Humans; Hyperprolactinemia; Life Expectancy; Male; Medicare; Microsurgery; Middle Aged; Monte Carlo Method; Neuroendoscopy; Pituitary Neoplasms; Prolactinoma; Quality-Adjusted Life Years; Sphenoid Sinus; Time Factors; Treatment Outcome; United States | 2016 |
Duration of drug action of dopamine D2 agonists in mice with 6-hydroxydopamine-induced lesions.
Topics: Animals; Antiparkinson Agents; Apomorphine; Azepines; Benzothiazoles; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Ergolines; Indoles; Injections, Intraventricular; Male; Mice; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pramipexole; Quinolines; Receptors, Dopamine D2; Tetrahydronaphthalenes; Thiophenes | 2015 |
A man with breast discharge and headache.
Topics: Adult; Brain; Cabergoline; Dopamine Agonists; Erectile Dysfunction; Ergolines; Headache; Humans; Magnetic Resonance Imaging; Male; Nipple Discharge; Pituitary Neoplasms; Prolactinoma | 2016 |
Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Cabergoline; Circadian Rhythm; Dopamine Agonists; Ergolines; Female; Humans; Hydrocortisone; Male; Middle Aged; Pituitary ACTH Hypersecretion; Prospective Studies; Saliva | 2016 |
Patterns of pharmacologic treatment in US patients with acromegaly.
Topics: Acromegaly; Adult; Cabergoline; Databases, Factual; Ergolines; Female; Human Growth Hormone; Humans; Male; Middle Aged; Octreotide; Peptides, Cyclic; Retrospective Studies; Somatostatin | 2016 |
Macular amyloidosis complicating macroprolactinoma--a novel clinical association.
Topics: Adrenal Insufficiency; Adult; Amyloidosis, Familial; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Hyperprolactinemia; Macula Lutea; Male; Pituitary Neoplasms; Prolactinoma; Retinal Diseases; Skin Diseases, Genetic | 2015 |
Evaluation of atherosclerosis after cessation of cabergoline therapy in patients with prolactinoma.
Topics: Adolescent; Adult; Atherosclerosis; Brachial Artery; Cabergoline; Carotid Intima-Media Thickness; Cross-Sectional Studies; Ergolines; Female; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies; Young Adult | 2016 |
Inhibiting the onset of lactation. Is cabergoline an alternative to bromocriptine?
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Europe; Female; France; Humans; Lactation | 2015 |
Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Topics: Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Deprescriptions; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Neoplasm Recurrence, Local; Patient Selection; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Time Factors; Tumor Burden; Young Adult | 2016 |
Mean platelet volume in patients with prolactinoma.
Topics: Adolescent; Adult; Biomarkers, Tumor; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Humans; Male; Mean Platelet Volume; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Reference Values; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult | 2016 |
Prolactinomas: evolution after menopause.
Topics: Adenoma; Adult; Bromocriptine; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Menopause; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Treatment Outcome; Withholding Treatment | 2016 |
Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Heart Diseases; Humans; Prolactinoma; Prospective Studies; Pulmonary Fibrosis; Time Factors; Treatment Outcome; Young Adult | 2016 |
Comparison between resveratrol and cabergoline in preventing ovarian hyperstimulation syndrome in a rat model.
Topics: Animals; Antioxidants; Cabergoline; Disease Models, Animal; Dopamine Agonists; Ergolines; Female; Ovarian Hyperstimulation Syndrome; Ovary; Random Allocation; Rats; Rats, Wistar; Resveratrol; Stilbenes | 2016 |
Chronic cluster headache and the pituitary gland.
Topics: Adenoma; Cabergoline; Central Nervous System Cysts; Cluster Headache; Diagnosis, Differential; Dopamine Agonists; Ergolines; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Sumatriptan; Treatment Outcome; Verapamil | 2016 |
Successful Improvement of Metabolic Disorders, Including Osteopenia, by a Dopamine Agonist in a Male Patient with Macro-Prolactinoma.
Topics: Adult; Bone Diseases, Metabolic; Cabergoline; Dopamine Agonists; Ergolines; Glucose Intolerance; Humans; Hypertriglyceridemia; Male; Overweight; Pituitary Neoplasms; Prolactinoma | 2016 |
Somatic GPR101 Duplication Causing X-Linked Acrogigantism (XLAG)-Diagnosis and Management.
Topics: Cabergoline; Child, Preschool; Ergolines; Gene Duplication; Gigantism; Human Growth Hormone; Humans; Male; Pituitary Gland; Receptors, G-Protein-Coupled | 2016 |
Concomitant Cushing's Disease and Marked Hyperprolactinemia: Response to a Dopamine Receptor Agonist.
Topics: Adrenocorticotropic Hormone; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hydrocortisone; Hyperprolactinemia; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Prolactin; Prolactinoma | 2016 |
Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
Topics: Adolescent; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Child; Ergolines; Female; Galactorrhea; Headache; Hormone Antagonists; Humans; Male; Middle Aged; Neurosurgical Procedures; Pituitary Neoplasms; Prolactinoma; Sexual Dysfunction, Physiological; Treatment Outcome; Tumor Burden; Vision Disorders; Young Adult | 2016 |
Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists.
Topics: Adenoma; Adult; Aged; Bromocriptine; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Receptors, Dopamine; Receptors, Estrogen; Treatment Outcome | 2016 |
Hyperprolactinemia induced by hCG leads to metabolic disturbances in female mice.
Topics: Animals; Blood Glucose; Cabergoline; Chorionic Gonadotropin, beta Subunit, Human; Ergolines; Female; Glucose Intolerance; Hyperinsulinism; Hyperprolactinemia; Hypertriglyceridemia; Insulin; Insulin Resistance; Mice; Mice, Transgenic; Prolactin; Triglycerides | 2016 |
Cabergoline inhibits prolactin secretion and accelerates involution in dairy cows after dry-off.
Topics: Animals; Cabergoline; Cattle; Cell Count; Ergolines; Female; Lactation; Mammary Glands, Animal; Milk; Prolactin | 2016 |
Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
Topics: Adult; Aged; Biomarkers; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prognosis; Prolactinoma; Tomography, X-Ray Computed; Withholding Treatment | 2016 |
Spontaneous subarachnoid hemorrhage due to ruptured cavernous internal carotid artery aneurysm after medical prolactinoma treatment.
Topics: Aneurysm, Ruptured; Antineoplastic Agents; Cabergoline; Carotid Artery, Internal; Cavernous Sinus; Cerebral Angiography; Ergolines; Humans; Male; Middle Aged; Prolactinoma; Rupture, Spontaneous; Skull Base; Subarachnoid Hemorrhage | 2016 |
Spontaneous subarachnoid hemorrhage due to ruptured cavernous internal carotid artery aneurysm after medical prolactinoma treatment.
Topics: Aneurysm, Ruptured; Cabergoline; Carotid Artery Diseases; Carotid Artery, Internal; Cavernous Sinus; Ergolines; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Skull Base; Subarachnoid Hemorrhage; Treatment Outcome | 2017 |
Equine Chorionic Gonadotropin and Human Chorionic Gonadotropin Stimulation Increase the Number of Luteinized Follicles and the Progesterone Level Compared with Cabergoline Stimulation in Anoestrus Bitches.
Topics: Animals; Cabergoline; Chorionic Gonadotropin; Dogs; Dopamine Agonists; Ergolines; Estrus; Female; Horses; Humans; Ovarian Follicle; Ovulation; Progesterone | 2016 |
Evaluaton of therapy with cabergoline in men with macroprolactinoa.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Male; Middle Aged; Pituitary Neoplasms; Poland; Prolactinoma; Young Adult | 2015 |
Cabergoline treatment for recurrent Cushing's disease during pregnancy.
Topics: Adult; Antineoplastic Agents; Biomarkers; Cabergoline; Ergolines; Female; Humans; Hydrocortisone; Live Birth; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neoplasm, Residual; Pituitary ACTH Hypersecretion; Pregnancy; Pregnancy Complications; Remission Induction; Treatment Outcome | 2016 |
Peripartum Cardiomyopathy Treatment with Dopamine Agonist and Subsequent Pregnancy with a Satisfactory Outcome.
Topics: Adolescent; Cabergoline; Cardiomyopathies; Dopamine Agonists; Ergolines; Female; Humans; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Puerperal Disorders | 2016 |
Topiramate Overcoming Dopamine Agonist-Induced Migraine Exacerbation and Avoiding Transsphenoidal Surgery in a Young Boy With a Macroprolactinoma.
Topics: Brain; Cabergoline; Central Nervous System Agents; Child; Dopamine Agonists; Ergolines; Fructose; Humans; Male; Migraine Disorders; Pituitary Neoplasms; Prolactinoma; Topiramate | 2016 |
Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.
Topics: Acromegaly; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Peptides, Cyclic; Retrospective Studies; Somatostatin | 2016 |
[Serum concentrations of glucose, cholesterol and triglycerides in men with prolactinoma treated with cabergoline].
Topics: Adult; Antineoplastic Agents; Biomarkers; Blood Glucose; Cabergoline; Cholesterol; Ergolines; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Treatment Outcome; Triglycerides | 2016 |
Prolactinomas may have unusual presentations resulting from massive extrasellar tumor extension.
Topics: Adolescent; Adult; Antineoplastic Agents; Cabergoline; Cerebrospinal Fluid Leak; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Sella Turcica; Time Factors; Treatment Outcome; Tumor Burden; Young Adult | 2016 |
Cabergoline can induce mania with psychotic features in bipolar I disorder: a case report.
Topics: Adult; Antineoplastic Agents; Bipolar Disorder; Cabergoline; Ergolines; Female; Humans; Pituitary Neoplasms; Prolactinoma; Psychoses, Substance-Induced | 2016 |
Sellar Wegener Granulomatosis Masquerading as Cabergoline-Resistant Prolactinoma.
Topics: Adult; Antineoplastic Agents; Cabergoline; Diagnosis, Differential; Drug Resistance, Neoplasm; Ergolines; Female; Glucocorticoids; Granulomatosis with Polyangiitis; Humans; Immunosuppressive Agents; Pituitary Neoplasms; Prolactinoma; Rituximab; Sella Turcica | 2016 |
Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas.
Topics: Adult; Cabergoline; Cholesterol; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Lipoproteins, HDL; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Treatment Outcome | 2017 |
Mixed Pituitary Gangliocytoma and Prolactinoma Resistant to the Cabergoline Treatment.
Topics: Adolescent; Antineoplastic Agents; Cabergoline; Disease Progression; Drug Resistance, Neoplasm; Ergolines; Ganglioneuroma; Humans; Hydrocephalus; Magnetic Resonance Imaging; Male; Neoplasms, Complex and Mixed; Neuroendoscopy; Pituitary Neoplasms; Prolactinoma | 2016 |
An update on the prevention of ovarian hyperstimulation syndrome.
Topics: Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Ergolines; Estradiol; Estrogens; Female; Fertility Agents, Female; Gonadotropin-Releasing Hormone; Humans; Kisspeptins; Leuprolide; Luteinizing Hormone; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Recombinant Proteins; Reproductive Control Agents; Risk Assessment | 2016 |
A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline.
Topics: Adult; Aged; Cabergoline; Dopamine Agonists; Echocardiography; Ergolines; Female; Follow-Up Studies; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Middle Aged; Prevalence; United Kingdom | 2016 |
Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.
Topics: Adult; Aged; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hypogonadism; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Sexual Dysfunction, Physiological | 2017 |
Dopamine Activation Preserves Visual Motion Perception Despite Noise Interference of Human V5/MT.
Topics: Adult; Analysis of Variance; Cabergoline; Domperidone; Dopamine; Dopamine Agonists; Dopamine Antagonists; Ergolines; Female; Humans; Male; Motion; Motion Perception; Noise; Photic Stimulation; Prolactin; Signal-To-Noise Ratio; Transcranial Magnetic Stimulation; Visual Cortex; Young Adult | 2016 |
Long-term outcome of macroprolactinomas.
Topics: Adolescent; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; France; Humans; Hyperprolactinemia; Hypopituitarism; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Long-term results of cabergoline therapy for macroprolactinomas and analyses of factors associated with remission after withdrawal.
Topics: Adolescent; Adult; Cabergoline; Cavernous Sinus; Ergolines; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Prolactin; Prolactinoma; Recurrence; Remission Induction; Retrospective Studies; Young Adult | 2017 |
SURGICAL OUTCOMES OF PROLACTINOMAS IN RECENT ERA: RESULTS OF A HETEROGENOUS GROUP.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Pituitary Neoplasms; Prolactinoma; Remission Induction; Retrospective Studies; Treatment Failure; Treatment Outcome; Tumor Burden; Young Adult | 2017 |
10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Humans; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |
Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.
Topics: Antineoplastic Agents; Cabergoline; Carcinoid Tumor; Cell Line, Tumor; Cell Survival; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Everolimus; Humans; Lung Neoplasms; Octreotide; Receptors, Dopamine D2; Receptors, Somatostatin; Signal Transduction; Somatostatin; TOR Serine-Threonine Kinases | 2017 |
Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
Topics: Adult; Cabergoline; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Heart Valves; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Prospective Studies; Treatment Outcome; Young Adult | 2017 |
Low Testosterone in Men Should Be a Sign Rather Than a Number to Increase: A Teachable Moment.
Topics: Cabergoline; Dopamine Agonists; Ergolines; Eunuchism; Hormone Replacement Therapy; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Testosterone | 2016 |
Management of prolactinomas: a survey of physicians from the Middle East and North Africa.
Topics: Adult; Africa, Northern; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Middle East; Physicians; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma; Surveys and Questionnaires | 2017 |
Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment.
Topics: Adolescent; Adult; Cabergoline; Case-Control Studies; Child; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Female; Genotype; Humans; Male; Middle Aged; Polymorphism, Genetic; Prolactinoma; Receptors, Dopamine D2; Retrospective Studies; Young Adult | 2017 |
SERUM LEVELS OF FIBROBLAST GROWTH FACTOR-23, OSTEOPROTEGERIN, AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND IN PATIENTS WITH PROLACTINOMA.
Topics: Adult; Amino Acids; Antineoplastic Agents; Biomarkers, Tumor; Bone Density; Cabergoline; Cross-Sectional Studies; Ergolines; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Middle Aged; Osteocalcin; Osteoprotegerin; Pituitary Neoplasms; Prolactinoma; Prospective Studies; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Vitamin D | 2017 |
Dopamine Alters the Fidelity of Working Memory Representations according to Attentional Demands.
Topics: Adult; Attention; Cabergoline; Dopamine; Dopamine Agonists; Ergolines; Female; Humans; Male; Memory, Short-Term; Mental Recall; Receptors, Dopamine D2; Task Performance and Analysis; Visual Perception; Young Adult | 2017 |
Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy.
Topics: Adult; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Infertility, Female; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactinoma; Treatment Outcome; Young Adult | 2017 |
Macroprolactinomas and Nonfunctioning Pituitary Adenomas and Pregnancy Outcomes.
Topics: Adenoma; Adult; Amenorrhea; Antineoplastic Agents; Bromocriptine; Cabergoline; Case-Control Studies; Cesarean Section; Dopamine Agonists; Ergolines; Female; Galactorrhea; Humans; Incidence; Pituitary Neoplasms; Pre-Eclampsia; Preconception Care; Pregnancy; Pregnancy Complications, Neoplastic; Premature Birth; Prolactinoma; Prospective Studies; Stillbirth; United Kingdom; Vision Disorders; Young Adult | 2017 |
Cabergoline for Cushing's disease: a large retrospective multicenter study.
Topics: Adolescent; Adult; Aged; Cabergoline; Child; Ergolines; Female; Humans; Hydrocortisone; Male; Middle Aged; Pituitary ACTH Hypersecretion; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |
Remission of acromegaly after treatment withdrawal in patients controlled by cabergoline alone or in combination with octreotide: results from a multicenter study.
Topics: Acromegaly; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Ergolines; Female; Follow-Up Studies; Humans; Male; Middle Aged; Octreotide; Prognosis; Prospective Studies; Remission Induction; Withholding Treatment | 2017 |
MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment.
Topics: Adult; Aminoquinolines; Belgium; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; France; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies | 2017 |
Angiogenic properties of endometrial mesenchymal stromal cells in endothelial co-culture: an in vitro model of endometriosis.
Topics: Angiogenesis Inhibitors; Biomarkers; Cabergoline; Cadherins; Cell Communication; Cell Differentiation; Cell Proliferation; Coculture Techniques; Endometriosis; Endometrium; Ergolines; Female; Gene Expression; Human Umbilical Vein Endothelial Cells; Humans; Mesenchymal Stem Cells; Models, Biological; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Primary Cell Culture; Proto-Oncogene Proteins c-myc; Receptor, TIE-2; Syndecan-2; Vascular Endothelial Growth Factor Receptor-2; Vimentin | 2017 |
Effect of a single injection of cabergoline at dry off on udder characteristics in high-yielding dairy cows.
Topics: Animals; Cabergoline; Cattle; Dairying; Ergolines; Female; Injections; Lactation; Mammary Glands, Animal; Milk; Parity | 2017 |
Cabergoline for hyperprolactinemia: getting to the heart of it.
Topics: Cabergoline; Dopamine Agonists; Ergolines; Heart; Humans; Hyperprolactinemia | 2017 |
Combining several interventions to reduce the incidence of OHSS: A prospective cohort study.
Topics: Adult; Aspirin; Cabergoline; Chorionic Gonadotropin; Drug Therapy, Combination; Ergolines; Female; Gonadotropin-Releasing Hormone; Humans; Infertility, Female; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Pregnancy Rate; Reproductive Control Agents; Severity of Illness Index | 2017 |
Template synthesis of maghemite nanoparticle in carboxymethyl cellulose and its application for electrochemical cabergoline sensing.
Topics: Cabergoline; Carboxymethylcellulose Sodium; Electrodes; Ergolines; Ferric Compounds; Metal Nanoparticles | 2017 |
Classification of Patients With GH Disorders May Vary According to the IGF-I Assay.
Topics: Acromegaly; Adenoma; Adult; Aged; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Drug Therapy, Combination; Dwarfism, Pituitary; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Immunoassay; Insulin-Like Growth Factor I; Male; Middle Aged; Neurosurgical Procedures; Somatostatin; Young Adult | 2017 |
Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal.
Topics: Adolescent; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Prolactin; Prolactinoma; Retrospective Studies; Young Adult | 2017 |
Activation of DRD5 (dopamine receptor D5) inhibits tumor growth by autophagic cell death.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Autophagosomes; Autophagy; Cabergoline; Cell Line, Tumor; Cell Proliferation; Ergolines; Humans; Mice, Nude; Pituitary Neoplasms; Rats; Reactive Oxygen Species; Receptors, Dopamine D5; Superoxide Dismutase; TOR Serine-Threonine Kinases | 2017 |
BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY.
Topics: 14-alpha Demethylase Inhibitors; ACTH-Secreting Pituitary Adenoma; Adenoma; Adolescent; Adrenalectomy; Adult; Aged; Antineoplastic Agents; Cabergoline; Comorbidity; Enzyme Inhibitors; Ergolines; Female; Follow-Up Studies; Hirsutism; Hormone Antagonists; Hormones; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Ketoconazole; Male; Metyrapone; Middle Aged; Mifepristone; Muscle Weakness; Muscular Atrophy; Neurosurgical Procedures; Obesity, Abdominal; Pituitary ACTH Hypersecretion; Pituitary Irradiation; Polycystic Ovary Syndrome; Retrospective Studies; Rosiglitazone; Somatostatin; Striae Distensae; Thiazolidinediones; Treatment Outcome; Tumor Burden; Young Adult | 2017 |
An Overlooked Cause of Hypokalemia.
Topics: 14-alpha Demethylase Inhibitors; Adenoma; Cabergoline; Cushing Syndrome; Dopamine Agonists; Ergolines; Female; Humans; Hypokalemia; Ketoconazole; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Neoplasms | 2017 |
Pregnancy and Tumor Outcomes in Women with Prolactinoma.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Outcome Assessment, Health Care; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactinoma; Retrospective Studies; Young Adult | 2017 |
Use of cabergoline for the management of persistent Cushing's disease in pregnancy.
Topics: Adult; Antineoplastic Agents; Cabergoline; Diagnosis, Differential; Ergolines; Female; Humans; Pituitary ACTH Hypersecretion; Pregnancy; Pregnancy Complications; Prenatal Diagnosis; Recurrence; Remission Induction | 2017 |
Best candidates for dopamine agonist withdrawal in patients with prolactinomas.
Topics: Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prolactinoma; Retrospective Studies; Young Adult | 2017 |
Effects of Cabergoline on Thyroid Hormones and Semen Quality of Dog.
Topics: Animals; Cabergoline; Dogs; Ergolines; Male; Prolactin; Semen Analysis; Thyroid Hormones | 2017 |
The Clinical Follow-Up of Estradiol Benzoate Priming During Induction of Estrus With Cabergoline in Dogs.
Topics: Animals; Cabergoline; Dogs; Ergolines; Estradiol; Estrus; Female; Follow-Up Studies; Progesterone | 2017 |
An unusual case of Cushing's syndrome due to bihormonal ACTH-prolactin secreting pituitary macroadenoma with rapid response to cabergoline.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Agents; Cabergoline; Cushing Syndrome; Ergolines; Humans; Male; Pituitary Neoplasms; Prolactinoma; Young Adult | 2017 |
Prolactinoma in a Dog.
Topics: Adenoma; Animals; Cabergoline; Dogs; Dopamine Agonists; Ergolines; Fatal Outcome; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Tomography Scanners, X-Ray Computed | 2017 |
[A rare case of giant galactocele associated with prolactinoma].
Topics: Adult; Antineoplastic Agents; Breast Cyst; Cabergoline; Ergolines; Female; Humans; Pituitary Neoplasms; Prolactinoma | 2017 |
Use of cabergoline for oestrus induction in multiparous anoestrous Beagle bitches.
Topics: Anestrus; Animals; Breeding; Cabergoline; Dogs; Ergolines; Estrus; Female; Ovulation Induction; Pregnancy; Pregnancy Rate; Progesterone | 2017 |
The efficacy of medical treatment in patients with acromegaly in clinical practice.
Topics: Acromegaly; Adenoma; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Cohort Studies; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Female; Follow-Up Studies; Growth Hormone-Secreting Pituitary Adenoma; Hospitals, University; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Neoplasm Grading; Republic of Korea; Retrospective Studies; Somatostatin; Tumor Burden | 2018 |
Body Composition and Ectopic Lipid Changes With Biochemical Control of Acromegaly.
Topics: Acromegaly; Adipose Tissue; Adult; Aged; Blood Glucose; Body Composition; Cabergoline; Case-Control Studies; Cross-Sectional Studies; Ergolines; Female; Gonadal Steroid Hormones; Human Growth Hormone; Humans; Insulin Resistance; Insulin-Like Growth Factor I; Lipid Metabolism Disorders; Lipodystrophy; Male; Middle Aged; Peptides, Cyclic; Prednisone; Somatostatin | 2017 |
Beneficial Effects of High Doses of Cabergoline in the Treatment of Giant Prolactinoma Resistant to Dopamine Agonists: A Case Report with a 21-Year Follow-Up.
Topics: Cabergoline; Child; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Follow-Up Studies; Humans; Male; Pituitary Neoplasms; Prolactin; Prolactinoma | 2018 |
Inhibiting prolactin by cabergoline accelerates mammary gland remodeling during the early dry period in dairy cows.
Topics: Animals; Biomarkers; Cabergoline; Cattle; Dairying; Ergolines; Female; Injections, Intramuscular; Lactation; Mammary Glands, Animal; Prolactin | 2017 |
Pituitary Tumor Suppression by Combination of Cabergoline and Chloroquine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Cell Death; Cells, Cultured; Chloroquine; Ergolines; Female; Hep G2 Cells; Humans; Mice; Mice, Nude; Pituitary Neoplasms; Prolactinoma; Rats; Rats, Inbred F344; Xenograft Model Antitumor Assays | 2017 |
Novel Germline p.Gly42Val
Topics: Adult; Amino Acid Substitution; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Dopamine Agonists; Ergolines; Family Health; Germ-Line Mutation; Heterozygote; Humans; Male; Multiple Endocrine Neoplasia Type 1; Mutation, Missense; Pancreatectomy; Parathyroidectomy; Proto-Oncogene Proteins; Treatment Outcome | 2017 |
Large pituitary gland with an expanding lesion in the context of neurofibromatosis 1.
Topics: Acromegaly; Adult; Antineoplastic Agents; Cabergoline; Central Nervous System Cysts; Ergolines; Female; Human Growth Hormone; Humans; Magnetic Resonance Imaging; Neurofibromatosis 1; Pituitary Gland; Pituitary Neoplasms | 2017 |
Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective.
Topics: Adult; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Diagnosis, Differential; Dopamine Agonists; Ergolines; Fibrosis; Humans; Hypogonadism; Hypothyroidism; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma; Thyroxine; Tricuspid Valve Insufficiency | 2017 |
Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bromocriptine; Cabergoline; Combined Modality Therapy; Dacarbazine; Drug Substitution; Ergolines; Fatal Outcome; Headache; Humans; Hyperprolactinemia; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Proton Therapy; Temozolomide | 2017 |
Secondary Resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man.
Topics: Adult; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Humans; Male; Pituitary Neoplasms; Prolactinoma; Time Factors | 2016 |
Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report.
Topics: Acromegaly; Adult; Antineoplastic Agents; Cabergoline; Drug Therapy, Combination; Ergolines; Hormones; Human Growth Hormone; Humans; Male; Prognosis; Salvage Therapy; Somatostatin | 2018 |
Ectopic Prolactinoma Presenting as Bacterial Meningitis: A Diagnostic Conundrum.
Topics: Cabergoline; Cerebrospinal Fluid Rhinorrhea; Diagnosis, Differential; Dopamine Agonists; Ergolines; Female; Humans; Meningitis, Bacterial; Middle Aged; Penicillin G; Pituitary Neoplasms; Prolactinoma; Streptococcus pneumoniae; Treatment Outcome | 2018 |
Transnasal Transsphenoidal Elevation of Optic Chiasm in Secondary Empty Sella Syndrome Following Prolactinoma Treatment.
Topics: Cabergoline; Dopamine Agonists; Empty Sella Syndrome; Ergolines; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Optic Chiasm; Pituitary Neoplasms; Prolactinoma; Treatment Outcome | 2018 |
Dysregulated genes and their functional pathways in luteinized granulosa cells from PCOS patients after cabergoline treatment.
Topics: Adult; Biomarkers; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Gene Expression Regulation; Granulosa Cells; Humans; Luteal Cells; Ovary; Polycystic Ovary Syndrome; Transcriptome | 2018 |
Transient Splenial Lesion of the Corpus Callosum After Cabergoline Treatment.
Topics: Antineoplastic Agents; Cabergoline; Corpus Callosum; Ergolines; Humans; Magnetic Resonance Imaging; Male; Time Factors; Treatment Outcome; Young Adult | 2018 |
IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas.
Topics: Acromegaly; Adenoma; Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Prolactinoma | 2018 |
Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal.
Topics: Adolescent; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Menopause; Postmenopause; Prolactin; Prolactinoma; Retrospective Studies; Withholding Treatment; Young Adult | 2018 |
Response to Letter to the Editor: "A Meta-Analysis of the Prevalence of Cardiac Valvulopathy in Patients With Hyperprolactinemia Treated With Cabergoline".
Topics: Cabergoline; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Prevalence | 2019 |
Letter to the Editor: "A Meta-Analysis of the Prevalence of Cardiac Valvulopathy in Patients With Hyperprolactinemia Treated With Cabergoline".
Topics: Cabergoline; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Prevalence | 2019 |
Effects of cabergoline therapy on serum IGF-1 concentrations in prolactinoma patients.
Topics: Cabergoline; Dopamine Agonists; Ergolines; Humans; Insulin-Like Growth Factor I; Pituitary Neoplasms; Prolactinoma | 2020 |
[The effect of the dopamine D2 receptor agonist cabergoline on the content of catecholamines and expression of BDNF mRNA in the rat midbrain and hypothalamus].
Topics: Animals; Brain-Derived Neurotrophic Factor; Cabergoline; Catecholamines; Ergolines; Hypothalamus; Male; Mesencephalon; Rats; Rats, Wistar; Receptors, Dopamine D2; RNA, Messenger | 2019 |
High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?
Topics: Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma | 2020 |
Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not be indicated.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma | 2021 |
[Changes in the morphological structure of giant prolactinoma during treatment with cabergoline].
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactinoma | 2020 |
Letter to "High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?"
Topics: Cabergoline; Ergolines; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactinoma | 2021 |
Response to Letter to the Editor: "High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?"
Topics: Cabergoline; Ergolines; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactinoma | 2021 |
A Hard Look at Cardiac Safety with Dopamine Agonists in Endocrinology.
Topics: Cabergoline; Dopamine Agonists; Ergolines; Humans | 2021 |
Evaluation of cabergoline for lactation inhibition in women living with HIV.
Topics: Cabergoline; Ergolines; Female; HIV Infections; Humans; Lactation; Prolactin | 2021 |
Long-term response to cabergoline and multi-modal treatment in men with macroprolactinoma: Does size really matter?
Topics: Cabergoline; Dopamine Agonists; Ergolines; Humans; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Treatment Outcome | 2021 |
Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients.
Topics: Anastrozole; Cabergoline; Dopamine Agonists; Ergolines; Humans; Male; Pituitary Neoplasms; Prolactin; Prolactinoma | 2021 |
Resistant prolactinomas: a case series of 26 patients.
Topics: Adenoma; Adolescent; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Young Adult | 2022 |
Ectopic Cavernous Sinus Microprolactinoma Treated Medically.
Topics: Adult; Cabergoline; Cavernous Sinus; Dopamine; Ergolines; Humans; Male; Pituitary Neoplasms; Prolactin; Prolactinoma | 2023 |
Hydroxychloroquine overcomes cabergoline resistance in a patient with Lactotroph Pituitary neuroendocrine tumor: a case report.
Topics: Adult; Cabergoline; Ergolines; Humans; Hydroxychloroquine; Lactotrophs; Male; Neuroendocrine Tumors; Pituitary Neoplasms; Prolactin; Prolactinoma; Young Adult | 2022 |
Effect of Cabergoline Treatment on Disease Control in Acromegaly Patients.
Topics: Acromegaly; Cabergoline; Ergolines; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Prolactin; Retrospective Studies | 2022 |
Long-term low-dose cabergoline usage: Another association with cardiac valvulopathy.
Topics: Bromocriptine; Cabergoline; Ergolines; Heart Valve Diseases; Humans; Middle Aged; Pituitary Neoplasms | 2023 |
PRL-R Variants Are Not Only Associated With Prolactinomas But Also With Dopamine Agonist Resistance.
Topics: Animals; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Humans; Male; Mice; Mice, Knockout; Pituitary Neoplasms; Prolactin; Prolactinoma; Receptors, Prolactin; Retrospective Studies | 2023 |
Italian Guidelines for the Management of Prolactinomas.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Pituitary Neoplasms; Prolactin; Prolactinoma | 2023 |
Does cabergoline administration affect endometrial VEGFR-2 expression in a rat model of ovarian hyperstimulation syndrome?
Topics: Animals; Cabergoline; Dopamine Agonists; Ergolines; Female; Ovarian Hyperstimulation Syndrome; Rats; Rats, Wistar; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2023 |